<SEC-DOCUMENT>0001104659-23-068500.txt : 20230606
<SEC-HEADER>0001104659-23-068500.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230606152618
ACCESSION NUMBER:		0001104659-23-068500
CONFORMED SUBMISSION TYPE:	N-CSRS
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230606
EFFECTIVENESS DATE:		20230606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tekla World Healthcare Fund
		CENTRAL INDEX KEY:			0001635977
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			MA

	FILING VALUES:
		FORM TYPE:		N-CSRS
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-23037
		FILM NUMBER:		23995920

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		(617) 772-8515

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSRS
<SEQUENCE>1
<FILENAME>tm2312569d1_ncsrs.htm
<DESCRIPTION>N-CSRS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Thu Jun 01 15:21:26 UTC 2023 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ck0001635977="http://www.teklacap.com/20230331" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2023"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>Tekla World Healthcare Fund - 1635977 - 2023</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20221001to20230331"  id="Fdei_AmendmentFlag20230531213420896" >false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20221001to20230331"  id="Fdei_EntityCentralIndexKey20230531213500677" >0001635977</ix:nonNumeric><ix:nonNumeric name="dei:DocumentType" contextRef="C_20221001to20230331"  id="Fxbrl_20230531183730917" >N-CSRS</ix:nonNumeric><ix:footnote id="FN20230531185159692" xml:lang="en-US">The closing price at which the Fund's shares were traded on the exchange.</ix:footnote>
<ix:footnote id="FN20230531185215394" xml:lang="en-US">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="ck0001635977-20230331.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20221001to20230331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200930"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190930"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180930"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210930"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="Percent"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20230531184037380" toRefs="FN20230531185159692"/><ix:relationship fromRefs="Fxbrl_20230531184049150" toRefs="FN20230531185215394"/></ix:resources></ix:header></div><div>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">

      <tr>
        <td colspan="3" style="padding:0pt 0.7pt 13pt 0pt;text-align:left;width:6%" valign="bottom">&#160;</td>
        <td colspan="1" style="width:73%">&#160;</td>
        <td colspan="3" style="padding:0pt 0.7pt 13pt 0pt;text-align:left;line-height:1.6;width:21%" valign="bottom"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">OMB APPROVAL</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">OMB Number: 3235-0570</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Expires: September 30, 2025</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Estimated average burden hours per response 7.8</span></td>
      </tr>

  </table>
  <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:12pt;font-family:Times New Roman, Times, serif">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br />Washington, D.C. 20549</span></p>
  <p style="margin:15pt 0pt 0pt 0pt;text-align:center"><span style="font-size:14pt;font-family:Arial, Helvetica"><strong>FORM <span style="-sec-ix-hidden:Fxbrl_20230531183730917">N-CSR</span></strong></span></p>
  <p style="margin:13pt 0pt 13pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Times New Roman, Times, serif"><strong>CERTIFIED SHAREHOLDER REPORT OF REGISTERED<br />MANAGEMENT INVESTMENT COMPANIES</strong></span></p>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Investment Company Act file number 811-23037</span></p>
  <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:14pt;font-family:Times New Roman, Times, serif"><ix:nonNumeric id="Fxbrl_20230531183746369" name="dei:EntityRegistrantName" contextRef="C_20221001to20230331">Tekla World Healthcare Fund</ix:nonNumeric></span></p>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Exact name of registrant as specified in charter)</span></p>
  <table border="0" cellpadding="0" cellspacing="0" width="100%">

      <tr>
        <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:21" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p>
        </td>
        <td colspan="1">&#160;</td>
        <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:189" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">100 Federal Street, 19<sup>th</sup> Floor, Boston, MA</span></p>
        </td>
        <td colspan="1">&#160;</td>
        <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">02110</span></p>
        </td>
        <td colspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;width:21" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p>
        </td>
        <td colspan="1">&#160;</td>
        <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;width:189" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Address of principal executive offices)</span></p>
        </td>
        <td colspan="1">&#160;</td>
        <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;width:73" valign="bottom">
          <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Zip code)</span></p>
        </td>
        <td colspan="1">&#160;</td>
      </tr>

  </table>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Name and address of agent for service)</span></p>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Registrant's telephone number, including area code: 617-772-8500</span></p>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Date of fiscal year end: September 30</span></p>
  <p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Date of reporting period: October 1, 2022 to March 31, 2023</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;margin-bottom:10pt" />
  <div style="break-before:page;margin-bottom:25pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>ITEM 1. REPORTS TO STOCKHOLDERS.</strong></span></div>
  <div style="margin:0pt 0pt 8pt 0pt">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><img alt="j23125692_ab001.jpg" src="j23125692_ab001.jpg" /></p>
  </div>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always;margin-top:10pt;margin-bottom:10pt" />
<p><img alt="j23125692_ac002.jpg" src="j23125692_ac002.jpg" style="width:146px;height:146px" /></p><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><br /><span style="font-size:12pt;font-family:Arial, Helvetica">Semiannual Report</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:30pt;font-family:Arial, Helvetica">Tekla<br />World Healthcare Fund</span></p><p style="margin:11pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica">March 31, 2023</span></p></div><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Tekla World Healthcare Fund</span></p></div><div style="margin:8pt 0pt 8pt 0pt;line-height:1.35"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Distribution policy:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund has implemented a managed distribution policy (the Policy) that provides for monthly distributions at a rate set by the Board of Trustees. Under the current Policy, the Fund intends to make monthly distributions at a rate of $0.1167 per share to shareholders of record. The Policy would result in a return of capital to shareholders if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The amounts and sources of distributions reported in the Fund's notices pursuant to Section 19(a) of the Investment Company Act of 1940 are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that tells you how to report distributions for federal income tax purposes.</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">You should not draw any conclusions about the Fund's investment performance from the amount of distributions pursuant to the Policy or from the terms of the Policy. The Policy has been established by the Trustees and may be changed or terminated by them without shareholder approval. The Trustees regularly review the Policy and the frequency and rate of distributions considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions. The suspension or termination of the Policy could have the effect of creating a trading discount or widening an existing trading discount. At this time there are no reasonably foreseeable circumstances that might cause the Trustees to terminate the Policy.</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Consider these risks before investing:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> As with any investment company that invests in equity securities, the Fund is subject to market risk&#8212;the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market generally and market sectors in particular. You could lose money over short or long periods of time. Political and economic news can influence marketwide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares. Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity securities of healthcare companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.</span></p></div><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Tekla World Healthcare Fund</span></p></div><div style="margin:8pt 0pt 8pt 0pt;line-height:1.35"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Dear Shareholders,</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In our view, the healthcare sector represents an attractive sector of the economy in which to invest over any reasonable timeframe and in particular in the current uncertain macro-environment. The sector has performed well over intermediate and long timeframes and is generally thought of as defensive. In addition, the sector is quite diverse, consisting of at least ten subsectors. We like the fact that these subsectors are diversified and often perform differently in divergent macroeconomic environments. Therefore, we can almost always identify a subsector which will benefit from, and hopefully outperform, in the current environment.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Macroeconomics provides much of the uncertainty currently. There is much debate about whether a U.S. and/or worldwide recession looms. Multi-decade highs in interest rates and inflation, an inverted yield curve and a potential housing slump after a Covid associated boom certainly raise the likelihood of a recession in the next year. But historically low unemployment, adequate real 4Q22 GDP growth and a favorable stock market argue against. Our view tips toward the likelihood of a modest recession sometime in the next year. But we have found over a career that while trying to time the market can be difficult, attempting to predict the timing of the next recession is about impossible. As Paul Samuelson once joked, "the stock market has predicted nine of the last five recessions". We think investment in healthcare could serve to blunt the potential impact of any recession.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare, along with consumer staples and utilities, are generally thought of as defensive. These sectors tend to address basic non-cyclical needs and therefore tend to deliver consistent earnings and stable dividends. As a sector that addresses the wellness of the population, healthcare spending will be among the last things people give up as money gets tight.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare can certainly exhibit ups and downs but has performed well over the long-term as can be seen in the following table. Over multiple timeframes, the S&#38;P Composite 1500<sup>&#174;</sup> Healthcare Index* (S15HLTH), representing the broad healthcare space, has performed well in comparison to the S&#38;P 500<sup>&#174;</sup> Index* (SPX), the broad market standard against which many or most investment approaches are typically compared.</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:44" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Index</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:74" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>One Year (%)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:75" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Five Year (%)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:72" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Ten Year (%)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:85" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Twenty Year (%)</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:44;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">SPX</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-7.8</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.2</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:56;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">12.2</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:69;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">10.4</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:44" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">S15HLTH</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-4.4</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.5</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:56" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">12.9</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:69" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">10.6</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We are particularly attracted to the diversity of investment opportunity provided by individual healthcare subsectors. These subsectors include pharmaceuticals, biotechnology, managed care (i.e., MCOs), providers (hospitals), medical technology (medtech), life science tools (LST), distributors, healthcare services and healthcare information technology.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Varying macroeconomic situations often influence our subsector allocation decision making. For example, when investment capital is freely available, speculation typically abounds. At </span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 1</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt;line-height:1.40"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">such times, innovative, pre-profit or even pre-revenue companies in the biotech sector can be good investments. By contrast, when interest rates are high and capital is less available, profitable growing companies, including pharmaceuticals, can be better investments. At the moment, there is limited availability of capital. As such we are tending to be underweight not-yet profitable biotech companies and overweight profitable pharmaceuticals.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In an analogous way, when jobs are plentiful and wages are growing, individuals tend to seek more elective medical procedures. In this case, there is more demand for medical products and hospitals are busier. In this situation, managed care companies, which pay for medical procedures, tend to be more challenged. By contrast, when jobs are tight, demand for medical products and services often declines while managed care companies have lessened reimbursement demands and often perform better. At the moment, utilization of products and services is generally up, so we tend to be overweight medtech and hospitals and underweight managed care.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In large part, our management approach is to bias our subsector allocations based on macro factors while using our knowledge of associated individual companies to create a portfolio that is likely to perform well. In general, we seek to produce a solid risk adjusted performance that allows the Fund to continue to deliver the distributions to which shareholders have become accustomed. We summarize some of the macro factors that currently shape our views:</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Clinical and commercial progress is always a key contributor to sentiment toward the healthcare area. In the last several years, particularly lately, we have seen some interesting developments that look to be creating enormous opportunities to address the needs of large groups of older patients. One example is the recent approval of Leqembi, a drug that slows the progression of Alzheimer's disease. This drug reduces the presence of beta amyloid plaque in the brain and has demonstrated an ability to slow the progression of Alzheimer's. Several other drugs are in late-stage development in the Alzheimer's disease space. The Alzheimer's Association reports that about one in every nine people over 65 have Alzheimer's.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Diabetes and obesity represent two of the biggest health issues we have seen in recent decades. Each of these conditions represents enormous challenges for the healthcare system. Approximately one in ten Americans have diabetes and approximately 40% of American adults over 20 are obese. This twin condition is often referred to as diabesity. In the last year or two we have seen the development of several drugs (i.e., Mounjaro, Wegovy and Ozempic) in the GLP 1 class that have had impact in one or both of these conditions. This class of drugs has the potential to dramatically impact diabesity with a market size that could reach $100B.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There has also been notable progress in the area of a condition called fatty liver which may affect 25% of the adult American population and particularly in an associated liver condition NASH (Non Alcoholic Steatohepatitus) which is thought to effect up to 6.5% of American </span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">2 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt;line-height:1.35"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">adults with fatty liver. After many years and multiple attempts, we have, in the last year, seen a positive clinical trial (i.e., the MAESTRO_NASH study by Madrigal Pharmaceuticals, Inc.). This Phase III study showed, for the first time, statistically significant benefits in both NASH resolution and fibrosis improvement in a pivotal study. It has reignited the interests of both investors and biopharma companies to NASH, which is a potentially multi-billion dollar market that has heretofore seen few, if any, positive developments.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Merger &#38; Acquisition (M&#38;A) activity also contributes to sentiment in the healthcare space, particularly in the biotech subsector. It is notable that M&#38;A activity is up as we write this letter in late April 2023. Importantly we have recently seen acquisitions of both large (i.e., Horizon Therapeutics plc and Seagen, Inc.) and small (i.e., Prometheus Biosciences, Inc., Bellus Health, Inc., Provention Bio, Inc., Concert Pharmaceuticals, Inc. and CinCor Pharma, Inc.) biotech companies. We are hopeful that this is the start of a longer M&#38;A trend.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">On the Regulatory/Legislative side, we note that In August 2022, President Biden signed into law the Inflation Reduction Act (IRA), which contains several material changes to Medicare reimbursement and drug pricing policies. While some aspects of the law may serve to lower patients' financial burden while also increasing access to medicines, such as a cap on Part D out-of-pocket spending, other portions may alter how and which drugs are developed by the biopharma industry. Most notably, beginning in 2026 Medicare will be able to "negotiate" prices for an increasing number of drugs with high overall Medicare spend that have been on the market for a certain length of time. This may result in companies re-evaluating the costs, risks and benefits of bringing certain medicines to market. Importantly, we may see a shift towards the development of more complex biologic drugs, as the IRA provides 13 years of protection prior to negotiation eligibility compared to only 9 years for oral "small molecule" drugs. Another provision of the law imposes a penalty on any company raising the price of their existing drugs more than the rate of inflation, although the impact of this may be limited given that annual price increases have moderated in recent years. The market has taken these developments in stride, but there may be increasing focus on the impacts of the law once CMS releases the initial list of negotiation-eligible drugs later in 2023.</span></p><p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Overall, despite a challenging macro environment that seems to have held the market back a bit, we see more positives than negatives in the above developments. In the short-term we see the defensive characteristics of healthcare as attractive. In the intermediate and longer-term, we see the underlying fundamentals combined with favorable U.S. population demographics compelling in comparison to most other sectors.</span></p><p style="margin:9pt 0pt 1pt 0pt;text-align:bottom"><span style="font-size:10pt;font-family:Arial, Helvetica">Be well,</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:8" valign="bottom"><img alt="j23125692_ba003.jpg" src="j23125692_ba003.jpg" style="width:186px;height:39px" /> <img alt="j23125692_ba004.jpg" src="j23125692_ba004.jpg" /></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daniel R. Omstead<br />President and Portfolio Manager</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 3</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <p style="margin:8pt 0pt 0pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Fund Essentials</strong></span></p>
  <div style="line-height:1.45">
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Objective of the Fund</strong></span></p>
    <p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Fund's investment objective is to seek current income and long-term capital appreciation.</span></p>
  </div>
  <div style="width:48%;float:left;margin-top:10pt;margin-right:3%">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Description of the Fund</strong></span></p>
    <div style="margin:2pt 0pt 0pt 0pt;line-height:1.60"><span style="font-size:8pt;font-family:Arial, Helvetica">Tekla World Healthcare Fund (THW) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THW. THW employs a versatile growth and income investment strategy investing across all healthcare subsectors and across a company's full capital structure. THW invests at least 40% of AUM in ex-U.S. companies or those with substantial ex-U.S. revenues.</span></div>
    <div style="margin:6pt 0pt 0pt 0pt;text-align:left;line-height:1.60"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Philosophy</strong></span></div>
    <div style="margin:2pt 0pt 0pt 0pt;line-height:1.50"><span style="font-size:8pt;font-family:Arial, Helvetica">Tekla Capital Management LLC, the Investment Adviser to the Fund, believes that:</span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.60"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Aging demographics and adoption of new medical products and services may provide long-term tailwinds for healthcare companies</span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.50"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Opportunities outside the United States may be underappreciated and timely</span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.60"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Investment opportunity spans the globe including biotechnology, healthcare technology, life sciences and medical devices</span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.60"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;The potential for value creation may exist in companies both inside and outside the United States that are commercializing novel technologies</span></div>
  </div>
  <div style="width:48%;float:left;margin-top:10pt;margin-right:0%;line-height:1.60">
    <p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund Overview and Characteristics </strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">as of 3/31/23</span></p>
    <table border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Market Price<sup>1</sup></span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20230531184037380" name="us-gaap:SharePrice" contextRef="C_20230331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.74</ix:nonFraction></strong></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">NAV<sup>2</sup></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20230531184049150" name="us-gaap:NetAssetValuePerShare" contextRef="C_20230331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.64</ix:nonFraction></strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Premium/(Discount)</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20230531184153743" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20221001to20230331" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.70</ix:nonFraction></strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%</strong></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Average 30 Day Volume</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>83,612</strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net Assets</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>479,622,074</strong></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Managed Assets</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>599,622,074</strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Leverage Outstanding</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>120,000,000</strong></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total Leverage Ratio<sup>3</sup></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>20.01</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%</strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ticker</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:99;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW</strong></span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">NAV Ticker</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:99" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>XTHWX</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Commencement of</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Operations Date</span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:99;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6/30/15</strong></span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:85" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Fiscal Year to Date</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Distributions</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Per Share</span></td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:57" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20230531184228957" name="cef:AnnualDividendPayment" contextRef="C_20221001to20230331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.70</ix:nonFraction></strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>

    </table>
    <p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>1</sup></i><i> The closing price at which the Fund's shares were traded on the exchange.</i></span></p>
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>2</sup></i><i> Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</i></span></p>
    <p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>3</sup></i><i> As a percentage of managed assets.</i></span></p>
  </div>
  <div style="margin:8pt 0pt 8pt 0pt;clear:both">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Holdings of the Fund </strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>(Data is based on net assets)</i></span></p>
  </div>
  <div style="width:48%;float:left;margin-top:10pt;margin-right:3%">
    <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset Allocation as of 3/31/23</span></p>
    <p style="margin:0pt 0pt 0pt 0pt"><img alt="j23125692_ba005.jpg" src="j23125692_ba005.jpg" /></p>
  </div>
  <div style="width:48%;float:left;margin-top:10pt;margin-right:0%">
    <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sector Diversification as of 3/31/23</span></p>
    <p style="margin:0pt 0pt 0pt 0pt"><img alt="j23125692_ba006.jpg" src="j23125692_ba006.jpg" /></p>
  </div>
  <div style="clear:both">&#160;</div>
  <div style="margin:8pt 0pt 8pt 0pt">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:7pt;font-family:Times New Roman, Times, serif"><i>This data is subject to change on a daily basis.</i></span></p>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">4 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt">
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Largest Holdings by Issuer</strong></span></div>
    <div style="margin:2pt 0pt 0pt 0pt;text-align:left;line-height:1.45"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>(Excludes Short-Term Investments)</strong></span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.45"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>As of March 31, 2023</i></span></div>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left;line-height:1.45"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></div>
    <table border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td colspan="3" style="padding:11pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:225" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Issuer</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i> &#8211; Sector</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:11pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.6" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>% of Net</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>UnitedHealth Group, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38; Services</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.8</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Johnson &#38; Johnson</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.1</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Pfizer, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.5</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>AbbVie, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Biotechnology</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Eli Lilly &#38; Co.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.9</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>AstraZeneca plc</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.5</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Abbott Laboratories</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Equipment &#38; Supplies</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.5</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Roche Holding AG</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Merck &#38; Co., Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.9</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Novo Nordisk A/S</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.7</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Elevance Health, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38; Services</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.3</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Cigna Corp.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38; Services</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.3</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Amgen, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Biotechnology</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.3</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Thermo Fisher Scientific, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Life Sciences Tools &#38; Services</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.8</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Novartis AG</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.6</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Bristol-Myers Squibb Co.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.4</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Sanofi</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.9</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Illumina, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Life Sciences Tools &#38; Services</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.9</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Bayer AG</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.7</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>IDEXX Laboratories, Inc.</strong></span><span style="font-size:9pt;font-family:Arial, Helvetica"> </span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>&#8211; Health Care Equipment &#38; Supplies</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.6</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>

    </table>
    <p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td colspan="3" style="padding:7pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;line-height:1.6" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>COUNTRY DIVERSIFICATION</strong></span><br /><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>As of March 31, 2023</i></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:7pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.6" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>% of Net</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:7pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.6" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>% of Managed</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United States</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">68.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">54.7</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United States (with substantial ex-U.S. revenue)</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">29.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">23.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Switzerland</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">8.8</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.1</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United Kingdom</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.6</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.5</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Denmark</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.8</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">France</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.4</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Japan</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.8</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.5</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Germany</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.7</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.4</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Australia</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.6</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Netherlands</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.4</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.1</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Ireland</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.3</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.0</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">China</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:170;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Israel</span></p>
          </td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:65;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.1</span></p>
          </td>
          <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:23;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p>
          </td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 5</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.35">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Fund Performance</strong></span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund and Benchmark Performance and Other Influencing Factors</strong></span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">THW is a closed-end fund which invests predominantly in healthcare companies. Subject to regular consideration, the Trustees of THW have instituted a policy of making monthly distributions to shareholders.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund invests in equity and debt of healthcare companies. The Fund seeks to benefit from the earnings growth of the healthcare industry while capturing income. Income is derived from multiple sources including equity dividends, fixed income coupons, real estate investment trust distributions, convertible securities coupons and selective equity covered call writing premiums. In order to accomplish its objectives, THW often holds a majority of its assets in equities. Allocation of assets to various healthcare sectors can vary significantly, as can the percentage of the portfolio which is overwritten. Under normal market conditions, the Fund expects to invest at least 40 percent of its managed assets in companies organized or located outside of the U.S. or companies that do a substantial amount of business outside the U.S. (Foreign Issuers).</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to 20 percent of managed assets, measured at the time of investment, in non-convertible debt of healthcare companies. It may also invest up to 20 percent of managed assets in healthcare REITs. The Fund may also hold up to 30 percent of managed assets in convertible securities and may invest a portion of its assets in restricted securities. In order to generate additional "current" income, THW often sells (or writes) calls against a material portion of its equity assets. The portion of equity assets overwritten can vary, but usually represents less than 20 percent of managed assets. At times, the overwritten portion of assets is materially less than 20 percent of managed assets. The use of covered calls is intended to produce "current" income but may limit upside in bullish markets. The Fund may also use leverage to enhance yield. The Fund may incur leverage up to 20 percent of managed assets at the time of borrowing. "Managed Assets" means the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund's accrued liabilities (other than liabilities representing borrowings for investment purposes).</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund considers investments in companies of all sizes and in all healthcare subsectors, including, but not limited to, biotechnology, pharmaceuticals, healthcare equipment, healthcare supplies, life science tools and services, healthcare distributors, managed healthcare, healthcare technology and healthcare facilities. The Fund expects to invest at least 40 percent of managed assets in companies organized or located outside the United States or companies that do a substantial amount of business outside the United States. The Fund also emphasizes innovation, investing both in public and pre-public venture companies. The Fund considers its pre-public and other restricted investments to be a differentiating characteristic. Among the various healthcare subsectors, THW has considered the biotechnology subsector, including both pre-public and public companies, to be a key contributor to the healthcare sector. The Fund holds biotech assets, including both public and pre-public, often representing 10-25% of net assets.</span></p>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">6 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.35">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There is no commonly published index which matches the investment strategy of THW. With respect to the Fund's equity investments, THW often holds 10-25% of its assets in biotechnology. By contrast, the S&#38;P Global 1200 Healthcare Index<sup>&#174;</sup>* (SGH) consists of approximately 110 global companies representing most or all of the healthcare subsectors in which THW typically invests; biotechnology often represents up to 20% of this index. By contrast, the NASDAQ Biotechnology Index<sup>&#174;</sup>* (NBI) which contains approximately 270 constituents, is much more narrowly constructed. The vast majority of this index is comprised of biotechnology, pharmaceutical and life science tools companies. In recent years, biotechnology has often represented 72-82% of the NBI. Neither the SGH nor NBI indices contain any material amount of pre-public company assets.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The S&#38;P 500<sup>&#174;</sup> Health Care Corporate Bond Index* (SP5HCBIT) measures the performance of U.S. corporate debt issued by constituents in the healthcare sector of the SPX. This index is generally reflective of the debt assets in which THW invests though the Fund invests in the SPX index debt components as well as those of smaller capitalization companies.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The S&#38;P Composite 1500<sup>&#174;</sup> Health Care REITs Index* (S15HCRT) is comprised of U.S. publicly traded REITs in the healthcare sector. This index is generally reflective of the REITs in which THW invests.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Given the circumstances, we present both NAV and stock returns for the Fund in comparison to several commonly published indices. We note that THW is a dynamically configured multi-asset class global healthcare growth and income fund. There is no readily available index comprised of similar characteristics to THW and to which THW can directly be compared. Therefore, we provide returns for a number of indices representing the major components of THW's assets. Having said this, we note that there are no readily available indices representing the covered call strategy employed by THW or the restricted security components of THW.</span></p>
    <p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund Performance for the Period ended March 31, 2023</strong></span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">For the six-month period ended March 31, 2023, the Fund net asset value was up 10.2% and market value up 12.8%, including reinvestment of dividends and distributions. Over the same period the SGH was up 11.2%, the SP5HCBIT was up 7.5%, and the S15HCRT was up 3.5%, including reinvestment of dividends.</span></p>
    <table border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:46" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Period</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:76" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW NAV (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW MKT (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:56" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NBI (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:59" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SGH (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:57" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SPX (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SP5HCBIT (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:74" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>S15HCRT (%)</strong></span></p>
          </td>
          <td colspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:46;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica">6 </span><span style="font-size:9pt;font-family:Arial, Helvetica">month</span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">10.15</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">12.75</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">9.91</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:43;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.25</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">15.60</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.53</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.52</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:46" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica">1 </span><span style="font-size:9pt;font-family:Arial, Helvetica">year</span></td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-4.80</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.36</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-0.14</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:43" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-3.19</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-7.75</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-5.28</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-26.64</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:46;background-color:#cceeff" valign="bottom"><span style="font-size:9pt;font-family:Arial, Helvetica">5 </span><span style="font-size:9pt;font-family:Arial, Helvetica">year</span></td>
          <td colspan="1" style="background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">8.51</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">12.27</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.92</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:43;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">10.61</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.17</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.10</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.71</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:46" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">inception</span></p>
          </td>
          <td colspan="1">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.75</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.22</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.32</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:43" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.71</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.07</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:61" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.75</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom">
            <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.25</span></p>
          </td>
          <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td>
          <td colspan="1" style="width:8">&#160;</td>
        </tr>

    </table>
    <p style="margin:3pt 0pt 9pt 0pt"><span style="font-size:6pt;font-family:Times New Roman, Times, serif"><i>Inception date June 26, 2015</i></span></p>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 7</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.35">
    <p style="margin:10pt 0pt 0pt 0pt;text-align:left"><img alt="j23125692_ba007.jpg" src="j23125692_ba007.jpg" /></p>
    <p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Change in the value of a $10,000 investment</strong></span></p>
    <div style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Cumulative total return from 6/26/2015 to 3/31/2023</span></div>
    <div style="margin:9pt 0pt 5pt 0pt;text-align:left;line-height:1.35"><img alt="j23125692_ba008.jpg" src="j23125692_ba008.jpg" /></div>
    <div style="margin:0pt 0pt 0pt 0pt;line-height:1.55"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>All performance over one-year has been annualized. Performance data quoted represents past performance, which is no guarantee of future results, and current performance may be lower or higher than the figures shown. The NAV total return takes into account the Fund's total annual expenses and does not reflect transaction charges. If transaction charges were reflected, NAV total return would be reduced. All distributions are assumed to be reinvested either in accordance with the dividend reinvestment plan (DRIP) for market price returns or NAV for NAV returns. Until the DRIP price is available from the Plan Agent, the market price returns reflect the reinvestment at the closing market price on the last business day of the month. Once the DRIP is available around mid-month, the market price returns are updated to reflect reinvestment at the DRIP price. The graph and table do not reflect the deduction of taxes a shareholder would pay on fund distributions or the sale of fund shares.</i></span></div>
    <div style="line-height:1.35">
      <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>Risk Adjusted NASDAQ Biotechnology Index</i><i><sup>&#174;</sup></i><i> computed by the Adviser using Bloomberg data for the NBI and applying the Fund's computed 0.90 beta to NBI performance to reflect the Fund's lower historical risk.</i></span></p>
      <p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Portfolio Management Commentary</strong></span></p>
      <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The largest positive contribution to Fund relative performance was company stock selection and an overweight allocation to health care facilities. Company stock selection was most positive in large cap biotechnology companies such as Horizon Therapeutics plc (HZNP) and in healthcare equipment companies such as DexCom, Inc. (DXCM). On December 12, 2022, Amgen, Inc. (AMGN) announced its nearly $28 billion acquisition offer (at a 36% premium) for Horizon, which develops treatments for thyroid eye disease. DexCom, which was up 44% in the period, is a leading provider of continuous glucose monitor devices for diabetes patients and continued its robust sales growth. The Fund had a positive industry allocation effect being overweight facilities including leading provider HCA Healthcare, Inc. (HCA), up 44% in the past six months.</span></p>
    </div>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">8 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.35">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The largest negative contribution to Fund relative performance was company stock selection and foreign exchange hedging. Stock selection resulted in underperformance managed care companies including the fund holding Molina Healthcare, Inc. (MOH), which fell 19% in the past six months. The Fund hedges 50 percent of the foreign currency exposure from international equity positions to reduce portfolio risk. In the past six-months this resulted in losses as foreign currencies like the Euro, up over 10% versus the US Dollar, gained in value following a multi-year period of decline. We also estimate that the venture portfolio returns lagged the benchmark in the past six months detracting from performance.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We also note that interest expenses constituted a significant portion of overall Fund expenses in the reporting period and had a detrimental impact on performance.</span></p>
    <p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Portfolio Highlights as of March 31, 2023</strong></span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Among other investments, Tekla World Healthcare Fund's performance benefited in the past six-month period by the following:</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>CVS Health Corp. (CVS)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a large vertically integrated managed care organization and is one of the largest retail pharmacies and pharmacy benefit managers (PBMs) in the U.S. Recent underperformance has come on the heels of growing PBM political scrutiny and ongoing retail pharmacy reimbursement pressure. Additionally, a recent large PBM customer loss represents a headwind to the Company's 2024 outlook. The Fund benefited from being underweight CVS during this period of underperformance.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Horizon Therapeutics plc (HZNP)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a specialty pharmaceuticals company transitioning to a focused orphan disease business model. With 12 marketed therapies, including first-in-class Tepezza for thyroid eye disease, and a pipeline of over 20 programs in development, Horizon was recently acquired by Amgen for $28 billion. The Fund was overweight Horizon which had a strong positive return following Amgen's acquisition offer in December 2022.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>IDEXX Laboratories, Inc. (IDXX)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading global animal health company providing diagnostics and lab testing services to veterinarians for pets as well as for the livestock, dairy and poultry industry. The Fund benefited from an overweight position in IDEXX as pet healthcare spending remains elevated from pre-pandemic levels, driving superior stock price performance.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Among other examples, Tekla World Healthcare Fund's performance was negatively impacted by the following investments:</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Guardant Health, Inc. (GH)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading precision oncology company focused on using liquid biopsy for cancer detection and diagnostics through its proprietary blood tests, vast data sets and advanced analytics. The Fund has maintained an overweight position in the stock as it underperformed in the six-month period due to disappointing results from its colorectal cancer or CRC screening product. While the accuracy of the Guardant CRC screening test is not best in class, it did meet the bar needed for reimbursement and may see clinical adoption due to its convenience.</span></p>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 9</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.40">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Molina Healthcare, Inc. (MOH)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> provides Medicaid managed care services and has exposure to Medicare and state health insurance exchanges. In 2021 and 2022, Molina saw its Medicaid membership growth accelerate from new contract wins and from a halt in state Medicaid redeterminations during the COVID pandemic. More recently, the stock underperformed in anticipation that some of the membership gains would reverse once state Medicaid redeterminations resume and the Federal Public Health Emergency ends. The Fund was overweight during this period of underperformance.</span></p>
    <p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Roche Holding AG (ROG SW)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading global developer of pharmaceuticals and diagnostics that primarily serve cancer patients. The Company's stock price declined in the six-month period and lagged its peers while the Fund held an overweight position. Stock weakness was partly due to a sales decline of its cancer fighting therapies Avastin and Herceptin which face generic competition. In addition, an experimental treatment in Roche's pipeline for Alzheimer's read out unsuccessfully.</span></p>
  </div>
  <div style="margin:8pt 0pt 8pt 0pt;line-height:1.55">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*The trademarks NASDAQ Biotechnology Index<sup>&#174;</sup>, S&#38;P Global 1200 Health Care Index<sup>&#174;</sup>, S&#38;P Composite 1500<sup>&#174;</sup> Health Care REITs Index, S&#38;P 500<sup>&#174;</sup> Health Care Corporate Bond Index, and S&#38;P 500<sup>&#174;</sup> Index referenced in this report are the property of their respective owners. These trademarks are not owned by or associated with the Fund or its service providers, including Tekla Capital Management LLC.</span></p>
  </div>
  <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">10 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
<p style="margin:8pt 0pt 8pt 0pt"><span style="font-size:19pt;font-family:Arial, Helvetica">Schedule of Investments</span></p><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>March 31, 2023</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> (Unaudited)</i></span></p></div><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Non-Convertible Notes 17.1%</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 0.5%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sanofi, 3.63% due 06/19/28</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:19;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,600,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,536,096</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.4%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endo Dac/Endo Finance LLC/Endo Finco, Inc., 9.50% due 07/31/27 <sup>(a)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">516,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">39,345</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endo Dac/Endo Finance LLC/Endo Finco, Inc., 6.00% due 06/30/28 <sup>(a)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">789,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">59,175</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mallinckrodt International Finance S.A., 10.00% due 06/15/29 <sup>(a)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">997,897</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">545,222</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shire Acquisitions Investments Ireland DAC, 3.20% due 09/23/26</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,500,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,425,758</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,069,500</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United Kingdom 1.0%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc, 3.38% due 11/16/25</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,000,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>4,884,826</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 15.2%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories, 4.75% due 11/30/36</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,652,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,862,695</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc., 4.50% due 05/14/35</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,098,836</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc., 4.45% due 05/14/46</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,705,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,539,982</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc., 3.63% due 05/22/24</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,000,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,971,165</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc., 2.00% due 01/15/32</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,555,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,264,674</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Baxalta, Inc., 4.00% due 06/23/25</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">831,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">813,457</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Becton, Dickinson and Co., 3.73% due 12/15/24</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">328,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">320,642</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co., 3.40% due 07/26/29</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,330,394</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cigna Corp., 3.50% due 06/15/24</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,785,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,731,417</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cigna Corp., 2.38% due 03/15/31</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,697,225</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">CVS Health Corp., 1.88% due 02/28/31</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,448,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,981,547</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DH Europe Finance II Sarl, 3.25% due 11/15/39</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">985,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">820,498</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Elevance Health, Inc., 2.55% due 03/15/31</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,745,272</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">EMD Finance LLC, 3.25% due 03/19/25 <sup>(a)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,000,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,880,344</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GlaxoSmithKline Capital plc, 3.00% due 06/01/24</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,371,574</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GlaxoSmithKline Capital plc, 3.38% due 06/01/29</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,000,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">948,432</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA, Inc., 5.38% due 02/01/25</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,250,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,250,004</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA, Inc., 5.25% due 04/15/25</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">600,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">598,960</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IQVIA, Inc., 5.00% due 05/15/27 <sup>(a)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">710,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">697,639</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson, 2.45% due 03/01/26</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,300,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,129,139</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson, 2.90% due 01/15/28</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,340,278</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Laboratory Corporation of America Holdings, 3.60% due 02/01/25</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,360,926</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medtronic, Inc., 4.38% due 03/15/35</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,675,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,649,896</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc., 2.80% due 05/18/23</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,396,607</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc., 2.75% due 02/10/25</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,463,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,428,043</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novartis Capital Corp., 3.40% due 05/06/24</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,115,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,086,282</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 11</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States (continued)</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Par Pharmaceutical, Inc., 7.50% due 04/01/27 <sup>(a)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:19" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">193,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,898</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc., 3.45% due 03/15/29</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,300,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,111,960</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc., 4.00% due 12/15/36</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,800,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,729,383</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Senior Housing Properties Trust, 4.75% due 05/01/24</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,750,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,576,073</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Syneos Health, Inc., 3.63% due 01/15/29 <sup>(a)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,300,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,893,712</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc., 3.88% due 12/15/28</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,560,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,502,272</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc., 4.20% due 05/15/32</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,060,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,930,273</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zimmer Biomet Holdings, Inc., 4.25% due 08/15/35</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,000,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,391,828</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>72,595,327</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Non-Convertible Notes (Cost $88,162,242)</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>82,085,749</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Convertible Preferreds (Restricted) </strong><strong><sup>(b)</sup></strong><strong> 1.8%</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 0.5%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amolyt Pharma SAS Series C</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">686,916</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,594,215</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Flamingo Therapeutics, Inc. Series A3</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">136,337</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">903,409</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,497,624</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.5%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Priothera Ltd. Series A, 6.00%</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">194,134</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,105,383</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 0.8%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Aristea Therapeutics, Inc. Series B, 8.00%</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">290,187</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,600,004</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endeavor Biomedicines, Inc. Series B, 8.00%</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">424,079</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,999,999</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IO Light Holdings, Inc. Series A2</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">101,839</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">343,706</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>3,943,709</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Convertible Preferreds (Cost $10,955,883)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,546,716</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:6pt .7pt 6pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Common Stocks 104.3%</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Australia 1.6%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">CSL Ltd.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">38,719</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>7,461,700</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Canada 0.0%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fusion Pharmaceuticals, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,378</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">27,815</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fusion Pharmaceuticals, Inc. (Restricted) <sup>(b) (c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,689</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,517</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>40,332</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>China 0.2%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">BeiGene Ltd. ADR <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,114</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">886,690</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">I-Mab ADR <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">38,848</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">134,414</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,021,104</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">12 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Denmark 3.8%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">MorphoSys AG ADR <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">81,867</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">323,375</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novo Nordisk A/S ADR</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">111,323</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,715,942</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>18,039,317</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 1.4%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sanofi ADR</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">123,454</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,718,367</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Germany 1.8%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Affimed N.V. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,456</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bayer AG</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">131,684</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,385,879</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,393,335</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.4%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">ICON plc <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,534</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,395,597</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Perrigo Co. plc</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,882</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">569,687</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,965,284</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Israel 0.2%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Teva Pharmaceutical Industries Ltd. ADR <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,281</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>798,987</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Japan 1.8%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Astellas Pharma, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">44,419</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">629,945</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Daiichi Sankyo Co., Ltd.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">54,075</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,963,846</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Eisai Co., Ltd.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,830</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">386,009</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Hoya Corp.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,682</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,061,720</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">M3, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,436</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">184,871</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Olympus Corp.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,940</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">505,347</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ono Pharmaceutical Co., Ltd.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,330</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">235,859</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Otsuka Holdings Co., Ltd.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,808</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">658,678</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shionogi &#38; Co., Ltd.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,707</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">346,938</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sysmex Corp.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,715</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">241,828</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Takeda Pharmaceuticals Co., Ltd.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,600</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">314,517</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Takeda Pharmaceuticals Co., Ltd. ADR</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">105,073</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,731,603</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Terumo Corp.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,288</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">465,354</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,726,515</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Netherlands 1.4%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">argenx SE ADR <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,509</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,660,603</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Koninklijke Philips N.V.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">109,860</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,015,931</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,676,534</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Switzerland 8.8%</i></strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Lonza Group AG</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,711</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,604,789</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novartis AG ADR</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">136,225</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,532,700</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Roche Holding AG ADR</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">562,829</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,183,048</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Oculis Holding AG (Restricted) <sup>(b)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">304,333</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,988,512</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>42,309,049</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 13</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United Kingdom 4.6%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc ADR <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">242,692</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,845,252</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Smith &#38; Nephew plc ADR <sup>(e)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">181,710</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,071,526</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>21,916,778</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 78.5%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">153,165</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,509,488</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">122,534</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,528,244</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Acadia Healthcare Co., Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">51,920</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,751,220</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Align Technology, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,572</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">859,408</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc. <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">51,124</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,359,227</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ardelyx, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">282,002</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,350,790</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Avantor, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">142,388</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,010,082</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Biogen, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,808</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,673,128</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Biohaven Ltd. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,100</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">178,946</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Boston Scientific Corp. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">145,111</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,259,903</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co. <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">147,326</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,211,165</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Catalent, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,095</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">794,763</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Charles River Laboratories International, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23,664</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,775,869</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Cigna Group <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">40,328</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,305,014</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Community Health Systems, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,700</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">42,630</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Community Healthcare Trust, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,900</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">545,340</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Danaher Corp.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">30,958</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,802,654</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DexCom, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">64,567</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,501,394</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Diversified Healthcare Trust REIT</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">63,841</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">86,185</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Edwards Lifesciences Corp. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">43,150</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,569,800</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Elevance Health, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,373</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,046,189</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Eli Lilly &#38; Co. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">69,036</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23,708,343</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Galera Therapeutics, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">161,709</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">413,975</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Gilead Sciences, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">87,662</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,273,316</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Global Medical REIT, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,229</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,304,816</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GSK plc ADR</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41,852</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,489,094</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Guardant Health, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">53,333</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,250,126</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA Healthcare, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18,103</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,773,399</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Healthcare Realty Trust, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">149,567</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,891,130</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Healthpeak Properties, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">83,601</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,836,714</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Humana, Inc. <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,425</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,575,461</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IDEXX Laboratories, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,748</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,875,260</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Illumina, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">39,207</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,117,588</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Intuitive Surgical, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">29,795</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,611,729</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IQVIA Holdings, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,104</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,407,365</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">182,963</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,359,265</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">14 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States (continued)</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Laboratory Corporation of America Holdings</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,189</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,649,300</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">LTC Properties, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">46,903</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,647,702</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mallinckrodt plc <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">35,048</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">255,503</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">McKesson Corp.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,501</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,094,931</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medical Properties Trust, Inc. <sup>(e)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">145,186</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,193,429</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medtronic plc</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">79,482</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,407,839</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">149,510</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,906,369</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Moderna, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,416</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,214,009</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Molina Healthcare, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,583</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,900,807</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">National Health Investors, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,442</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">229,118</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Omega Healthcare Investors, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">71,075</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,948,166</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">475,473</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,399,298</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Physicians Realty Trust</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">291,309</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,349,243</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">R1 RCM, Inc. <sup>(c)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">124,297</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,864,455</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Regeneron Pharmaceuticals, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,845</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,802,661</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">ResMed, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,089</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,399,290</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sabra Health Care REIT, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,781</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,043,982</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Stryker Corp. <sup>(e)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,321</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,659,156</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Thermo Fisher Scientific, Inc. <sup>(d)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23,270</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,412,130</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">61,534</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">29,080,353</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Universal Health Realty Income Trust</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,183</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">393,684</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ventas, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">66,681</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,890,621</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Veradigm, Inc. <sup>(c)</sup></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,363</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,179,237</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vertex Pharmaceuticals, Inc. <sup>(c) (d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,833</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,303,573</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Welltower, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41,484</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,973,988</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">West Pharmaceutical Services, Inc.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,370</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,167,604</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zimmer Biomet Holdings, Inc.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23,986</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,098,991</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zoetis, Inc. <sup>(d)</sup></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">29,308</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,878,024</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>376,392,483</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Common Stocks (Cost $495,708,240)</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>500,459,785</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Short-Term Investments 2.6%</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Repurchase Agreement, Fixed Income Clearing Corp., </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">repurchase value $7,531,904, 1.44%, dated 03/31/23, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">due 04/03/23 (collateralized by U.S. Treasury Note 2.625%, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">due 04/15/25, market value $7,681,712)</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:19;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,531,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,531,000</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 15</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">State Street Institutional U.S. Government Money Market Fund, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Institutional Class, 4.67%, <sup>(f)</sup></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,998,623</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:50;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,998,623</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Short-Term Investments (Cost $12,529,623)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>12,529,623</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Investments Before Milestone Interest 125.8%</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(Cost $607,355,988)</strong></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>603,621,873</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Interests</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Milestone Interest (Restricted) </strong><strong><sup>(b)</sup></strong><strong> 0.0%</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Biotechnology 0.0%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Rainier Therapeutics Milestone Interest</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:50" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">131,009</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Milestone Interest (Cost $143,115)</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>131,009</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Number of Contracts</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(100 shares each)/</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Notional Amount ($)</strong></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;width:480" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Option Contracts Written 0.0%</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:480;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Call Option Contracts Written 0.0%</i></strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories Apr23 110 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">228/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,508,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(3,192</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc. Apr23 155 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">31/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(480,500)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(15,655</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc. Apr23 255 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">66/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,683,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,640</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc Apr23 70 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">364/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,548,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(37,492</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Biogen, Inc. Apr23 300 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(480,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,344</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Boston Scientific Corp. Apr23 50 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">280/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,400,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(25,200</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co. Apr23 75 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">218/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,635,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(436</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cigna Corp. Apr23 310 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">39/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,209,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(390</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DexCom, Inc. Apr23 125 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">70/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(875,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5,950</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Edwards Lifesciences Corp. Apr23 80 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">61/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(488,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(21,960</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Eli Lilly &#38; Co. Apr23 350 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">103/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(3,605,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(45,423</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA Healthcare, Inc. Apr23 270 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(486,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(9,504</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Humana, Inc. Apr23 530 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(742,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,540</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IDEXX Laboratories, Inc. Apr23 510 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,173,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(21,160</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Illumina, Inc. Apr23 220 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">42/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(924,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(55,440</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Intuitive Surgical, Inc. Apr23 250 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">44/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,100,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(53,240</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson Apr23 165 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">181/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,986,500)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(3,077</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Molina Healthcare, Inc. Apr23 310 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(434,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,720</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc. Apr23 45 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">577/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,596,500)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,731</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">ResMed, Inc. Apr23 220 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(418,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,885</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Thermo Fisher Scientific, Inc. Apr23 570 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(855,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(23,700</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc. Apr23 510 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">91/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4,641,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(11,375</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">16 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:218" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Number of Contracts</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(100 shares each)/</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Notional Amount ($)</strong></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vertex Pharmaceuticals, Inc. Apr23 310 Call</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:87;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16/</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(496,000)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,720</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zoetis, Inc. Apr23 180 Call</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:87" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18/</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(324,000)</span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(270</span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);line-height:1.7" valign="bottom"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Total Option Contracts Written </i></strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(Premiums received ($579,144))</strong></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(370,044</strong></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:9pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Investments 125.8% (Cost $606,919,959)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:9pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td><td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>603,382,838</strong></span></p></td><td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:218;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Other Liabilities in Excess of Assets (25.8)%</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:3pt .7pt 0pt 0pt;width:156;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(123,760,764</strong></span></p></td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:3pt .7pt 0pt 0pt;text-align:left;width:218" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net Assets 100%</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:3pt .7pt 0pt 0pt;width:156" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p></td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:59" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>479,622,074</strong></span></p></td><td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><div style="line-height:1.50"><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">The percentage shown for each investment category in the Schedule of Investments is based on net assets.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(a)&#160;&#160;Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(b)&#160;&#160;Security fair valued using significant unobservable inputs. See Investment Valuation and Fair Value Measurements.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(c)&#160;&#160;Non-income producing security.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(d)&#160;&#160;A portion of security is pledged as collateral for call options written.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(e)&#160;&#160;All or a portion of this security is on loan as of March 31, 2023. See Note 1.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(f)&#160;&#160;This security represents the investment of cash collateral received for securities lending and is a registered investment company advised by State Street Global Advisors. The rate shown is the annualized seven-day yield as of March 31, 2023.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">ADR&#160;&#160;American Depository Receipt</span></p><p style="margin:6pt 0pt 6pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The following forward contracts were held as of March 31, 2023:</span></p></div><table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%"><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Description</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Counterparty</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Settlement<br />Date</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Currency</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Settlement<br />Value (in USD)</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Current<br />Value</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;line-height:1.7" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Unrealized<br />Gain/(Loss)</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="27" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255)" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Contracts Sold:</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Australian Dollar</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">4,572,304 AUD</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,060,019</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,058,978</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,041</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">British Pound</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">9,440,375 GBP</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,633,625</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,651,458</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(17,833</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Danish Krone</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">48,474,501 DKK</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,045,462</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,067,693</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(22,231</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Euro</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">11,686,116 EUR</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,654,299</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,690,602</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(36,303</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:1%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Israeli Sheqel</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">4,457,647 ILS</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,250,544</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,240,297</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,247</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Japanese Yen</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">523,322,125 JPY</span></p></td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,020,056</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,955,063</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">64,993</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:15%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Swiss Franc</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:19%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/28/23</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:14%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">20,140,361 CHF</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:12%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">22,085,824</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">22,069,424</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;text-align:right;width:9%" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,400</span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;width:1%" valign="bottom">&#160;</td><td colspan="1" style="width:1%">&#160;</td></tr><tr><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255)">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:rgb(204, 238, 255)">&#160;</td><td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>61,733,515</strong></span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>16,314</strong></span></p></td><td colspan="1" style="padding:0pt 0.7pt 0pt 0pt;border-right:none;border-left:none;border-image:initial;border-top:1pt solid windowtext;border-bottom:2.25pt double windowtext;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 17</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  <div style="line-height:1.35">
    <p style="margin:8pt 0pt 8pt 0pt"><span style="font-size:19pt;font-family:Arial, Helvetica">Financial statements</span></p>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF ASSETS AND LIABILITIES </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>MARCH 31, 2023 (Unaudited)</i></span></p>
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>ASSETS</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments, at value (cost $607,355,988), including $4,985,118 of securities loaned</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">603,621,873</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Milestone interests, at value (cost $143,115)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">131,009</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total investments</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>603,752,882</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cash</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,053</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency, at value (cost $7,040)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,053</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividends and interest receivable</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,957,112</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Securities lending income receivable</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">656</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Prepaid expenses</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">96,512</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Prepaid offering expenses (see Note 5)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">271,108</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized appreciation on forward currency contracts</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">92,681</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total assets</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>607,180,057</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>LIABILITIES</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized depreciation on forward currency contracts</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">76,367</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued advisory fee</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">486,800</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued investor support service fees</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">24,340</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued shareholder reporting fees</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">64,125</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued trustee fees</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,490</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Payable upon return of securities loaned</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,998,623</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Loan payable</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120,000,000</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Options written, at value (premium received $579,144)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">370,044</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest payable</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,253,760</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued other</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">279,434</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total liabilities</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>127,557,983</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Commitments and Contingencies (see Notes 1 and 4)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:98;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET ASSETS</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>479,622,074</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SOURCES OF NET ASSETS CONSIST OF</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Shares of beneficial interest, par value $.01 per share, unlimited number of shares authorized, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">amount paid in on 37,945,713 shares issued and outstanding</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">379,457</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Additional paid-in-capital</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">523,878,937</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total distributable earnings (loss)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(44,636,320</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total net assets (equivalent to $12.64 per share based on <ix:nonFraction id="Fxbrl_20230601110456264" name="cef:OutstandingSecurityHeldShares" contextRef="C_20221001to20230331" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">37,945,713</ix:nonFraction> </strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">shares outstanding)</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:21;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>479,622,074</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:10pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p>
    </div>
    <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">18 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
    <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF OPERATIONS </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>SIX-MONTHS ENDED MARCH 31, 2023 (Unaudited)</i></span></p>
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>INVESTMENT INCOME</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend income (net of foreign tax of $247,983)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,985,099</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Non-cash dividend income</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">418,590</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest and other income</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,404,666</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Securities lending</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,907</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total investment income</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,813,262</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>EXPENSES</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest expense</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,121,892</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Advisory fees</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,967,080</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investor support service fees</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">148,354</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Custodian fees</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">82,620</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustees' fees and expenses</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">80,251</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Administration fees</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">65,784</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Legal fees</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">65,368</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shareholder reporting</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">63,486</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Professional services fees</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41,912</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Transfer agent fees</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,310</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other (see Note 2)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">169,584</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total expenses</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,820,641</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net investment loss</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(7,379</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>REALIZED AND UNREALIZED GAIN (LOSS)</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized gain (loss) on</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,376,737</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Closed or expired option contracts written</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,726,367</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency transactions</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,346</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward contracts</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5,201,583</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized loss</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(4,848,607</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net change in unrealized appreciation (depreciation) on</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:98" valign="bottom">&#160;</td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">49,843,484</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Milestone interests</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,511</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Option contracts written</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(29,675</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">30,743</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward contracts</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">685,635</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net change in unrealized appreciation (depreciation)</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>50,522,676</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized and unrealized gain (loss)</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>45,674,069</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net increase in net assets resulting from operations</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>45,666,690</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:10pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p>
    </div>
    <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 19</span></p>
    <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENTS OF CHANGES IN NET ASSETS</strong></span></p>
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td colspan="3" style="padding:8pt .7pt 0pt 0pt;width:225" valign="bottom">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:106" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Six-months ended</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">March 31, 2023 </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">(Unaudited)</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:97" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Year ended</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">September 30, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">2022</span></td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:436;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>INCREASE (DECREASE) IN NET ASSETS FROM OPERATIONS</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income gain (loss)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,379</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,947,208</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain (loss)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4,848,607</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,964,884</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Change in net unrealized appreciation (depreciation)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">50,522,676</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(90,748,168</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net increase (decrease) in net assets resulting from operations</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>45,666,690</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(62,836,076</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:436" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>DISTRIBUTIONS TO SHAREHOLDERS (See Note 1)</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Distributions</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(26,370,226</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(31,069,521</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Return of capital</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(21,264,321</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total distributions</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(26,370,226</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(52,333,842</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:436" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CAPITAL SHARE TRANSACTIONS</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds from at-the-market offering (274,984 and 0 shares, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">respectively)</span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,950,593</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses in connection with the at-the-market offering ( See Note 5)</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,478</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Reinvestment of distributions (150,459 and 265,352 shares, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">respectively)</span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,039,745</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,830,775</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total capital share transactions</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>5,982,860</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>3,830,775</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net increase (decrease) in net assets</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>25,279,324</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(111,339,143</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:18;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:436" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET ASSETS</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Beginning of period</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:67;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">454,342,750</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:59;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">565,681,893</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:225" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>End of period</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:67" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>479,622,074</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:59" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>454,342,750</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:18" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:10pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p>
    </div>
    <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">20 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
    <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF CASH FLOWS </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>SIX-MONTHS ENDED MARCH 31, 2023 (Unaudited)</i></span></p>
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Purchases of portfolio securities</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">104,638,870</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Securities lending income</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,732</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net maturities of short-term investments</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,613,018</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales of portfolio securities</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">116,841,693</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds from option contracts written</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,388,929</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest income received</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,747,063</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend income received</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,075,827</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other operating receipts (expenses paid)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,636,905</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash provided from operating activities</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>20,395,487</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:387;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cash distributions paid</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(24,330,481</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net proceeds from at-the-market offering</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,950,593</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses in connection with the at-the-market offering</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,478</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash used for financing activities</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(20,387,366</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET INCREASE IN CASH</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,121</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH AT BEGINNING OF YEAR</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>985</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH AT END OF SIX MONTHS</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>9,106</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>*</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="7" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">RECONCILIATION OF NET INCREASE IN NET ASSETS</strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">RESULTING FROM OPERATIONS TO NET CASH</strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">PROVIDED FROM OPERATING ACTIVITIES</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net increase in net assets resulting from operations</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">45,666,690</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Purchases of portfolio securities</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(104,638,870</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net maturities of short-term investments</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,613,018</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales of portfolio securities</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">116,841,693</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds from option contracts written</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,388,929</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accretion of discount</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">347,717</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized loss on investments, options, foreign currencies and forwards</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,848,607</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in net unrealized (appreciation) depreciation on investments, options, foreign </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">currencies and forwards</span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(50,522,676</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in dividends and interest receivable</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(333,182</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in securities lending income receivable</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(175</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Decrease in accrued other expenses</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(201,808</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in interest payable</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">497,335</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in prepaid expenses and other assets</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:21" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(111,791</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash provided from operating activities</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:21;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>20,395,487</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:289" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Supplemental disclosure: Cash paid for interest </span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,624,557</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>

      </table>
      <p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*&#160;&#160;Includes: $7,053 foreign currency.</span></p>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p>
    </div>
    <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 21</span></p>
    <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Financial highlights</span></p>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td colspan="3" style="padding:0pt .7pt 1.5pt 0pt;width:117" valign="bottom">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt 0.7pt 1.5pt 0pt;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Six-months </strong></span><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">ended</strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">March 31, 2023</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="19" style="padding:0pt .7pt 1.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:419" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Years ended September 30,</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:117" valign="bottom">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:110" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(Unaudited)</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:79" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2022</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:76" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2021</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:78" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2020</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:78" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2019</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:76" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2018</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:654;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>OPERATING PERFORMANCE PER SHARE</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Net asset value per share, </strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Beginning of period</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>12.11</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>15.18</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>14.14</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>13.51</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>15.24</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>15.55</strong></span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income <sup>(1)</sup></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>(2)</sup></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.05</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.08</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.10</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.06</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.11</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized and </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">unrealized gain (loss)</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.22</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4.52</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.36</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.93</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.40</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.96</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total increase (decrease) </strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>from investment operations</strong></span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1.22</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:30;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(4.47</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2.44</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2.03</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(0.34</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1.07</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="top">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Distributions to </strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">shareholders from</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:110" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:79" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:76" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:78" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:78" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:76" valign="top">&#160;</td>
            <td colspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.70</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.33</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.14</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.05</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.19</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.60</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized capital gains</span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.50</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Return of capital (tax basis)</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:30;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.57</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.26</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.35</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.21</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.80</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total distributions</strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(0.70</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:30" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1.40</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1.40</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1.40</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1.40</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1.40</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Increase resulting from</strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">shares repurchased </strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(1)</sup></strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:30;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><sup>(2)</sup></strong></span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0.01</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0.02</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Increase resulting from </strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">at-the-market offering </strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(1)</sup></strong></span></p>
            </td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0.01</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt" valign="bottom">
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Net asset value per share,</strong></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">end of period</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20230531221358456" name="us-gaap:NetAssetValuePerShare" contextRef="C_20230331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.64</ix:nonFraction></strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:30;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>12.11</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>15.18</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>14.14</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>13.51</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:24;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>15.24</strong></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt">Per share market value, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt">end of period</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531221149029" name="us-gaap:SharePrice" contextRef="C_20230331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.74</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.86</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.45</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.33</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.44</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.03</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Total investment return </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">at market value</span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.75</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%*</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(13.65</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26.00</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18.14</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6.80</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6.91</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Total investment return </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">at net asset value</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.15</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:30" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%*</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(11.94</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.91</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.97</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.10</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8.66</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:654;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>RATIOS</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income to average </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">net assets</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:30" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>(3)</sup>**</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.37</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.53</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.68</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.45</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.78</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses to average net assets</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.82</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%**</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.91</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.74</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.16</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.53</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.28</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses, excluding interest </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">expense, to average net assets</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.53</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:30" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%**</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.53</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.51</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.57</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.59</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:24" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:20" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.57</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:22" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:654;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SUPPLEMENTAL DATA</strong></span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Net assets at end of period </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">(in millions)</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">480</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">454</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">566</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">427</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">407</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">463</span></p>
            </td>
            <td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Portfolio turnover rate</span></p>
            </td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.45</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%*</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">43.87</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">69.37</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">48.11</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">55.17</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">54.60</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Senior securities (loan facility) </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">outstanding (in millions)</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184656843" name="cef:SeniorSecuritiesAmt" contextRef="C_20230331" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184949168" name="cef:SeniorSecuritiesAmt" contextRef="C_20220930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184951894" name="cef:SeniorSecuritiesAmt" contextRef="C_20210930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184706797" name="cef:SeniorSecuritiesAmt" contextRef="C_20200930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184708901" name="cef:SeniorSecuritiesAmt" contextRef="C_20190930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184711640" name="cef:SeniorSecuritiesAmt" contextRef="C_20180930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117;background-color:#cceeff" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset coverage ratio on revolving </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">credit facility at period end</span></td>
            <td colspan="1" style="background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">500</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:30;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">479</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">571</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">455</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">440</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:24;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">486</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:22;background-color:#cceeff" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p>
            </td>
            <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:117" valign="bottom"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset coverage per $1,000 on </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">revolving credit facility at </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">period end</span></td>
            <td colspan="1">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:60" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184727098" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20230331" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,997</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:30" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:35" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184957071" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20220930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,786</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184750037" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20210930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,714</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184752956" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20200930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,554</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184755513" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20190930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,396</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:24" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:34" valign="bottom">
              <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20230531184758054" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20180930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,861</ix:nonFraction></span></p>
            </td>
            <td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td>
            <td colspan="1" style="width:8">&#160;</td>
          </tr>

      </table>
      <p style="margin:3pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*&#160;&#160;Not annualized.</span></p>
      <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">**&#160;&#160;Annualized.</span></p>
      <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(1)&#160;&#160;Computed using average shares outstanding.</span></p>
      <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(2)&#160;&#160;Amount represents less than $0.005 per share.</span></p>
      <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(3)&#160;&#160;Rounds to less than 0.05%.</span></p>
    </div>
    <div style="margin:8pt 0pt 8pt 0pt">
      <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p>
    </div>
    <p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">22 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p>
    <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
  </div>
<div style="line-height:1.35"><p><span style="font-family:Arial,Helvetica,sans-serif"><span><span style="font-size:19pt">Notes to financial statements</span></span></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> MARCH 31, 2023 (Unaudited)</i></span></p><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>(1)&#160;&#160;Organization and Significant Accounting Policies</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Tekla World Healthcare Fund (the Fund) is a Massachusetts business trust formed on March 5, 2015 and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund commenced operations on June 30, 2015. The investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry (including equity securities and debt securities). The Fund invests primarily in securities of public and private companies believed by the Fund's Investment Adviser, Tekla Capital Management LLC (the Adviser), to have significant potential for above-average growth.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The preparation of these financial statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual results could differ from these estimates and such differences could be material. The following is a summary of significant accounting policies followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America (GAAP). The Fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board Accounting Standards Codification 946. Events or transactions occurring after March 31, 2023, through the date that the financial statements were issued, have been evaluated in the preparation of these financial statements.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The market value of the Fund's investments will move up and down, sometimes rapidly and unpredictably, based upon political, regulatory, market, economic and social conditions, as well as developments that impact specific economic sectors, industries or segments of the market, including conditions that directly relate to the issuers of the Fund's investments, such as management performance, financial condition and demand for the issuers' goods and services. The Fund is subject to the risk that geopolitical events will adversely affect global economies and markets. War, terrorism and related geopolitical events have led, and in the future may lead, to increased short-term market volatility and may have adverse long-term effects on global economies and markets. Likewise, natural and environmental disasters and epidemics or pandemics may be highly disruptive to economies and markets. This means that the Fund may lose money on its investment due to unpredictable drops in a security's value or periods of below-average performance in a given security or in the securities market as a whole.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Investment Valuation</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price as of the close of trading, generally 4 p.m. Eastern Time. The Fund holds securities, currencies and other assets that are denominated in a foreign currency. The Fund will normally use the currency exchange rates as </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 23</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">of 4:00 p.m. (Eastern Time) when valuing such assets. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Puts and calls generally are valued at the close of regular trading on the securities or commodities exchange on which they are primarily traded. Options on securities generally are valued at their last sale price in the case of exchange traded options or, in the case of OTC-traded options, the average of the last sale price as obtained from two or more dealers unless there is only one dealer, in which case that dealer's price is used. Forward foreign currency contracts are valued on the basis of the value of the underlying currencies at the prevailing forward exchange rates. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by the Adviser also using fair valuation policies and procedures approved by the Trustees described below. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">24 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these financial statements.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Milestone Interests</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund holds financial instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The milestone interests were received as part of the proceeds from the sale of one private company. Any payments received are treated as a reduction of the cost basis of the milestone interests with payments received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the milestone interests provide for payments at various stages of the development of Rainier Therapeutics' principal product candidate as of the date of the sale.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The following is a summary of the impact of the milestone interests on the financial statements as of and for the six-months ended March 31, 2023:</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:231;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Statement of Assets and Liabilities, Milestone interests, at value</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:231" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Statement of Assets and Liabilities, Total distributable earnings</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">12,106</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:231;background-color:#cceeff" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Statement of Operations, Change in unrealized appreciation (depreciation)</span><br /><span style="font-size:8pt">on milestone interests</span></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">7,511</span></span></p></td><td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Options on Securities</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">An option contract is a contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund's obligation under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price or in the absence of a sale, the mean between the closing bid and asked prices. Gain or loss is recognized when the option contract expires, is exercised or is closed.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">If the Fund writes a covered call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the market value of the underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential inability of counterparties to meet the terms of </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 25</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">their contracts. The Fund's maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may arise upon entering into option contracts including the risk that an illiquid secondary market will limit the Fund's ability to close out an option contract prior to the expiration date and that a change in the value of the option contract may not correlate exactly with changes in the value of the securities or currencies hedged.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">All options on securities and securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the securities subject to the option or may maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the option. The prices provided by a pricing service take into account broker dealer market price quotations for institutional size trading in similar groups of securities, yields or securities with similar characteristics, security quantity, maturity, coupon and other security characteristics as well as any developments related to the specific securities. The pricing service may use a matrix approach, regarding securities with similar characteristics to determine the valuation for a security. When the Fund writes a put option, this means that the Fund will maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price of the option.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The average number of outstanding call options written six-months ended March 31, 2023 was 3,489.</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Derivatives not accounted<br />for as hedging instruments<br />under ASC 815</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="7" style="padding:0pt .7pt 0pt 0pt;width:0" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="7" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Statement of Assets and<br />Liabilities Location</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="7" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Statement of Operations Location</strong></span></span><br />&#160;</p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Equity Contracts<br />&#160;<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="7" style="padding:0pt .7pt 0pt 0pt;text-align:center;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Liabilities, options<br />written, at value<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><br /><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$370,044<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Net realized gain (loss) on<br />closed or expired option<br />contracts written</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$1,726,367</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Change in unrealized<br />appreciation (depreciation)<br />on option contracts written</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($29,675)</span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Forward Currency<br />Contracts<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="7" style="padding:0pt .7pt 0pt 0pt;text-align:center;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Unrealized appreciation<br />on forward currency<br />contract</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><br /><br /><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$92,681</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Net realized gain (loss)<br />on forward contracts<br />&#160;</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($5,201,583)</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#160;<br />&#160;<br />&#160;</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Unrealized depreciation<br />on forward currency<br />contracts</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><br /><br /><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($76,367)</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Change in unrealized<br />appreciation (depreciation)<br />on forward contracts</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;width:0" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$685,635</span></span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Forward Contracts</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">26TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. Forward contracts may also be used to attempt to protect the value of the Fund's existing holdings of foreign securities. Forward contracts may also be used for non-hedging purposes to pursue the Fund's investment objective. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Average notional amount of forward contracts for the six-months ended March 31, 2023 was $61,620,558.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Investment Transactions and Income</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Investment transactions are recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the ex-dividend date, less any foreign taxes withheld. Upon notification from issuers, some of the dividend income received may be redesignated as a reduction of cost of the related investment if it represents a return of capital. Stock dividends are reflected as non-cash dividend income on the Statement of Operations.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The aggregate cost of purchases and proceeds from sales of investment securities (other than short-term investments) for the six-months ended March 31, 2023 totaled $101,984,839 and $115,564,086, respectively.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Securities Lending</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund may lend its securities to approved borrowers to earn additional income. The Fund receives cash collateral from the borrower and the initial collateral received by the Fund is required to have a value of at least 102% of the current value of the loaned securities traded on U.S. exchanges, and a value of at least 105% for all other securities. The Fund will invest its cash collateral in State Street Institutional U.S. Government Money Market Fund (SAHXX), which is registered with the Securities and Exchange Commission (SEC) as an investment company. SAHXX invests substantially all of its assets in the State Street U.S. Government Money Market Portfolio. The Fund will receive the benefit of any gains and bear any losses generated by SAHXX with respect to the cash collateral.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund has the right to recall loaned securities on demand. If a borrower fails to return loaned securities when due, then the lending agent is responsible and indemnifies the Fund for the lent securities. The lending agent uses the collateral received from the borrower to purchase replacement securities of the same issue, type, class and series of the loaned securities. If the value of the collateral is less than the purchase cost of replacement </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 27</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">securities, the lending agent is responsible for satisfying the shortfall but only to the extent that the shortfall is not due to any decrease in the value of SAHXX.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Although the risk of loss on securities lent is mitigated by receiving collateral from the borrower and through lending agent indemnification, the Fund could experience a delay in recovering securities or could experience a lower than expected return if the borrower fails to return the securities on a timely basis. The Fund receives compensation for lending its securities by retaining a portion of the return on the investment of the collateral and compensation from fees earned from borrowers of the securities. Securities lending income received by the Fund is net of fees retained by the securities lending agent. Net income received from SAHXX is a component of securities lending income as recorded on the Statement of Operations.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Obligations to repay collateral received by the Fund are shown on the Statement of Assets and Liabilities as Payable upon return of securities loaned and are secured by the loaned securities. As of March 31, 2023 the Fund loaned securities valued at $4,985,118 and received $4,998,623 of cash collateral.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Repurchase Agreements</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">In managing short-term investments the Fund may from time to time enter into transactions in repurchase agreements. In a repurchase agreement, the Fund's custodian takes possession of the underlying collateral securities from the counterparty, the market value of which is at least equal to the principal, including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the agreement, realization and/or retention of the collateral by the Fund may be delayed. The Fund may enter into repurchase transactions with any broker, dealer, registered clearing agency or bank. Repurchase agreement transactions are not counted for purposes of the limitations imposed on the Fund's investment in debt securities.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Distribution Policy</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Pursuant to a Securities and Exchange Commission exemptive order the Fund may make periodic distributions that include capital gains as frequently as 12 times in any one taxable year in respect of its common shares, and the Fund has implemented a managed distribution policy (the Policy) providing for monthly distributions at a rate set by the Trustees. Under the current Policy, the Fund intends to make monthly distributions at a rate of $0.1167 per share to shareholders of record. If taxable income and net long-term realized gains exceed the amount required to be distributed under the Policy, the Fund will at a minimum make distributions necessary to comply with the requirements of the Internal Revenue Code. The Policy has been established by the Trustees and may be changed by them without shareholder approval. The Trustees regularly review the Policy and the frequency and </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">28 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">distribution rate considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Share Repurchase Program</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">In March 2023, the Trustees approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July 14, 2024. Prior to this renewal, in March 2022, the Trustees approved the renewal of the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2023. The share repurchase program is intended to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the Fund's net asset value.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">During the six-months ended March 31, 2023 and the year ended September 30, 2022, the Fund did not repurchase any shares through the repurchase program.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Federal Taxes</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">It is the Fund's policy to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders substantially all of its taxable income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision is required.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">As of March 31, 2023, the Fund had no uncertain tax positions that would require financial statement recognition or disclosure. The Fund's federal tax returns are subject to examination by the Internal Revenue Service for a period of three years.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Distributions</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund records all distributions to shareholders on the ex-dividend date. Such distributions are determined in conformity with income tax regulations, which may differ from GAAP. These differences include temporary and permanent differences from losses on wash sale transactions, distribution re-designations, return of capital distributions, passive foreign investment company transactions, foreign currency gains and losses, distributions from real estate investment trusts, losses disallowed on straddles, forward contracts mark-to-market, premium amortization accruals and book to tax difference due to merger. Reclassifications are made to the Fund's capital accounts to reflect income and gains available for distribution under income tax regulations.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The cumulative distributions paid this fiscal year-to-date are currently estimated to be from the following sources: net investment income, net realized short-term capital gains, and return of capital or other capital source. The amounts and sources of distributions are only estimates and not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment </span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 29</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">experience during the remainder of its fiscal year and may be subject to changes based on tax regulations.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Statement of Cash Flows</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The cash and restricted cash amount shown in the Statement of Cash Flows is the amount included in the Fund's Statement of Assets and Liabilities and represents cash and restricted cash on hand at March 31, 2023.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Commitments and Contingencies</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">Under the Fund's organizational documents, its officers and Trustees may be indemnified against certain liabilities and expenses arising out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Loan Payable</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund maintains a $125,000,000 line of credit with the Bank of Nova Scotia (the Line of Credit) which expires on January 24, 2024. As of March 31, 2023, the Fund had drawn down $120,000,000 from the Line of Credit, which was the maximum borrowing outstanding during the period. Between October 1, 2022 through January 27, 2023, the Fund was charged interest at the rate of 0.75% plus a SOFR Adjustment plus the relevant SOFR rate. Starting January 28, 2023, the Fund is charged interest at the rate of 0.95% plus a SOFR Adjustment plus the relevant SOFR rate. The Fund is also charged a commitment fee on the daily unused balance of the line of credit at the rate of 0.10% (per annum). Per the Line of Credit agreement, the Fund paid an upfront fee of 0.05% on the total line of credit balance, which is being amortized through January 28, 2023. The Fund pledges its investment securities as the collateral for the line of credit per the terms of the agreement. The weighted average interest rate and the average outstanding loan payable for the period from October 1, 2022 to March 31, 2023 were 5.2088% and $120,000,000, respectively. The stated carrying amount of the line of credit approximates its fair value based upon the short term nature of the borrowings and the interest rates being based upon the market terms. The borrowings under the line of credit would be considered as Level 2 in the fair value hierarchy (See Note 3) at March 31, 2023.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>Investor Support Services</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund has retained Destra Capital Advisors LLC (Destra) to provide investor support services in connection with the ongoing operation of the Fund. The Fund pays Destra a fee in an annual amount equal to 0.05% of the average aggregate daily value of the Fund's Managed Assets pursuant to the investor support services agreement.</span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">30 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>(2)&#160;&#160;Investment Advisory and Other Affiliated Fees</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund has entered into an Investment Advisory Agreement (the Advisory Agreement) with the Adviser. Pursuant to the terms of the Advisory Agreement, the Fund pays the Adviser a monthly fee at the rate when annualized of 1.00% of the average daily value of the Fund's Managed Assets. Managed Assets means the total assets of the Fund minus the Fund's liabilities other than the loan payable.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund has entered into a Services Agreement (the Agreement) with the Adviser. Pursuant to the terms of the Agreement, the Fund reimburses the Adviser for certain services related to a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the six-months ended March 31, 2023, these payments amounted to $35,380 and are included in the Other category of expenses in the Statement of Operations, together with insurance and other expenses incurred to unaffiliated entities. Expenses incurred pursuant to the Agreement as well as certain expenses paid for by the Adviser are allocated to the Fund in an equitable fashion as approved by the Trustees or officers of the Fund who are also officers of the Adviser.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund pays compensation to Independent Trustees in the form of a retainer, attendance fees and additional compensation to Board and Committee chairpersons. The Fund does not pay compensation directly to Trustees or officers of the Fund who are also officers of the Adviser.</span></span></p><p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>(3)&#160;&#160;Fair Value Measurements</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">For the six-month period ended March 31, 2023, there were no transfers between levels.</span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 31</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The following is a summary of the levels used as of March 31, 2023 to value the Fund's investments.</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Assets at Value</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:97" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Level 1</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:91" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Level 2</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Level 3</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:97" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Total</strong></span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:482;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Non-convertible Notes</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">France</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,536,096</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,536,096</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Ireland</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,069,500</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,069,500</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United Kingdom</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">4,884,826</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">4,884,826</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United States</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">72,595,327</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">72,595,327</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:482" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Convertible Preferreds</strong></span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">France</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,497,624</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,497,624</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Ireland</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,105,383</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,105,383</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United States</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3,943,709</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3,943,709</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:482" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Common Stocks</strong></span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Australia</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">7,461,700</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">7,461,700</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Canada</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">27,815</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">12,517</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">40,332</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">China</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,021,104</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,021,104</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Denmark</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">18,039,317</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">18,039,317</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">France</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6,718,367</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6,718,367</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Germany</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">8,393,335</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">8,393,335</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Ireland</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,965,284</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,965,284</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Israel</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">798,987</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">798,987</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Japan</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">8,726,515</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">8,726,515</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Netherlands</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6,676,534</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6,676,534</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Switzerland</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">40,320,537</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,988,512</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">42,309,049</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United Kingdom</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">21,916,778</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">21,916,778</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United States</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">376,392,483</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">376,392,483</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Short-term Investments</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">4,998,623</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">7,531,000</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">12,529,623</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Milestone Interest</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Total</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>503,457,379</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>91,617,778</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>8,677,725</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>603,752,882</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:482;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Assets</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Forward Currency Contracts</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">92,681</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">92,681</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:482;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Liabilities</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Forward Currency Contracts</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(76,367</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(76,367</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Options Contracts Written</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">370,044</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">370,044</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:96" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Total</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>($</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>370,044</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>)</strong></span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>16,314</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>&#8212;</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>($</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>353,730</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>)</strong></span></span></p></td><td colspan="1" style="width:8">&#160;</td></tr></table></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">32 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:58" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Investments in</strong></span><span style="font-size:7pt"><strong>Securities</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:85" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Balance as of</strong></span><span style="font-size:7pt"><strong>September 30,</strong></span><span style="font-size:7pt"><strong>2022</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:98" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Net realized</strong></span><span style="font-size:7pt"><strong>gain (loss) and</strong></span><span style="font-size:7pt"><strong>change in</strong></span><span style="font-size:7pt"><strong>unrealized</strong></span><span style="font-size:7pt"><strong>appreciation</strong></span><span style="font-size:7pt"><strong>(depreciation)</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:78" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Cost of</strong></span><span style="font-size:7pt"><strong>purchases</strong></span><span style="font-size:7pt"><strong>and</strong></span><span style="font-size:7pt"><strong>conversions</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:90" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Proceeds</strong></span><span style="font-size:7pt"><strong>from</strong></span><span style="font-size:7pt"><strong>sales and</strong></span><span style="font-size:7pt"><strong>conversions</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:69" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Net</strong></span><span style="font-size:7pt"><strong>transfers</strong></span><span style="font-size:7pt"><strong>into</strong></span><span style="font-size:7pt"><strong>(out of)</strong></span><span style="font-size:7pt"><strong>Level 3</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Balance</strong></span><span style="font-size:7pt"><strong>as of </strong></span><span style="font-size:7pt"><strong>March 31,</strong></span><span style="font-size:7pt"><strong>2023</strong></span></span></td><td colspan="1">&#160;</td></tr><tr><td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:595;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Convertible Preferred</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">France</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">960,713</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">($</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">71,584</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,608,495</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,497,624</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Ireland</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,902,611</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">202,772</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,105,383</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Switzerland</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,047,583</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(336,172</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(1,711,411</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United States</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3,943,709</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(182</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">182</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3,943,709</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:595" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Milestone Interest</strong></span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">United States</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:57;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">138,520</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(7,511</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:18;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">)</span></span></p></td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:22;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:50;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:18;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">&#8212;</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Total</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:57" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>8,993,136</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>($</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>212,677</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>)</strong></span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>1,608,677</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:22" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>($</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:50" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>1,711,411</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;width:18" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>)</strong></span></span></p></td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>&#8212;</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:49" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>8,677,725</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="23" style="padding:2.5pt .7pt 3pt 0pt;text-align:left;width:510;background-color:#cceeff" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Net change in unrealized appreciation (depreciation) from </span><br /><span style="font-size:8pt">investments still held as of March 31, 2023 </span></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;text-align:right;width:49;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">123,495</span></span></p></td><td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table><p style="margin:6pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:6pt .7pt 2pt 0pt;width:88" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:79" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Fair Value at</strong></span><span style="font-size:7pt"><strong>March 31,</strong></span><span style="font-size:7pt"><strong>2023</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:74" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Valuation Technique</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:90" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Unobservable Input</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:111" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Range</strong></span><span style="font-size:7pt"><strong>(Weighted Average)</strong></span></span></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:88;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Convertible Preferred</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:51;background-color:#cceeff" valign="top"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">8,546,716</span><br /><span style="font-size:8pt">&#160;</span></span></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="top">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:74;background-color:#cceeff" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Transaction price</span><br /><span style="font-size:8pt">&#160;</span></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:74;background-color:#cceeff" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">(a)</span><br /><span style="font-size:8pt">Probability of events</span></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:95;background-color:#cceeff" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">N/A</span><br /><span style="font-size:8pt">&#160;</span></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:88" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>Milestone Interest</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:51" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:74" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Probability adjusted</span><br /><span style="font-size:8pt">value</span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:90" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Probability of events</span><br /><span style="font-size:8pt">Timing of events</span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:95" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">39.00%-99.00% (65.13%)</span><br /><span style="font-size:8pt">1.50-12.50 (4.11) years</span></span></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:88;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:51;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>8,677,725</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:74;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>&#160;</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:90;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>&#160;</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:111;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>&#160;</strong></span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr></table><p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt">(a) There is no quantitative information to provide as this method of measure is investment specific.</span></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>(4)&#160;&#160;Private Companies and Other Restricted Securities</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund may invest in private companies and other restricted securities if these securities would currently comprise 10% or less of Managed Assets. The value of these securities represented 2% of the Fund's Managed Assets at March 31, 2023.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">At March 31, 2023, the Fund had commitments of $1,003,008 relating to additional investments in two private companies.</span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 33</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at March 31, 2023. The Fund on its own does not have the right to demand that such securities be registered.</span></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:146" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Security</strong><strong><sup>#</sup></strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:107" valign="bottom"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Acquisition</strong></span><span style="font-size:7pt"><strong>Date</strong></span></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:81" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Cost</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Arial, Helvetica, sans-serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Carrying Value&#160;</strong></span><span style="font-size:7pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">per</strong></span></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Arial, Helvetica, sans-serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Unit</strong></span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:81" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt"><strong>Value</strong></span></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Amolyt Pharma SAS Series C Cvt. Pfd</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">01/25/23</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,608,363</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:19;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2.32</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">$</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,594,215</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Aristea Therapeutics, Inc. Series B Cvt. Pfd</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">07/27/21</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,600,004</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">5.51</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,600,004</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Flamingo Therapeutics, Inc. Series A3 Cvt. Pfd</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">04/21/20, 10/28/20</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3,142,774</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6.63</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">903,409</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Endeavor Biomedicines, Inc. Series B Cvt. Pfd</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">01/21/22</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,002,482</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">4.72</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,999,999</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Fusion Pharmaceuticals, Inc. Common</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">09/20/22</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">0</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3.39</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">12,517</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">IO Light Holdings, Inc. Series A2 Cvt. Pfd</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">04/30/20, 05/17/21, 09/15/21&#8224;</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">337,063</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">3.38</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">343,706</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Oculis Holding AG Common</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">03/06/23</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,558,401</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">6.53</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">1,988,512</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Priothera Ltd. Series A Cvt. Pfd</span></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">10/07/20,10/19/21</span></span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,265,198</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">10.84</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">2,105,384</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:146;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">Rainier Therapeutics Milestone Interest</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:107;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">09/28/21</span></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">143,115</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:19;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:58;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009.00</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:20;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;width:53;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt">131,009</span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:146" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:107" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>13,657,400</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;width:85" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>$</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;width:53" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:8pt"><strong>10,678,755</strong></span></span></p></td><td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt">&#160;&#160;#&#160;&#160;See Schedule of Investments and corresponding footnotes for more information on each issuer.</span></span></p><p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:7pt">&#160;&#160;&#8224;&#160;&#160;Interest received as part of a corporate action for a previously owned security.</span></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt"><strong>(5)&#160;&#160;At-the-Market Offering</strong></span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">The Fund has a registration statement on file with the SEC, initially effective on December 6, 2022, authorizing the Fund to issue shares through an At-the-Market Offering (ATM) having an aggregate value of up to $150,000,000. The offering costs associated with the Fund's ATM offering are approximately $278,586 of which $7,478 were charged to paid-in-capital upon the issuance of associated shares.</span></span></p><p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:10pt">On December 14, 2022, the Fund entered into a distribution agreement with Foreside Fund Services, LLC (Foreside), pursuant to which the Fund may offer and sell up to $150,000,000 of shares from time to time, through Foreside as its agent, in transactions deemed to be at the market as defined in Rule 415 under the Securities Act of 1933, as amended (the Offering). Under the Distribution Agreement, Foreside may enter into sub-placement agent agreements with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December 14, 2022 (the Sub-Placement Agent Agreement), with UBS Securities LLC (UBS) relating to the shares to be offered under the Distribution Agreement. During the period ended on March 31, 2023, 274,984 shares were sold under this agreement for $3,950,593 (net of commissions to Foreside and UBS of $39,906).</span></span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">34 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always;margin-bottom:0pt" /></div><div style="line-height:1.35;margin-top:0pt"><p style="margin:8pt 0pt 8pt 0pt"><span style="font-size:19pt;font-family:Arial, Helvetica">INVESTMENT ADVISORY AGREEMENT APPROVAL</span></p><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Investment Advisory Agreement (the Advisory Agreement) between the Fund and the Adviser continues in effect so long as its continuance is approved at least annually by (i) the Trustees of the Fund and (ii) a majority of the Trustees of the Fund who are not interested persons (the Independent Trustees), by vote cast in person at a meeting called for the purpose of voting on such approval.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">After considering the matter in a meeting held on March 16, 2023, the Board, and the Independent Trustees voting separately, determined that the terms of the Advisory Agreement are fair and reasonable and approved the continuance of the Advisory Agreement as being in the best interests of the Fund and its shareholders. In making its determination, the Board considered materials that were specifically prepared by the Adviser and by an independent data provider at the request of the Board and Fund counsel for purposes of the contract review process, including comparisons of (i) the Fund's performance to a blend of equity, debt and REIT benchmarks and to a peer universe of other investment companies, (ii) the Fund's expenses and expense ratios to those of a peer group of other investment companies, and (iii) the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers. The Trustees took into account that substantially all of the Adviser's business consists of providing investment management services to Tekla World Healthcare Fund, Tekla Life Sciences Investors, Tekla Healthcare Investors and Tekla Healthcare Opportunities Fund and the Adviser does not derive any significant benefit from its relationship with the Fund other than receipt of advisory fees pursuant to the Advisory Agreement, market research and potential marketing exposure for the Adviser. The Board also received and reviewed information throughout the year about the portfolio performance, the investment strategy, the portfolio management team and various fees and expenses of the Fund. In their deliberations, the Independent Trustees had the opportunity to meet privately without representatives of the Adviser present and were represented throughout the process by counsel to the Independent Trustees and the Fund.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In approving the Advisory Agreement, the Board considered, among other things, the nature, extent, and quality of the services to be provided by the Adviser, the investment performance of the Fund and the Adviser, the costs of services provided and profits realized by the Adviser and its affiliates, and whether fee levels reflect any economies of scale for the benefit of Fund shareholders and the extent to which economies of scale would be realized as the Fund grows. The Board reviewed information about the foregoing factors and considered changes, if any, in such information since its previous approval. The Board also evaluated the financial strength of the Adviser and the capability of the personnel of the Adviser, specifically the strength and background of its investment analysts. Fund counsel provided the Board with the statutory and regulatory requirements for approval and disclosure of investment advisory agreements. The Board, including the Independent Trustees, evaluated all of the foregoing and, considering all factors together, determined in the exercise of its business judgment that the continuance of the Advisory Agreement is in the best interests of the Fund and its </span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 35</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">shareholders. The following provides more detail on certain factors considered by the Trustees and the Board's conclusions with respect to each such factor.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><span style="text-decoration:underline">The nature, extent and quality of the services to be provided by the Adviser.</span> On a regular basis the Board considers the roles and responsibilities of the Adviser as a whole, along with specific portfolio management, support and trading functions the Adviser provides to the Fund. The Trustees considered the nature, extent and quality of the services provided by the Adviser to the Fund. The Trustees continue to be satisfied with the quality and value of the investment advisory services provided to the Fund by the Adviser, and, in particular, the management style and discipline followed by the Adviser and the quality of the Adviser's research, trading, portfolio management, compliance and administrative personnel. The Trustees also took into account the Adviser's significant investment in its business through the addition of portfolio management and administrative staff over the last several years and the Adviser's commitment to continue to build out its infrastructure as future circumstances require.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><span style="text-decoration:underline">The investment performance of the Fund and the Adviser.</span> On a regular basis the Board reviews performance information of the Fund and discusses the Fund's investment strategy with the Adviser. The Trustees reviewed performance information for the Fund for the one-, three- and five-year periods ended December 31, 2022 as compared to a blend of the S&#38;P Global 1200 Health Care Index<sup>&#174;</sup> (SGH), the S&#38;P 500<sup>&#174;</sup> Health Care Corporate Bond Index (SP5HCBIT) and the S&#38;P Composite 1500<sup>&#174;</sup> Health Care REITs Index (S15HCRT) (Blended Benchmark) and a peer universe of other investment companies identified by an independent service provider engaged by the Independent Trustees. The Trustees noted that the performance information reviewed reflects a view of the Fund's performance only as of a certain date, and that the results might be significantly different if a different date was selected to generate the performance information. Additionally, the Trustees recognized that longer periods of performance for the Fund may be adversely and disproportionately affected by significant underperformance in one more recent period, and that such underperformance may be caused by a small number of investment decisions or positions.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The objective of the Fund is to provide both growth and income to investors by using a variety of healthcare assets. Growth, in large part, is to be provided by the Fund's ownership of the stock of a broad mix of healthcare companies. Such breadth is to be provided by representative ownership of stock in most or all of ten major healthcare subsectors represented in the SGH. Income is to be provided by (i) ownership of a variety of assets including but not limited to a) dividend producing stocks of traditional healthcare companies and healthcare-related REITS, b) the corporate debt of a variety of healthcare companies and (ii) premium income from selling covered call options associated with healthcare companies. The Fund is also required to maintain at least 40% of assets in companies located or incorporated outside of the U.S. or that do substantial business outside of the U.S. The </span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">36 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Trustees considered that the performance associated with owning such a complex mix of assets by the Fund is likely to produce periods when the performance of the Fund would likely depart from the return associated with a single equity index. The Trustees thus considered that there may be periods when the Fund's NAV performance could be greater or lesser than that of relevant indices. The Trustees considered that determining such an exact combination of returns is difficult or impossible, given the general lack of appropriate component equity, debt, REIT, covered call and other indices.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Trustees noted the Fund's strong absolute performance as of December 31, 2022. In particular, the Trustees noted that on a net asset value basis, the Fund returned -7.64% for the one-year period and had annualized returns of .86% for the three-year period and .27% for the five-year period. The Trustees also noted that on a net asset value basis, as of December 31, 2022, the Fund slightly underperformed the Blended Benchmark for the one-, three- and five-year periods. The Trustees also noted that as of December 31, 2022, the Fund outperformed the peer universe average for the one-year period, slightly underperformed the peer universe average for the five-year period and underperformed the peer universe average for the three-year period.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In considering the Fund's relative performance, the Trustees recognized that the Fund's unique strategy presents challenges when comparing the Fund's performance to a benchmark or group of comparable funds. In particular, the Trustees observed that the Fund's strategy contemplates ownership of a variety of healthcare-related asset classes. The Trustees noted that, as a result, all other things being equal, in periods when one asset class performs relatively better than another asset class, the Fund might be expected to underperform a particular benchmark and/or the peer universe and vice versa. Additionally, the Trustees noted that unlike the indices comprising the blended benchmark and most of the peer universe, the Fund may maintain a meaningful allocation to venture and restricted securities. In light of these differences, the Trustees recognized the more limited usefulness of these performance comparisons for the Fund.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Trustees concluded they continue to be satisfied with the investment performance of the Fund and the Adviser.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><span style="text-decoration:underline">The costs of services to be provided and profits to be realized by the Adviser from its relationship with the Fund.</span> The Trustees considered the various services provided by the Adviser to the Fund and reviewed comparative information regarding the expenses and expense ratios of the Fund and a peer group of other investment companies identified by an independent service provider engaged by the Independent Trustees. The Trustees noted that the Adviser's fees are within the range of fees presented in the comparative information and noted that the Fund maintains a meaningful allocation to venture and restricted securities, a portfolio management service that can warrant higher management fees than those charged by the Adviser to the Fund. The Trustees also considered financial information provided by the </span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 37</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Adviser, including financial statements of the Adviser and a comparison of the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Trustees noted that the fees charged by the Adviser are within a reasonable range of fees as compared to fees charged by other investment advisers for similar services, and the services provided by the Adviser and the amounts paid under the Advisory Agreement are at least comparable to the services rendered and fees charged by others for similar services to warrant a finding that fees to be paid by the Fund are fair. Based on the information provided to and evaluated by the Trustees, the Trustees concluded that the fees charged by the Adviser are fair and reasonable in light of the quality and nature of the services provided by the Adviser and that the profitability of the Adviser's relationship with the Fund has not been excessive.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><span style="text-decoration:underline">Whether fee levels reflect economies of scale and the extent to which economies of scale would be realized as the Fund grows.</span> The Trustees considered the advisory fee schedule in the Advisory Agreement and noted that it does not provide for breakpoints that might reduce the effective fee to the extent the Fund's net assets should increase. The Trustees noted that although the Fund has a closed-end structure and any significant growth generally occurs through appreciation in the value of the Fund's investment portfolio, the Fund had commenced an at-the-market offering in January 2023 and the Board would have an opportunity to evaluate any economies of scale generated by this offering in connection with future renewals of the Advisory Agreement.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">38 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PRIVACY NOTICE:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> If you are a registered shareholder of the Fund, the Fund and Tekla Capital Management LLC, the Fund's investment adviser, may receive nonpublic personal information about you from the information collected by the transfer agent from your transactions in Fund shares. Any nonpublic personal information is not disclosed to third parties, except as permitted or required by law. In connection with servicing your account and effecting transactions, the information received may be shared with the investment adviser and non-affiliates, including transfer agents, custodians or other service companies. Access to your nonpublic personal information is restricted to employees who need to know that information to provide products or services to you. To maintain the security of your nonpublic personal information, physical, electronic, and procedural safeguards are in place that comply with federal standards. The policies and practices described above apply to both current and former shareholders.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">If your Fund shares are held in "street name" at a bank or brokerage, we do not have access to your personal information and you should refer to your bank's or broker's privacy policies for a statement of the treatment of your personal information.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>FOR MORE INFORMATION:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A description of the Fund's proxy voting policies and procedures and information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available (i) without charge, upon request by calling 1-800-451-2597; (ii) by writing to Tekla Capital Management LLC at 100 Federal Street, 19th Floor, Boston, MA 02110; (iii) on the Fund's website at www.teklacap.com; and (iv) on the SEC's website at www.sec.gov.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's proxy committee (Proxy Committee) identifies any potential conflicts of interest. Each potential conflict must be addressed in a manner that will be in the best interest of the Fund and its shareholders. If any potential conflict is identified the Proxy Committee consults with the Fund's counsel. Where conflicts of interest arise between the Fund's shareholders, on the one hand, and those of the Adviser, the Fund's principal underwriter, or any affiliated person on the other hand, the Adviser may convene an ad-hoc committee to debate the conflict and to give a ruling on a preferred course of action. If the ad-hoc committee determines that the Adviser, the Fund's principal underwriter, or any affiliated person has a conflict of interest in any instance, the Adviser's Chief Compliance Officer shall disclose the conflict to the Board and seek voting instructions.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Adviser may cause the proxies to be voted in accordance with the recommendations of an independent third-party service provider that the Adviser may use to assist in voting proxies.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's complete Schedule of Investments for the first and third quarters of its fiscal year will be filed with the SEC on Form N-PORT. These will also be available on the Fund's website at www.teklacap.com or the SEC's website at www.sec.gov.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT 39</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">You can find information regarding the Fund at the Fund's website, www.teklacap.com. The Fund regularly posts information to its website, including information regarding daily share pricing, distributions, press releases and links to the Fund's SEC filings. The Fund currently publishes and distributes quarterly fact cards, which include performance, portfolio holdings and sector information for each fiscal quarter. These fact cards will be available on the Fund's website and by request from the Fund's marketing and investor support services agent, Destra Capital Advisors LLC, at 1-877-855-3434.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>DISTRIBUTION POLICY:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund has a managed distribution policy as described in the Notes to Financial Statements. For more information contact your financial adviser.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>SHARE REPURCHASE PROGRAM:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> In March 2023, the Trustees reauthorized the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2024.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PORTFOLIO MANAGEMENT:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy Gasperoni, M.B.A., Ph.D., Ashton L. Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, Jack Liu, M.B.A., Ph.D., Christopher Seitz, M.B.A., Loretta Tse, Ph.D.; and Graham Attipoe, M.B.A., M.D. are members of a team that analyzes investments on behalf of the Fund. Dr. Omstead exercises ultimate decision making authority with respect to investments.</span></p><p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>HOUSEHOLDING:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A number of banks, brokers and financial advisers have instituted "householding". Under this practice, which has been approved by the SEC, only one copy of shareholder documents may be delivered to multiple shareholders who share the same address and satisfy other conditions. Householding is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. If you do not want the mailing of your shareholder documents to be combined with those of other members of your household, please contact your bank, broker or financial adviser.</span></p></div><p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">40 TEKLA WORLD HEALTHCARE FUND | SEMIANNUAL REPORT</span></p></div><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="line-height:1.35"><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Tekla World Healthcare Fund</span></p><p style="margin:7pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">New York Stock Exchange Symbol: THW<br />NAV Symbol: XTHWX</span></p><p style="margin:7pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">100 Federal Street, 19th Floor<br />Boston, Massachusetts 02110<br />617-772-8500<br />www.teklacap.com</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Officers</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daniel R. Omstead, Ph.D., President<br />Laura Woodward, CPA, Chief Compliance Officer,<br />Secretary and Treasurer</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Trustees</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Jeffrey A. Bailey</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Kathleen L. Goetz</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Rakesh K. Jain, Ph.D.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Thomas M. Kent, CPA</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daniel R. Omstead, Ph.D.</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">W. Mark Watson, CPA</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Adviser</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Tekla Capital Management LLC</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Administrator &#38; Custodian</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">State Street Bank and Trust Company</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Transfer Agent</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Computershare, Inc.</span></p><p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Legal Counsel</strong></span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Dechert LLP</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Shareholders with questions regarding share transfers may call</span></p><p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:14pt;font-family:Arial, Helvetica"><strong>1-800-426-5523</strong></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daily net asset value may be obtained from<br />our website (</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>www.teklacap.com</i></span><span style="font-size:10pt;font-family:Arial, Helvetica">)</span></p></div><hr style="height:2px;text-align:center;width:100%;background-color:gray" /></div></div><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0">&#xa0;</p><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. CODE OF ETHICS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. AUDIT COMMITTEE FINANCIAL EXPERT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. INVESTMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Registrant&#x2019;s Schedule of Investments
is included as part of the Report to Shareholders filed under Item 1 of this form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES
FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT
COMPANIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT
INVESTMENT COMPANY AND AFFILIATED PURCHASERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Period</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(a)&#xa0;Total&#xa0;No.<br /> of&#xa0;Shares<br /> Purchased&#xa0;(1)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(b)&#xa0;Average<br /> Price&#xa0;Paid&#xa0;per<br /> Share</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(c)&#xa0;Total&#xa0;No.<br /> of&#xa0;Shares<br /> Purchased&#xa0;as<br /> Part&#xa0;of<br /> Publicly<br /> Announced&#xa0;Plans<br /> or&#xa0;Programs</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(d)&#xa0;Maximum&#xa0;No.<br /> of&#xa0;Shares&#xa0;that<br /> May&#xa0;Yet&#xa0;Be<br /> Purchased&#xa0;Under<br /> the&#xa0;Plans&#xa0;or<br /> Programs</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font: bold 10pt Times New Roman, Times, Serif; text-indent: -10.1pt; padding-left: 10.1pt">Month #1 (Oct.&#xa0;1, 2022 &#x2014; Oct.&#xa0;31, 2022)</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -10.1pt; padding-left: 10.1pt">Month #2 (Nov.&#xa0;1, 2022 &#x2014; Nov.&#xa0;30, 2022)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -10.1pt; padding-left: 10.1pt">Month #3 (Dec.&#xa0;1, 2022 &#x2014; Dec.&#xa0;31, 2022)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -10.1pt; padding-left: 10.1pt">Month #4 (Jan.&#xa0;1, 2023 &#x2014; Jan.&#xa0;31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -10.1pt; padding-left: 10.1pt">Month #5 (Feb.&#xa0;1, 2023 &#x2014; Feb.&#xa0;28, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt">Month #6 (Mar.&#xa0;1, 2023 &#x2014; Mar.&#xa0;31, 2023)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,493,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td>On December&#xa0;3, 2015, the share repurchase program was announced, which has been subsequently reviewed and approved by
the Board of Trustees. On March&#xa0;17, 2022, the Trustees approved the renewal of the repurchase program allowing the Registrant
to repurchase up to 12% of its outstanding shares in the open market for a one year period ending July&#xa0;14, 2023. On March&#xa0;16, 2023, the Trustees approved the renewal of the repurchase program allowing the Registrant to repurchase up to 12% of its outstanding
shares in the open market for a one year period ending July&#xa0;14, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no material changes to the procedures by which
the shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees, where those changes were implemented after
the Registrant last provided disclosure in response to the requirements of Item 7(d)(2)(ii)(G)&#xa0;of Schedule 14A, or this Item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 36.2pt"></td><td style="width: 20.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td>In the opinion of the principal executive officer and principal financial officer, based on their evaluation which took place
within 90 days of this filing, the Registrant&#x2019;s disclosure controls and procedures are adequately designed and are operating
effectively to ensure (i)&#xa0;that material information relating to the Registrant, including its consolidated subsidiaries, is
made known to them by others within those entities, particularly during the period in which this report is being prepared; and
(ii)&#xa0;that information required to be disclosed by the registrant on Form&#xa0;N-CSR is recorded, processed, summarized and
reported within the time period specified in the Securities and Exchange Commission&#x2019;s rules&#xa0;and forms.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td>There were no changes in the Registrant&#x2019;s internal control over financial reporting that occurred during the Registrant&#x2019;s
most recent fiscal half-year that have materially affected or that are reasonably likely to materially affect the Registrant&#x2019;s
internal control.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 12. Disclosure
of Securities Lending Activities for Closed-End Management Investment Companies.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to this semi-annual filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"></td><td style="text-align: justify">(a)(1) <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
of Ethics - </span>Not applicable to this semi-annual filing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"></td><td style="text-align: justify"><a href="tm2312569d1_ex99-cert.htm" style="-sec-extract: exhibit">(a)(2) Separate certifications of the Principal Executive and Financial Officers as required
                                                by Rule&#xa0;30a-2(a)&#xa0;under the 1940 Act and Section&#xa0;302 of the Sarbanes-Oxley Act of 2002 are attached hereto
                                                (Exhibit&#xa0;1 and 2).</a></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"></td><td style="text-align: justify"><a href="tm2312569d1_ex99-section19a.htm" style="-sec-extract: exhibit">(a)(3) Notices to Fund&#x2019;s shareholders in accordance with Investment Company Act
                                                Section&#xa0;19(a)&#xa0;and Rule&#xa0;19a-1 (Exhibit&#xa0;3).</a></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"></td><td style="text-align: justify"><a href="tm2312569d1_ex99-906cert.htm" style="-sec-extract: exhibit">(b) Certifications pursuant to Section&#xa0;906 of the Sarbanes-Oxley Act of 2002 are
                                                attached hereto (Exhibit&#xa0;4).</a></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEKLA
    WORLD HEALTHCARE FUND</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By (Signature and
    Title)*</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel R. Omstead</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel R. Omstead,
    President</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">6/6/23</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td></tr>
<tr>
    <td style="width: 5%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 16%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 33%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 46%"><span style="font-size: 10pt">&#xa0;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By (Signature and
    Title)*</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Laura Woodward</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laura Woodward,
    Treasurer</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">6/6/23</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#xa0;</span></td></tr>
<tr>
    <td style="width: 5%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 16%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 33%"><span style="font-size: 10pt">&#xa0;</span></td>
    <td style="width: 46%"><span style="font-size: 10pt">&#xa0;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#xa0;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Print the name and title of each signing officer under his
or her signature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: Last --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>2
<FILENAME>tm2312569d1_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;99.CERT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;1: CERTIFICATION OF PRINCIPAL
EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Daniel R. Omstead, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD>I have reviewed this report on Form&nbsp;N-CSR of TEKLA WORLD HEALTHCARE FUND;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements
are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this
report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the registrant&rsquo;s auditors and the audit
committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize, and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">6/6/23</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel R. Omstead</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel R. Omstead</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;2: CERTIFICATION OF PRINCIPAL
FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Laura Woodward, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD>I have reviewed this report on Form&nbsp;N-CSR of TEKLA WORLD HEALTHCARE FUND;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements
are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this
report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the registrant&rsquo;s auditors and the audit
committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize, and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">6/6/23</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Laura Woodward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Laura Woodward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.SECTION19(A)
<SEQUENCE>3
<FILENAME>tm2312569d1_ex99-section19a.htm
<DESCRIPTION>EXHIBIT 99.SECTION19(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.Section 19(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT 3: SECTION 19(a)
NOTICE TO FUND&rsquo;S SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">T</FONT><FONT STYLE="font-size: 14pt">EKLA
</FONT><FONT STYLE="font-size: 18pt">W</FONT><FONT STYLE="font-size: 14pt">ORLD </FONT><FONT STYLE="font-size: 18pt">H</FONT><FONT STYLE="font-size: 14pt">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt">F</FONT><FONT STYLE="font-size: 14pt">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;December 30, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated amounts of the current
distribution, paid December 30, 2022, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment
income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The
Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current <BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage <BR> Breakdown <BR> of Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Cumulative<BR> Distributions for the <BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage Breakdown <BR> of the Total Cumulative<BR> Distributions for the<BR> </B></FONT><B><FONT STYLE="font-size: 10pt">Fiscal Year to Date<SUP>1</SUP></FONT></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.3329</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.3501</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below includes information relating to the Fund&rsquo;s performance
based on its NAV for certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from November 30, 2017 through November 30, 2022</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">9.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of November 30, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through November 30, 2022<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of November 30, 2022<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not draw any conclusions about the Fund&rsquo;s investment
performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The composition of this and subsequent distribution
may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of
the net unrealized depreciation of portfolio securities and net realized losses on sale of securities is -$6,909,543, of which $1,618,823
represents net unrealized depreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts and sources of distributions reported in this 19(a) Notice
are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting
purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject to changes
based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions
for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1</TD><TD STYLE="text-align: justify">The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through November 30, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla World Healthcare Fund<BR>
CUSIP: 87911L108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tekla
Capital Management LLC<BR>
100 Federal Street, 19</FONT><SUP>th</SUP> <FONT STYLE="font-size: 10pt">Floor<BR>
Boston, Massachusetts 02110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03QFIA</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">002CSND6AC</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">T</FONT><FONT STYLE="font-size: 14pt">EKLA
</FONT><FONT STYLE="font-size: 18pt">W</FONT><FONT STYLE="font-size: 14pt">ORLD </FONT><FONT STYLE="font-size: 18pt">H</FONT><FONT STYLE="font-size: 14pt">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt">F</FONT><FONT STYLE="font-size: 14pt">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January 31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated amounts of the current
distribution, paid January 31, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment
income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The
Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage<BR> Breakdown<BR> of Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Cumulative<BR> Distributions for the<BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage Breakdown<BR> of the Total Cumulative<BR> Distributions for the<BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.4496</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.4668</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below includes information relating to the Fund&rsquo;s performance
based on its NAV for certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from December 31, 2017 through December 31, 2022</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.27</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of December 31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through December 31, 2022<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of December 31, 2022<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not draw any conclusions about the Fund&rsquo;s investment
performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The composition of this and subsequent distribution
may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of
the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $4,626,970, of which $11,115,111
represents net unrealized appreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts and sources of distributions reported in this 19(a) Notice
are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting
purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject to changes
based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions
for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1</TD><TD>The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through December 31, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla World Healthcare Fund<BR>
CUSIP: 87911L108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla Capital Management LLC<BR>
100 Federal Street, 19<SUP>th</SUP> Floor<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: center">03QY6A</TD><TD STYLE="text-align: justify; width: 85%">002CSND7E0</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">T</FONT><FONT STYLE="font-size: 14pt">EKLA
</FONT><FONT STYLE="font-size: 18pt">W</FONT><FONT STYLE="font-size: 14pt">ORLD </FONT><FONT STYLE="font-size: 18pt">H</FONT><FONT STYLE="font-size: 14pt">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt">F</FONT><FONT STYLE="font-size: 14pt">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;February 28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table sets forth the estimated amounts of the
current distribution, paid February 28, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources:
net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital
source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Percentage <BR>
Breakdown</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Total Cumulative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Percentage Breakdown<BR>
 of the Total Cumulative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Current <BR>
Distribution</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">of Current <BR>
Distribution</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Distributions for the<BR>
    Fiscal Year to Date<SUP>1</SUP></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Distributions for the<BR>
 Fiscal Year to Date<SUP>1</SUP></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.5663</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.5835</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The table below includes information relating to the Fund&rsquo;s performance based on its NAV for certain periods. &nbsp; &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from January 31, 2018 through January 31, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.39</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of January 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cumulative total return at NAV for the fiscal year, through
    January 31, 2023<SUP>2</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.97</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cumulative fiscal year-to-date distribution rate expressed
    as a percentage of NAV as of January 31, 2023<SUP>1</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">You should not draw any conclusions about the Fund&rsquo;s
investment performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The composition of this and subsequent distributions may vary
from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net
unrealized depreciation of portfolio securities and net realized losses on sale of securities is $ -9,747,871, of which $ 4,297,773 represents
net unrealized depreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The amounts and sources of distributions reported in this
19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for
tax reporting purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject
to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these
distributions for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1</TD><TD>The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through January 31, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Tekla World Healthcare Fund</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">CUSIP: 87911L108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tekla
Capital Management LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">100
Federal Street, 19</FONT><SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: center">03RN5B</TD><TD STYLE="text-align: justify; width: 85%">002CSND9DC</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">T</FONT><FONT STYLE="font-size: 14pt">EKLA
</FONT><FONT STYLE="font-size: 18pt">W</FONT><FONT STYLE="font-size: 14pt">ORLD </FONT><FONT STYLE="font-size: 18pt">H</FONT><FONT STYLE="font-size: 14pt">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt">F</FONT><FONT STYLE="font-size: 14pt">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;March 31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated amounts of the current
distribution, paid March 31, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment
income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The
Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage<BR> Breakdown<BR> of Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Cumulative</B></FONT><FONT STYLE="font-size: 10pt"><BR> <B>Distributions for the<BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage Breakdown<BR> of the Total Cumulative</B></FONT><FONT STYLE="font-size: 10pt"><BR> <B>Distributions for the<BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.6830</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.7002</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below includes information relating to the Fund&rsquo;s performance
based on its NAV for certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from February 28, 2018 through February 28, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.85</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through February 28, 2023<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of February 28, 2023<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not draw any conclusions about the Fund&rsquo;s investment
performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
depreciation of portfolio securities and net realized losses on sale of securities is $ -22,401,326, of which $ 18,421,481 represents
net unrealized depreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts and sources of distributions reported in this 19(a) Notice
are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting
purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject to changes
based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions
for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1</TD><TD>The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through February 28, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla World Healthcare Fund<BR>
CUSIP: 87911L108<BR>
www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla Capital Management LLC<BR>
100 Federal Street, 19<SUP>th</SUP> Floor<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: center">03SLYB</TD><TD STYLE="text-align: justify; width: 85%">002CSNDB74</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; font-variant: small-caps">T</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">EKLA
</FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">W</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">ORLD </FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">H</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">F</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;April 28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated amounts of the current
distribution, paid April 28, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment
income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The
Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current <BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage <BR> Breakdown <BR> of Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Cumulative<BR> Distributions for the <BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage Breakdown <BR> of the Total Cumulative<BR> Distributions for the<BR> </B></FONT><B><FONT STYLE="font-size: 10pt">Fiscal Year to Date<SUP>1</SUP></FONT></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.7997</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.8169</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below includes information relating to the Fund&rsquo;s performance
based on its NAV for certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from March 31, 2018 through March 31, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.51</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of March 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.08</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through March 31, 2023<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of March 31, 2023<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not draw any conclusions about the Fund&rsquo;s investment
performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
appreciation of portfolio securities and net realized losses on sale of securities is $10,934,910, of which $15,941,416 represents net
unrealized appreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts and sources of distributions reported in this 19(a) Notice
are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting
purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject to changes
based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions
for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1</TD><TD>The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through March 31, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla World Healthcare Fund<BR>
CUSIP: 87911L108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla Capital Management LLC<BR>
100 Federal Street, 19<SUP>th</SUP> Floor<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: center">03TIFB</TD><TD STYLE="text-align: justify; width: 85%">002CSNDCC5</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; font-variant: small-caps">T</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">EKLA
</FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">W</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">ORLD </FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">H</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">EALTHCARE
</FONT><FONT STYLE="font-size: 18pt; font-variant: small-caps">F</FONT><FONT STYLE="font-size: 14pt; font-variant: small-caps">UND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notification of Sources of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distribution Paid Date: &nbsp;&nbsp;&nbsp;&nbsp;May 31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Amount Per Common Share:</FONT></TD>
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1167</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated amounts of the current
distribution, paid May 31, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment
income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The
Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid
back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused
with &lsquo;yield&rsquo; or &lsquo;income&rsquo;. All amounts are expressed per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current <BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage <BR> Breakdown <BR> of Current<BR> Distribution</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Cumulative<BR> Distributions for the <BR> Fiscal Year to Date<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage Breakdown <BR> of the Total Cumulative<BR> Distributions for the<BR> </B></FONT><B><FONT STYLE="font-size: 10pt">Fiscal Year to Date<SUP>1</SUP></FONT></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net Investment Income</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Return of Capital or Other Capital Source</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.9164</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">TOTAL (per common share):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.9336</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below includes information relating to the Fund&rsquo;s performance
based on its NAV for certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Average annual total return at NAV for the period from April 30, 2018 through April 30, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">9.20</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of April 30, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through April 30, 2023<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14.04</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of April 30, 2023<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not draw any conclusions about the Fund&rsquo;s investment
performance from the amount of this distribution or from the terms of the Fund&rsquo;s managed distribution policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
depreciation of portfolio securities and net realized losses on sale of securities is -$3,917,552, of which $231,521 represents net unrealized
depreciation of portfolio securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts and sources of distributions reported in this 19(a) Notice
are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting
purposes will depend upon the Fund&rsquo;s investment experience during the remainder of its fiscal year and may be subject to changes
based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions
for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1</TD><TD>The Fund&rsquo;s current fiscal year began on October 1, 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2</TD><TD>Cumulative total return at NAV is the percentage change in the Fund&rsquo;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September 30, 2022 through April 30, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla World Healthcare Fund<BR>
CUSIP: 87911L108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.teklacap.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tekla Capital Management LLC<BR>
100 Federal Street, 19<SUP>th</SUP> Floor<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-772-8500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: 617-772-8577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: center">03U6KA</TD><TD STYLE="text-align: justify; width: 85%">002CSNDDC0</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906 CERT
<SEQUENCE>4
<FILENAME>tm2312569d1_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906 CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.906CERT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;4: CERTIFICATION PURSUANT
TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26pt">Pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, each of the undersigned officers of TEKLA HEALTHCARE WORLD FUND, do hereby certify, to such officer&rsquo;s knowledge,
that the report on Form&nbsp;N-CSR of TEKLA WORLD HEALTHCARE FUND for the period ended March&nbsp;31, 2023 fully complies with
the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as applicable, and information
contained in the Form&nbsp;N-CSR fairly presents, in all material respects, the financial condition and results of operations of
TEKLA WORLD HEALTHCARE FUND for the stated period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">6/6/23</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daniel R.
    Omstead</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Laura Woodward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel R. Omstead</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Laura Woodward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;President</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section&nbsp;906
has been provided to TEKLA WORLD HEALTHCARE FUND and will be retained by TEKLA WORLD HEALTHCARE FUND and furnished to the SEC or
its staff upon request. This statement accompanies this report on Form&nbsp;N-CSR pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>j23125692_ab001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ab001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@  @+T P$1  (1 0,1 ?_$ :(    & @,!
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MU[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\
M/?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?
M^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]
MU[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_
MY[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[
M_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?
MNO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\
MI_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[
MKW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^
M>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_
M]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[
MKW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_
MSW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z
M]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_
M=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?^G_/?NO=>_\
M3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]U[KW_I_SW[KW
+7O\ T_Y[]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>j23125692_ac002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ac002.jpg
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MFPVD)X^/N8HGU RE87Q*Q[MV)MN(4+Q$9PW81DD:X=%</Y1E63QQG#=B:EI
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MOTOWO[_J?@Z?_]H # ,!  (1 Q$  !   (W']4    0 " !@    4#@ ,
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MXK4+47""<FT3WV2PP0Q"[BSD(YA$K9#0.+"S@0QQ$^],M0 >&&@@?8=#)N'
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MS.4PB)(F$1H1W. #>*@+=,IS/?@4JJ"R@*@50RF4..C07$<HO9$?AXH#"JJ
M!NJX#SI<>6(@B;B<&A,R+/R"H  BFP,B<'.YX<ZY(8SEY@ ":^^&4G<Q@P48
MS)0P$QI QJ(]6$M& $+DZ<&C"ZB.Y!3%Q:R!,-Y:HA!Z(=85 @_MV94H.H+1
MJ"%0J%MUBB.1Q'=.U98/&\":U"5$R0+A'74O@QCD3<8;I75E5>9X;(/; 9#9
M*@>H(@G(G'BL.B"?#&/?%V(EL,ER<'I"(NQ S')>41DVN##8PMOV>.1'FL=S
ME 5, 2,P7B$*8CFR%? (=0FB-GY%R#N(G/>! K#?3 P;AGN.3HE$=.2T^<"1
ME,D'L9L,&O?]$]]3 8A  $T2<%231-UO2\J#:QE".]X>V"JLQR>@#@*]#ABG
MV$$@*- )F(!I&@BX4/(;OR>#=+?L5 %(*ZDQ+4UA: *@1D5VK)G?@W,I_4Q[
M_JEHY\E4@*(E7N:#@!'J7TP[94S(].'NO!$:#JJ(-A L$%12\"M\6FM*Z88_
M"IR.>.5  "JH!E=(S (**80XHA$BS- 0/V8H*4U'*('1X;77"H["YBPE,!=&
M6CNQ^W[<\)&434?5%>Q$DK<1H0F(I>P<&2W.W"0?#W+7D3[H?&G</%T9V!H8
MPNC+P3Q"8#64+#)L[O "F8@,Q;NF+! **@(G"PS[&M41!:"@1.$YXI/5J1:4
MX'2N2$*:MNR#O *^VO'=*;F!H0W& G.2\"(ZBQ<T:TEB>$ "@;AM4+GK(,("
M >2TZW.JL-RC:Q47U?0[\GJYT[!@MUH^ZKQ&E:L%P(OL J] 5QI#XP_9'Y-\
MYY#&90^6CY/JT!M_[[MZ)MU+V',XKE?$RB^UB;]ZZ9T*)$!E'<H4Q1-QY/\
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?V31^81K^V?N?3M[->K/)]O\ /'U5M]+QUO?@?8C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>j23125692_ba003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ )P"Z P$1  (1 0,1 ?_$ :(    & @,!
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M/>XY+"2$"JEA]8]A<%0:*;82E6\.G2I[?[CRVSLQMWK?K;:D?8?<N]*+(97
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M&F7U.@86<J;3=;C[3WUCMK+]=NG,VWVI6ND*D=O=S"29A4^"I+.Q(I&(WD.
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MJ)-.BKV<V_V VVTO;;V);EAK;Q$:[.T36DYU-K,7U#V[R/\ [\\%9&HHUB,
M:NC$>P#U-/7O?NO=>]^Z]U[W[KW7O?NO=('L_%]?YS9&9PO9]1A:39N6..QM
M=5YW*4^#IJ;(UN4HJ;;U109J>IHWQ.X8=PR4K8NI@EBJX,D('IV6<1D'G+=S
MOMEO,-YRVLS[O%K=5C0R$HJ,90T8#:XC$'$R,I1HM8D!0MT#^?=OY-W;E2ZV
MOGY[6/EBY\.*1YY5@59'E1;9HYV9##<K<F(VDL;K,ER(F@83!#T \\OROZEQ
MM-A-O[:VE\GL12@TF(S>>WVG478M)CZ2C9J:/>-14[<W3MG=^2D:(0'(4O\
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..676H!4L"M/9/T*.O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>j23125692_ba004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ H@!T P$1  (1 0,1 ?_$ :(    & @,!
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M[J;%0$FRH3;\VO\ \5]^Z]U,6@<'E2#_ +'_ (W8^]=>Z<(\6Y4G3_AS^?\
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M-]GEJ4-P6L!JX(]TD'=^75XSCJC<038]G0JVF)PR2@']R._%C:X8%N03]?\
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M>]@.6+ &Y!_UC^/?NO=)*7_<;E-14BASLL<+L>%ILV D-'.;*=,>4B1:=O\
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K_F]_3_:O?AU[JSO_ +IN_P#=N=_V6G_Y:G_S(S_W_P#_ /*[[W^+KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>j23125692_ba005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba005.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K@#A P$1  (1 0,1 ?_$ :(    & @,!
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M0@8 *-,I\UC4='ZPV;P^XL;29G 93'YK$UT8FH\EBZN"NHJF,_VH:FF>2*0
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M-%#4^Z]T=';=!\6/[G4V[MQ; V?U'0]";PK\7D8NT*;;&TZSJS>NX<[L7?\
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MLL[N2S,?M)\J <  .OHZV/9-IY:V:UY>V&WCM=ELK=(8(4%$CBC4*B+Q- H
MJ22>))))Z?/:+HUZ0VYNT.M-E5\.*WEV'L;:64J*2/(08W<V[<!@:^>@EFJ*
M:*MAH\KD*2HDI)*BDEC655*%XW4&ZD ZV[EOF+>(#<[187MU;*Y4O#!+*H8
M$J616 8!E)%:T(/ CH*;[SYR/RO=KM_,V\[5MU^\8D6.ZN[>WD:,LRAPDLB,
M4+(RA@-)96 -0:<]L=F=<;VJZC'[,[ V3NZOI*;[RJHML;KP6?JZ:D$L</W5
M138JOJYH:;S2JFME"ZF O<CWK<N7>8-FB6?=["\M8&;2K30R1*6H3I!=5!-
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@O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>j23125692_ba006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba006.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!#0#A P$1  (1 0,1 ?_$ :(    & @,!
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M4%;0T>W]FI_$UH$$(AH2:E8 A,@/NO=8,/3="?(W;N\9*O86'WIA<C)@>O\
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M?;]I97L8HP RD'4>+,2,:F8EF^9ZY6<Y;KO6^<S7F[<P(\6Z3REF1P04'!$
M8 Z40!5]5 /2#]G?08Z][]U[H_?Q*[CSF0R>.ZCR]-D,U'4+-_=C)0QRU<^(
MAIH#++CLD5#,F%ABC)BG;BF)T-^T5\4'^Z/*=G!;R<TVK1PLM/&0D*')- Z?
M\,)/<OX_B'=75E)[%>X6XW-W%R)N"2W",#]/( 6,05:F.3B1" .US_9_">PK
MHM#H]IXQ(-&2IJ?)N^AI(ZN&.>D#(ZR)IIY5:-S'(H(9@2& (M[QOFW2Y+UM
MV:,#@5)#>G$9R/(?9GK,J'9[3P]-VB3$TJ& *X-1VG!H14$^8J*=*D    6
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MU&A%-:J!DTITE^[Q]X?F?WAYGOMCWRQL+6WM;#QU:#Q=1;Q8XZ'Q)'&FCDX
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ML$EK:O TL:*(Z;"YJDCDJ\?&.(C%4PJJ1PQ!ND_W<_=F;GK9'Y<W^77S1MR
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M<_;?<K\<FT(#_M;BXH?M[J?8!UV__NRKV:7V8WJQ?,4/,TK+DU'B65E5>-
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MDGS/7'WOJO7O?NO=;8/\K+9LVT_AQL:LJ8C!4;VSV\-Y/$SNSB&IS<^"Q\K
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MVV1>!MT$4$7HBA:_;0"I^9J>N4>[[_O?,%P;O?+NYN[G^*61G(^0U$Z1Z 4
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M$D\2?MZ[-VUS-9QK#;'1"@ 50!I  H !P  P *4'3P-V94  BE;_ !,+7/\
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/[W[KW7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>j23125692_ba007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba007.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ MP'+ P$1  (1 0,1 ?_$ :(    & @,!
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M[JW#75.:WW756YP,+N>.GH*662G6GJ8J2@R7NO=/6]_E#W=N[:6;INL>K/\
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M4H]MU^7JMO8K.9^K45&6KZ2E@K<Q5 3ULM1, _OW7NFO'=(=28K%4."HNO\
M;:87&UE-7TF)FH15XY*JCZM3I*G:6BJVGIZF->IXQ@6CE5XWQ_H9223[]U[I
MOP/0/5FV<AMO*8/!YB@R&U(VI</4KOC?D[G$I-+4XW;67%5N:=-R;/VU4S-)
MA<-DA5XK!2'5CZ>F-C[]U[I$]2?$KIKJ#8/6FQL#@)JB7K"'KQ\#NA\OGZ3<
M462ZUVM4;/VZ]!D:;,?>8+;--M_)Y&ACVY1RQ;>AQF6KJ!:/[.LJ89?=>Z54
M'QMZ/IHJREAZ[PZX^OVG_<FIPYJ,K)@6P)V30]:2>+ 29!\+39RHZYQ=+@)L
MM% F5FPM-%125+4T:1+[KW2NW)U?L[<V!WW@:K'-CT[&KJ?-;CRF(E-'FSNC
M&X;;N#P.\,;D"LS8W=6V*7:&)DQM9&HDHZG&T\R6DC#>_=>Z;=\=)=6]DKGA
MO?:%'GGW-1[<QV9J9ZS*TM=/C]IR[BEP5#39#'U])78RCIEW?EX98J62%*JF
MRM9!.)8:J>.3W7NE-M79."V=/NJJPT4RU6]-S-NO/SS2(?N,FF P&T\?'!!!
M%!245#B-J;5QN.IHHHT IZ-&D,DS2RR>Z]TKO?NO=>]^Z]T4#X/?\R8WK_XM
M_P#S"?\ X/KY+>_=>Z-_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*!\'O^9,;U_P#%O_YA
M/_P?7R6]^Z]T;_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4#X/?\R8WK_XM_\ S"?_ (/K
MY+>_=>Z-_P"_=>Z)OOGO?M+![+^3FY,9@^N\7D>@>S)MO8'&9>NS^='8NW$Z
M7ZW[(V[@:84G]VI<9V1V3NW?]/@,?##]]#12U4+)#DZA12U'NO=9NVODGF>N
M?D1U1TW3X;&U..[ 7:B_<U&,W'6?=ON;<&Y<'E9<KO7%"39W3J[4I<'3U&(C
MW0JGL3)5YPF!?^)4LP/NO='"]^Z]UQ=TC1I)&5$16=W=@J(B@LS,S$!54"Y)
MX ]^Z]TWT^9P]8^.CI,KC:I\QC9<SB$IZZEG?*8>G./6?*XY8I6-=C83EJ0/
M/%JB4U,5V'D2_NO=%W[\RM'V#TQOA>M=WUV8RVUMW;<H*U^K=TSR9BAW-MC>
M.VZ_*;4RU5M&L?)TLU+$Z')XQWC:6E8PU4;4TLD<GNO=%?SF6[!ZLJ_E9ANL
MAFNS-_[LV;WAG=@[FQ^P>S]OY_;G=.4J]X[JZAZ>R^Z=U5>]^OMRPU4.5F@Q
M&4QN/QN/P>-P=(N1@D7*8QI_=>Z--\4ZJMEZHAH)Z2LDQV$SE?C,#NNKHNR,
M,.PL8]'C<I4[RBV[W!G]T]G8*27/9*MQ]4N8KZJHKZ_'U&1CD:GK82?=>Z,I
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@MH^\NE,
MAM/.[]H.X.K:[8NU\E#AMS;TH^P-IU.T]NY>H?&Q08K.[CAR[X?$9*>3,T:I
M!431RLU5" I,J:O=>ZX[K[CV3M;:6SM[Q5-9N_;._-Z=:;(VSE]AT\>Z\96U
MG:N\,'LO;><DR^.G.%I-IPUV>BGJ<C+4I!X%T0>>JEIJ:?W7NL.'[83+[G[.
MV:=@[ZQNY.M,+B-R+C:_^Y3/OK;VX\AOO$[9R^RY\;O3(TJP[@R7762B@AS3
MX:JC(B>>*&.0/[]U[I\ZS["QG:.T8=VXO%YK!Q_Q[>>ULE@]Q1XM,UA-R=?;
MSW!L#=N'R!P>5SN$GFQ6Z=L5D FHZVKI)UC$D,LD;*Q]U[I?>_=>Z8<ENK;&
M&J*FDS&X\#B:JBP.0W564V2S&/H:BDVQB'BBRVXZF&JJ(I(,#C))T6HK' IX
M6=0[J2/?NO=,]7V7UQ0;:PF\Z[?^R:+9^Y9L73[<W75[JP5-MK/U&<_XLL&$
MSLU>F+RLV8_Y15@ED:H_W6&]^Z]TE<QW]T[@/[Z?Q??N'H_]'FZ-J[*WC=*^
M;^#;KWM_"_[LX%OMZ.7[[(9'^,T]TIO-]OJ;S&/Q2Z/=>Z4F>[*VCMG=^T]C
M9NJS%%G=[R5%/MV8;3W;5;9J*VGI*^N7&9#>]'@ZC96 S%=38NH-'1Y#(4M5
M7&)EIXY6X]^Z]TO/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(O$=D==[@_NG_ =^[+S?]_<7E,WL;^$;
MIP>2_OIA<']C_&LOM/[.NF_O'B\/_$Z;[JHH_-%3_<1>1E\B7]U[IZH]R;=R
M.:S6VL?G\+7;BVU#B:C<> H\I0U6:P%/GHZJ;!SYK%03O78J',PT,[TC3QQK
M4+"YC+!&M[KW3U[]U[KWOW7NO>_=>Z][]U[JE3J*3>N'VUW'D<;NOL3'[.R/
M=_RRBW<F(SNXL?@]J[)I_P";UWK0=M9_;?\ =TTU1MK=$/4>5SD]1FZ)ESE-
M!&DL-3$*2E\'NO=#5N3M+;,O3W6FQ\QVQN[;78F?[BR6W>GMXY+M'L78<N/V
M#D^R=]S]5]A[SW)59[!4':L./Z$V[!E*/&[LERU+N_,+14>1CJ)\H7D]U[HQ
M_9VS?C3NNNRV(WQ4[FHLB>T\'VYE_P"Z^]NY]D5<_9>U]DXO8&W\Y4Y+KS/X
M"6JAPVV<+0_;T/E;&1Y"AILB(/XC3Q52'UMRSOEY MS;P:H'%0=<8J/L+@_M
M'08O.<N6["Y>SN[G1<QFC#PY30_:$(/Y$]2\;L#XZ[Y[$I]U4D^ZL]O85N/S
MC??[][G?$Y&3:^[,AO[:\69V[E-R)M'.8G8F[\O4Y#;U!6TL]%M^HG8XV&F!
MM[:ON7]WVZ#ZF]AT0 @5UH<GAA6)_ET]MO-6P[O<BSV^?Q+D@FFB1<#CED _
MGT"<W<W:^W_F1G^M<KN?'4^VLKM/?M5CJ?<NY>K(^N,.CO\ 'S;O1K4>+P^8
M7MG#;HRW8O8U;B:VES*4L^X:W.+_  W[NEI:%*$FZ$/3Y\-M[;S[JV=WGMCM
MU*_>NV\/NS"[$E??.2ZAW?+F)-P=)=<YWM+:U?5=0564Z^SNVVW7NFNG@6%Y
M(H:7*''Z(%H_L:7W7NIO674^\NLJ?XU;XJNKZK-;MZH^"NZ.I]\8O;>0V#_?
M'*[RQ2?'K+[5ZOQ>5SNZL#M[(560R>T-QQT%1492GP%/5,SU%=315"S/[KW2
M-SB=AX_K_P"0O9.Y^NMR]);EW)O[:^W]J8K^,;"M'U;LK,38G9E12Y#K#?6Z
M::JR6XILED\Y7R5<6.K*4YQ,4150XV*JE'7MQ;V]US9!#=1I)"4EJK*&4TC8
MC!!&.HO]XKN[L>0KJYLI9(;@2PT9&*,*RJ#1E(.1@YZ*C_I"W]_SW&[_ /T)
M<U_]6^\D_P!Q;'_RAVG_ #AC_P"@>L,_ZT<S?]'&^_[*)?\ H/JTKJ'=ZX?H
M+:^[MRR[FS2TN-JI\A)B,!NK?NYJO7N"MHXS2X':^,W!NG-2IK0%::FG=(E+
MD"-&88O\]0PV_-EY#;HL<*NM%4!5'Z:' % .LWO:^YN+OD+;KF[D>6X:)]3.
MQ9C^K(,L22<"F3PZ<L?\B.J\LG4$F)R&[LLO>^W9=W=9C%]6=J9%\GM2"HV=
M33[EW#%1;+GDZ_P-/)O_ !!DJ]PC%4\<=:LC,$25D"70^Z&[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56O0GQP[*Z[ZDW'UWV?UUO;?N#
MS</5^=KJ&@[HP]+V#A=\]+8_9-%C\/U1O##YC8,^#ZAAR>Q\=6[#I*K,8_,8
M]X*R;+34L^0,4/NO=&RI]C;BK>C=E[;[EWFN/W!A=]]=[VK<U7UE'FZJ"FZ\
M[HP7:>T-H9C.)!A*;<.:I\!MBAP>0S"PQ&NJDFKA$2^@OVUK<7DO@VJ-)+2M
M%%30<<=)KN\M+"'ZB]D2* $#4Q %3P%3Z](?;^#S^!W'VSNB3Y"]09S*=D[L
MR&3HJK.=55U748?8U'M?>^$Z_P"L,Q)%W)3PYS:^QLMFL5D *&/""NEAS3/'
M'5Y^6LHC#]P;W_RBS_[P>BK^M'+O_*;;?[VO^?H:?CYUOC^INI=M[&Q>6V_F
ML?05^[\Q2U.T=M0[,V=21;PWKN+>7\"V7M&GRV>BVOLS;#9\XW$8\5U6:/&T
MD,1FD*ER630RV\K0SJ4E4T(."#\QT<03PW4*W%NRO XJ&!J"/4'H9_;?3W1.
M?D3TIN/?>_=N[YVGM?"YB?"]4[JP>XH:F;#8VJWY'B.[_CCVIM_J3+UV0BD,
MVW=]83K_ '-BF:J2?&T(RL[3(%J763W7N@!W-U)\EJFFZYRVR-JYS9V=VCV)
M\FM^8B@CR_3U=24&Z?D;O/LK>O7FY-XSU^4R*4N+ZK3+0X[>D&"6MR5=3;AK
M(<3/EH%J34^Z]T:S?/26?W3_ *=?L\MAZ?\ TJ?Z,?X/]R:W_<=_<?[3^(?Q
M+Q4LEON_MSX?%Y/J-6GW[KW7+<&T>Z]U]T=99K.8GK%NH>O,MN_<D-/0[YW9
M3[RFW;74&X-I;/W%5863KF;"9BEPNR,Y5B7&/DZ:$97)_=+,[8RE-1[KW1EO
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT$.3[0K\5W+M3J:?:$TL&\=L[KW3B=ST^?Q3E,9LD;>@W)65FW7\>3BQN.R^
M[\10-.C2$U.3@&C07=/=>ZP['['GW_N[MCK[-[)_A(Z\J,%B<G5OFL-N?"YH
M;KH,GDH</5K0K_N,SD.UUQ^1K,95)Y(\?G*&0ZEG'OW7N@5V;TKN_8]%T/EJ
M7:^!KL]U1@>X:3(T5'7XZ@J*R/<463J=I;=H,K)3^.*AJZR=$-_V*1I"Y6P/
MOW7NADVIL;*8WN[LKLN?#XW$X_?O5/1V"G%++2R9"IW=L?/=V56X/XHU-%&:
MQJ'";RP]-#5N6\T</C6R0J![KW0U>_=>Z][]U[KWOW7NO>_=>ZKZ^)&ZLGAN
MJ]YT=&M*8C\M?Y@DQ,T3N^M_GY\FU/*RH+60?CV(-LVRVN[;Q9=6K41@_9\N
M@MO.\W=A=B" )HT Y!)J2?F/3HU>)WMF:W)T%',M$(JFJAAD*02*^AW"MI)F
M8 V/]#[4W6SVD-L\J%]2J2,CR_+I'9<P7UQ=QP2"/0[@&@-:$_;T4KM+_F8.
MZ_\ M:R_]:X_<G\M_P#)"M?^:0_PGJ&>;_\ E9KS_FL?\ Z5/0G_ #,*F_[5
M>3_ZU)[+.=O^2$W_ #53_#T<>W/_ "LR_P#-&3_ .@PKOEQN2GRF69=@=?O4
M5%?2M6U;X^O-57S8*H!P]16S"N#U-1C'@1J=G),#*"FFP]GL/M#LDD*2&YNJ
MLH/^A^8K_!T#[C[P/,L-P\*V5B0CL/\ 1?(D?[\Z%#KKNK,[_P"M>YJ),#@-
MH0;1Z\SE?AEVE#58P4U578K<,[S0H*EDII(ZFG$JM$$82,6O?GV'MXY(VWEG
M?-G$$DDR7-_&KK($(H)(\4"BH.H@@U!'0MY>]S-YYTY8YA-U%#;2V>U2O&T)
M<-J:*;-2Q(*E05(H0<]$:_TA;^_Y[C=__H2YK_ZM]S9^XMC_ .4.T_YPQ_\
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MBF\;H+<0R"281IX4@=O$80:UJM0-"/4X-!GHH7^@3Y]_]X>]]_\ HY/B'_\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0AWO\
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*!\'O\
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M/86U]IY[%9[:>>R.VLY0UV#W+DL5EZ;[;+XJ98I6A$-5"$G@>6GEBE?W7NC
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MMP;AW5N#9/7?8.Z.X>J:O?&;R^Y]W1[.QVV>F]U]?9B'>NX]P5%9BLQG%G.
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M.Y]D3)F-R]8[-VOANP-H]PT_4.^LGUWV1O\ W1M'N;;M=D\9O?9F<R>W>O\
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MW;V_LG?&&W;B>HZ+#[ W1N_969WKD*C#;GW5F*_L/9]7W_G^UODM18_'XJ?
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@],V%S[-)49K*>>G&/]U[JY/W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>j23125692_ba008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23125692_ba008.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ D@'$ P$1  (1 0,1 ?_$ :(    & @,!
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M,N HX<2E17PTE=[KW4K^^/9O^A/^*?Z0]_\ _#D_^D'P_P"B/_2GVA_!]?\
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M';^_:ZJFI=MSI2TF[I_XKM3#UE-B-]P,N3Q,?V[Q'&3PNE55:BZ^IU[HS/\
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M;1FR$Z;%S:]K<^UZ[9. 'N2D$9\W-"?L7+']G14^\6Q8QV8>XF'E&*@?:^$
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M#4O]%JJ>!!'1<]P?$;XZ54C0;UZPQZTE95I#19C;6X=V;,C52L"+%6IM+/X
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MS@^3#!_ET]^T_2[KWOW7NO>_=>ZXNZ1HTDC*B(K.[NP5$1069F9B JJ!<D\
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MN30S2WOI _2?U#_$B_@[#'\<MQ)_I% _X]3_  ]4,_,\N(H+:+_3N3_QRO\
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M?@J?1#/<RRM0_B9A7!TKPZR?Z/?D9_WG%B/_ $1G5G_UZ]U_K7[9_P#3)?\
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MZBQN9WULW$9'<GQ=[/PVWL?D]SX2@K<]EZSMWJ9:/%86EJZZ*?*9*K:%Q'!
MLDLA0Z5-C[UU[HS?>G8^9ZAZDW]V=@]H+OFKV'MC-;MJ=O2[AI]K4]3B-N8Z
MIS>;EFS<V.S,E*T&)H)C"L5%5235/CC*HCO-%[KW2!V]W]E\UV)C<'4[$H\?
MUINKL#L3J/8_8$6\)*W<&;[*ZNHMP5.ZL7E^OSM6DCV]MYJGK[=<%%DAF*MY
MWP:,]-"E=3,?=>Z!7:OS)[&WWF-N[-V=T-@,GO\ WQTYMSY([(P%?W++B<16
M=%[IBS--CJ[<FY).K:@;?[3@W'2X['5& IZ7)XI'RT<T>;E@@JGB]U[K#_L\
MF3_T._[--_HOP'^RM?WA_A?][/\ 25FO],G\&_TF?Z)/[R?Z(/\ 11_=?[?^
M]/\ E7VW]\ONOX-^]I^\_P!Q_OW7NC^FAHF)9J.E9F)+,:>$DDFY))2Y)/OW
M7J#KK^'T'_*E2?\ G-#_ -&>_=:H.O?P^@_Y4:3_ ,YH?^C/?NMT'53GRH_D
MI?!/Y29N??&2ZZR7679NHU-'OGJ7>>_>LZRFR'FDJ8Z_[?KO=NT)(IXZJ>6;
M_)IJ82S2N\HEUN&$^V<PVL)6+?+&WO[,$5J7AEH/2:$JQ)\S()"?SZ!&]\HW
MURKW'+&Z7>T[B0:%1'<05/K;W"N@ & (C$!C!I3HC-=_+9^:WQP#OTS_ #1_
MGCUEBZ)53&9;L3^X/S]ZCH***-Q%09+9O>.TJCM7:V*IX8E35'D\DE.A"1.H
M56 MCV3DCF#OV"22*]8?[C2SK"X/EX;RI+'.>/:9H20."UZCJ?F/W4Y1[.:4
MM[C;%-3>Q6KW*$>?BI;RV\MJM*=XM;D*3Q>G2]VYNC^?OUQC(,GM:?\ EB_S
M&=C4C^1\K@X>POB_VWE:=?W'ILA-#E]Y=9X;,2Q>E8$Q1\;_ *R?T@CO.5=M
MM+@V=U?R6%X/PWUK-"#_ *1K;ZP,OHY"*>-:9Z$=A[@\PWEF-RM-EBW?;6X/
MM&XVMT5Q6DJ7XVHHU,F-#*XP*%L=8ZO^=3WOTF2/FK_)I^:?3%"DOADW9T95
M]9?)[9:A="S5IR$=;U'GFH(9"2QAQL\@3251BVGWZ/V[YGO*'9DMMR!.!9W,
M%Q(?^;$<AN%_VT2GIN?WO]OMKJ.:I;[8BHJS;G8WEE *8/\ CDT"V3T\S'<N
M!ZY'0X]>_P _K^49OBK@P^XODGC^A]T2,L=3M?Y-]5]G?'NMQ\[.(S3U.;[0
MV3M[9DLL;$Z_M\I.(P"6( )]AK<MEWG99? WBTN;2>M-,T3Q-7THZJ>A[L'-
M7*W-5O\ 6<K[EM^Y6A .NUN(;A*'@=4+NM#Y&O5I/5?<_0'>N(7<'2/;'3W<
M>!>"*J3-]5[[V5V%B'I9PIAJ5R6T<KEZ)H)@XTN'TM<6//LLZ/Z#IB[2^1_Q
M:Z-6H;NOOGH'I]:-#)5MVEVCUWU^M+&L,50SU!W9G,0($%/.CDM8:'5OH0??
MNO4'5?V[_P">E_*$VED:O#4OS%ZS[,S-&DCR8KH#:78GR0K) E4*(& =";&[
M&@EBDJ2 L@?Q%")-7C]?N\:22N(X@6D)H  22?0 9/3<TT%O$T]PR1P**LS$
M*H \R30 ?,] %N?^?Y\;X"U/UK\-/GGV;5U#B'$5F2Z#VCT'MK(S/(].D_\
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MA]!_RI4G_G-#_P!&>_=>H.O?P^@_Y4J3_P YH?\ HSW[KU!U[^'T'_*E2?\
MG-#_ -&>_=>H.O?P^@_Y4J3_ ,YH?^C/?NO4'7OX?0?\J5)_YS0_]&>_=>H.
MO?P^@_Y4J3_SFA_Z,]^Z]0=>_A]!_P J5)_YS0_]&>_=>H.B7[CV[M^N^?\
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MGA1\5G(YCQ(*RGF+KQ<<6%FW<Y;O96PVZ\\.^V@?Z!<KXJ#_ $A/?&0*T*,
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M&>YO?W^NC#;'_=/RWRS:@<"UHURX^>J[EF%0>!"C^0I7_@>+J_4_UGY[Y^W
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3W-?]E\=>?\
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MEO?NO=>_V1[IC_GM?E__ .G"?GU_]TM[]U[HK_R;^+.Q-C?Z!3M3LWYBX?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>ck0001635977-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:ck0001635977="http://www.teklacap.com/20230331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:cef-pre="http://xbrl.sec.gov/cef-pre/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.teklacap.com/20230331" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef-pre/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.teklacap.com/role/Cover" id="Cover">
        <link:definition>0000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/INVESTMENTOBJECTIVEANDPOLICIES" id="INVESTMENTOBJECTIVEANDPOLICIES">
        <link:definition>0001 - Disclosure - INVESTMENT OBJECTIVE AND POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AntiTakeoverProvisionsRiskMember" id="ck0001635977_AntiTakeoverProvisionsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BiotechnologyIndustryRiskMember" id="ck0001635977_BiotechnologyIndustryRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConcentrationInHealthcareIndustriesMember" id="ck0001635977_ConcentrationInHealthcareIndustriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleSecuritiesRiskMember" id="ck0001635977_ConvertibleSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CounterpartyRiskMember" id="ck0001635977_CounterpartyRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CreditDefaultRiskMember" id="ck0001635977_CreditDefaultRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativesRiskMember" id="ck0001635977_DerivativesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLinkedNotesMember" id="ck0001635977_EquityLinkedNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquitySecuritiesRiskMember" id="ck0001635977_EquitySecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExchangeTradedFundsRiskMember" id="ck0001635977_ExchangeTradedFundsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" id="ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForeignSecuritiesRiskMember" id="ck0001635977_ForeignSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForwardContractRiskMember" id="ck0001635977_ForwardContractRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentInterventionMember" id="ck0001635977_GovernmentInterventionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareDistributorsSectorRiskMember" id="ck0001635977_HealthcareDistributorsSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareEquipmentSectorRiskMember" id="ck0001635977_HealthcareEquipmentSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareFacilitiesSectorRiskMember" id="ck0001635977_HealthcareFacilitiesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareServicesSectorRiskMember" id="ck0001635977_HealthcareServicesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareSuppliesSectorRiskMember" id="ck0001635977_HealthcareSuppliesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareTechnologySectorRiskMember" id="ck0001635977_HealthcareTechnologySectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KeyPersonnelRiskMember" id="ck0001635977_KeyPersonnelRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeverageRiskMember" id="ck0001635977_LeverageRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LifeScienceAndToolsIndustryRiskMember" id="ck0001635977_LifeScienceAndToolsIndustryRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidityRiskMember" id="ck0001635977_LiquidityRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ManagedCareSectorRiskMember" id="ck0001635977_ManagedCareSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MarketDisruptionAndGeopoliticalRiskMember" id="ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonDiversificationRiskMember" id="ck0001635977_NonDiversificationRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonInvestmentGradeSecuritiesRiskMember" id="ck0001635977_NonInvestmentGradeSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PharmaceuticalSectorRiskMember" id="ck0001635977_PharmaceuticalSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PortfolioMarketRiskMember" id="ck0001635977_PortfolioMarketRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PotentialConflictsOfInterestRiskMember" id="ck0001635977_PotentialConflictsOfInterestRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrivateInvestmentInPublicEquityRiskMember" id="ck0001635977_PrivateInvestmentInPublicEquityRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegulationAsCommodityPoolMember" id="ck0001635977_RegulationAsCommodityPoolMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReitRiskMember" id="ck0001635977_ReitRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionsRiskMember" id="ck0001635977_RelatedPartyTransactionsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedSecuritiesAndValuationRiskMember" id="ck0001635977_RestrictedSecuritiesAndValuationRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAssociatedWithFundsOptionStrategyMember" id="ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAssociatedWithRegulatoryAndPolicyChangesMember" id="ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityMarketRiskDiscountToNetAssetValueMember" id="ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SelectionRiskMember" id="ck0001635977_SelectionRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SpecialPurposeAcquisitionCompanyRiskMember" id="ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VentureCapitalInvestmentsRiskMember" id="ck0001635977_VentureCapitalInvestmentsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ck0001635977-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_2"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_10"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_12"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_13"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_14"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_15"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_16"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_17"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_18"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_19"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_20"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_21"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_22"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_23"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_24"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_25"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_26"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_27"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_28"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_29"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_30"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_31"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_32"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_33"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_34"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_35"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_36"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_37"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_38"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_39"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_40"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_41"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_42"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_43"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_44"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_45"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_46"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_47"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_48"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_49"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_50"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_51"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_52"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_53"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_54"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_55"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_56"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_57"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_58"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_59"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_60"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_61"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_62"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_63"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_64"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_65"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_66"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_67"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_68"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_69"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_70"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_71"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_72"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_73"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_74"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_75"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_76"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_77"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_78"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_79"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_80"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_81"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_82"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_83"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_84"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_85"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_86"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230331.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_87"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_0" xml:lang="en-US">This member stands for Anti-Takeover Provisions Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_1" xml:lang="en-US">Anti Takeover Provisions Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_BiotechnologyIndustryRiskMember_0" xml:lang="en-US">This member stands for Biotechnology Industry Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_BiotechnologyIndustryRiskMember_1" xml:lang="en-US">Biotechnology Industry Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_0" xml:lang="en-US">This member stands for Concentration in the Healthcare Industries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_1" xml:lang="en-US">Concentration In Healthcare Industries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ConvertibleSecuritiesRiskMember_0" xml:lang="en-US">This member stands for Convertible Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ConvertibleSecuritiesRiskMember_1" xml:lang="en-US">Convertible Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_CounterpartyRiskMember_0" xml:lang="en-US">This member stands for Counterparty Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_CounterpartyRiskMember_1" xml:lang="en-US">Counterparty Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_CreditDefaultRiskMember_0" xml:lang="en-US">This member stands for Credit/Default Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_CreditDefaultRiskMember_1" xml:lang="en-US">Credit Default Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_DerivativesRiskMember_0" xml:lang="en-US">This member stands for Derivatives Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_DerivativesRiskMember_1" xml:lang="en-US">Derivatives Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_0" xml:lang="en-US">This member stands for Equity-Linked Notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_1" xml:lang="en-US">Equity Linked Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_2" xml:lang="en-US">Equity-linked Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_EquitySecuritiesRiskMember_0" xml:lang="en-US">This member stands for Equity Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_EquitySecuritiesRiskMember_1" xml:lang="en-US">Equity Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_0" xml:lang="en-US">This member stands for ETFs Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_1" xml:lang="en-US">Exchange Traded Funds Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_2" xml:lang="en-US">Exchange-Traded Funds Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_0" xml:lang="en-US">Represents information of failure of futures commission merchants and clearing organizations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_1" xml:lang="en-US">Failure Of Futures Commission Merchants And Clearing Organizations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ForeignSecuritiesRiskMember_0" xml:lang="en-US">This member stands for Foreign Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ForeignSecuritiesRiskMember_1" xml:lang="en-US">Foreign Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ForwardContractRiskMember_0" xml:lang="en-US">This member stands for Forward Contract Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ForwardContractRiskMember_1" xml:lang="en-US">Forward Contract Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_GovernmentInterventionMember_0" xml:lang="en-US">This member stands for Government Intervention.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_GovernmentInterventionMember_1" xml:lang="en-US">Government Intervention [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Distributors Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_1" xml:lang="en-US">Healthcare Distributors Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Equipment Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_1" xml:lang="en-US">Healthcare Equipment Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Facilities Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_1" xml:lang="en-US">Healthcare Facilities Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareServicesSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Services Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareServicesSectorRiskMember_1" xml:lang="en-US">Healthcare Services Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Supplies Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_1" xml:lang="en-US">Healthcare Supplies Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareTechnologySectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Technology Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareTechnologySectorRiskMember_1" xml:lang="en-US">Healthcare Technology Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_KeyPersonnelRiskMember_0" xml:lang="en-US">This member stands for Key Personnel Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_KeyPersonnelRiskMember_1" xml:lang="en-US">Key Personnel Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LeverageRiskMember_0" xml:lang="en-US">This member stands for Leverage Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LeverageRiskMember_1" xml:lang="en-US">Leverage Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_0" xml:lang="en-US">This member stands for Life Science and Tools Industry Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_1" xml:lang="en-US">Life Science And Tools Industry Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LiquidityRiskMember_0" xml:lang="en-US">This member stands for Liquidity Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LiquidityRiskMember_1" xml:lang="en-US">Liquidity Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ManagedCareSectorRiskMember_0" xml:lang="en-US">This member stands for Managed Care Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ManagedCareSectorRiskMember_1" xml:lang="en-US">Managed Care Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_0" xml:lang="en-US">This member stands for Market Disruption and Geopolitical Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_1" xml:lang="en-US">Market Disruption And Geopolitical Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_NonDiversificationRiskMember_0" xml:lang="en-US">This member stands for Non-Diversification Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_NonDiversificationRiskMember_1" xml:lang="en-US">Non Diversification Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_0" xml:lang="en-US">This member stands for Non-Investment Grade Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_1" xml:lang="en-US">Non Investment Grade Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PharmaceuticalSectorRiskMember_0" xml:lang="en-US">This member stands for Pharmaceutical Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PharmaceuticalSectorRiskMember_1" xml:lang="en-US">Pharmaceutical Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PortfolioMarketRiskMember_0" xml:lang="en-US">This member stands for Portfolio Market Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PortfolioMarketRiskMember_1" xml:lang="en-US">Portfolio Market Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_0" xml:lang="en-US">This member stands for Potential Conflicts of Interest Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_1" xml:lang="en-US">Potential Conflicts Of Interest Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_0" xml:lang="en-US">This member stands for private investments in public equity ("PIPEs") Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_1" xml:lang="en-US">Private Investment In Public Equity Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RegulationAsCommodityPoolMember_0" xml:lang="en-US">Represents information of regulation as commodity pool.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RegulationAsCommodityPoolMember_1" xml:lang="en-US">Regulation As Commodity Pool [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ReitRiskMember_0" xml:lang="en-US">This member stands for REIT Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ReitRiskMember_1" xml:lang="en-US">REIT Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RelatedPartyTransactionsRiskMember_0" xml:lang="en-US">This member stands for Related Party Transactions Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RelatedPartyTransactionsRiskMember_1" xml:lang="en-US">Related Party Transactions Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_0" xml:lang="en-US">This member stands for Restricted Securities and Valuation Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_1" xml:lang="en-US">Restricted Securities And Valuation Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_0" xml:lang="en-US">This member stands for Risks Associated with the Fund's Option Strategy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_1" xml:lang="en-US">Risks Associated With Funds Option Strategy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_0" xml:lang="en-US">This member stands for Risks Associated with Regulatory and Policy Changes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_1" xml:lang="en-US">Risks Associated With Regulatory And Policy Changes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_0" xml:lang="en-US">This member stands for security market risk-discount to net asset value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_1" xml:lang="en-US">Security Market Risk Discount To Net Asset Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_2" xml:lang="en-US">Security Market Risk-discount To Net Asset Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SelectionRiskMember_0" xml:lang="en-US">This member stands for Selection Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SelectionRiskMember_1" xml:lang="en-US">Selection Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_0" xml:lang="en-US">This member stands for Special Purpose Acquisition Company Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_1" xml:lang="en-US">Special Purpose Acquisition Company Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_0" xml:lang="en-US">This member stands for Venture Capital Investments Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_1" xml:lang="en-US">Venture Capital Investments Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_1" xlink:to="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_2" xlink:to="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_BiotechnologyIndustryRiskMember_3" xlink:to="lab_ck0001635977_BiotechnologyIndustryRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_BiotechnologyIndustryRiskMember_4" xlink:to="lab_ck0001635977_BiotechnologyIndustryRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_5" xlink:to="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_6" xlink:to="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7" xlink:to="lab_ck0001635977_ConvertibleSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConvertibleSecuritiesRiskMember_8" xlink:to="lab_ck0001635977_ConvertibleSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CounterpartyRiskMember_9" xlink:to="lab_ck0001635977_CounterpartyRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CounterpartyRiskMember_10" xlink:to="lab_ck0001635977_CounterpartyRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CreditDefaultRiskMember_11" xlink:to="lab_ck0001635977_CreditDefaultRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CreditDefaultRiskMember_12" xlink:to="lab_ck0001635977_CreditDefaultRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_DerivativesRiskMember_13" xlink:to="lab_ck0001635977_DerivativesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_DerivativesRiskMember_14" xlink:to="lab_ck0001635977_DerivativesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_15" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_16" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_17" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquitySecuritiesRiskMember_18" xlink:to="lab_ck0001635977_EquitySecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquitySecuritiesRiskMember_19" xlink:to="lab_ck0001635977_EquitySecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_20" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_21" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_22" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_23" xlink:to="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_24" xlink:to="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForeignSecuritiesRiskMember_25" xlink:to="lab_ck0001635977_ForeignSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForeignSecuritiesRiskMember_26" xlink:to="lab_ck0001635977_ForeignSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForwardContractRiskMember_27" xlink:to="lab_ck0001635977_ForwardContractRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForwardContractRiskMember_28" xlink:to="lab_ck0001635977_ForwardContractRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_GovernmentInterventionMember_29" xlink:to="lab_ck0001635977_GovernmentInterventionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_GovernmentInterventionMember_30" xlink:to="lab_ck0001635977_GovernmentInterventionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_31" xlink:to="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_32" xlink:to="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_33" xlink:to="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_34" xlink:to="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_35" xlink:to="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_36" xlink:to="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareServicesSectorRiskMember_37" xlink:to="lab_ck0001635977_HealthcareServicesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareServicesSectorRiskMember_38" xlink:to="lab_ck0001635977_HealthcareServicesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_39" xlink:to="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_40" xlink:to="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareTechnologySectorRiskMember_41" xlink:to="lab_ck0001635977_HealthcareTechnologySectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareTechnologySectorRiskMember_42" xlink:to="lab_ck0001635977_HealthcareTechnologySectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_KeyPersonnelRiskMember_43" xlink:to="lab_ck0001635977_KeyPersonnelRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_KeyPersonnelRiskMember_44" xlink:to="lab_ck0001635977_KeyPersonnelRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LeverageRiskMember_45" xlink:to="lab_ck0001635977_LeverageRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LeverageRiskMember_46" xlink:to="lab_ck0001635977_LeverageRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_47" xlink:to="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_48" xlink:to="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LiquidityRiskMember_49" xlink:to="lab_ck0001635977_LiquidityRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LiquidityRiskMember_50" xlink:to="lab_ck0001635977_LiquidityRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ManagedCareSectorRiskMember_51" xlink:to="lab_ck0001635977_ManagedCareSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ManagedCareSectorRiskMember_52" xlink:to="lab_ck0001635977_ManagedCareSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_53" xlink:to="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_54" xlink:to="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonDiversificationRiskMember_55" xlink:to="lab_ck0001635977_NonDiversificationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonDiversificationRiskMember_56" xlink:to="lab_ck0001635977_NonDiversificationRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_57" xlink:to="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_58" xlink:to="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PharmaceuticalSectorRiskMember_59" xlink:to="lab_ck0001635977_PharmaceuticalSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PharmaceuticalSectorRiskMember_60" xlink:to="lab_ck0001635977_PharmaceuticalSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PortfolioMarketRiskMember_61" xlink:to="lab_ck0001635977_PortfolioMarketRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PortfolioMarketRiskMember_62" xlink:to="lab_ck0001635977_PortfolioMarketRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_63" xlink:to="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_64" xlink:to="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_65" xlink:to="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_66" xlink:to="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RegulationAsCommodityPoolMember_67" xlink:to="lab_ck0001635977_RegulationAsCommodityPoolMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RegulationAsCommodityPoolMember_68" xlink:to="lab_ck0001635977_RegulationAsCommodityPoolMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ReitRiskMember_69" xlink:to="lab_ck0001635977_ReitRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ReitRiskMember_70" xlink:to="lab_ck0001635977_ReitRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RelatedPartyTransactionsRiskMember_71" xlink:to="lab_ck0001635977_RelatedPartyTransactionsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RelatedPartyTransactionsRiskMember_72" xlink:to="lab_ck0001635977_RelatedPartyTransactionsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_73" xlink:to="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_74" xlink:to="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_75" xlink:to="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_76" xlink:to="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_77" xlink:to="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_78" xlink:to="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_79" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_80" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_81" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SelectionRiskMember_82" xlink:to="lab_ck0001635977_SelectionRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SelectionRiskMember_83" xlink:to="lab_ck0001635977_SelectionRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_84" xlink:to="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_85" xlink:to="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_86" xlink:to="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_87" xlink:to="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ck0001635977-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/N2" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#N2"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140592003307584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>N-2 - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">0001635977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">N-CSRS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Tekla World Healthcare Fund<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,997<span></span>
</td>
<td class="nump">$ 4,786<span></span>
</td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_AnnualDividendPayment', window );">Annual Dividend Payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAssetValuePerShare', window );">NAV Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LatestPremiumDiscountToNavPercent', window );">Latest Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OutstandingSecurityHeldShares', window );">Outstanding Security, Held [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,945,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The closing price at which the Fund's shares were traded on the exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualDividendPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualDividendPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FinancialHighlightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FinancialHighlightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_GeneralDescriptionOfRegistrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_GeneralDescriptionOfRegistrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LatestPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LatestPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityHeldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityHeldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesCvgPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 3<br> -Subparagraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesCvgPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAssetValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-54B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 59<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-59<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAssetValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2312569d1_ncsrs_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cef="http://xbrl.sec.gov/cef/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001635977-20230331.xsd" xlink:type="simple"/>
    <context id="C_20221001to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_20221001to20230331"
      id="Fdei_AmendmentFlag20230531213420896">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_20221001to20230331"
      id="Fdei_EntityCentralIndexKey20230531213500677">0001635977</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_20221001to20230331"
      id="Fxbrl_20230531183730917">N-CSRS</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_20221001to20230331"
      id="Fxbrl_20230531183746369">Tekla World Healthcare Fund</dei:EntityRegistrantName>
    <us-gaap:SharePrice
      contextRef="C_20230331"
      decimals="2"
      id="Fxbrl_20230531184037380"
      unitRef="USD_Per_Share">13.74</us-gaap:SharePrice>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20230331"
      decimals="2"
      id="Fxbrl_20230531184049150"
      unitRef="USD_Per_Share">12.64</us-gaap:NetAssetValuePerShare>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20221001to20230331"
      decimals="4"
      id="Fxbrl_20230531184153743"
      unitRef="Percent">0.087</cef:LatestPremiumDiscountToNavPercent>
    <cef:AnnualDividendPayment
      contextRef="C_20221001to20230331"
      decimals="2"
      id="Fxbrl_20230531184228957"
      unitRef="USD_Per_Share">0.7</cef:AnnualDividendPayment>
    <cef:OutstandingSecurityHeldShares
      contextRef="C_20221001to20230331"
      decimals="0"
      id="Fxbrl_20230601110456264"
      unitRef="Shares">37945713</cef:OutstandingSecurityHeldShares>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20230331"
      decimals="2"
      id="Fxbrl_20230531221358456"
      unitRef="USD_Per_Share">12.64</us-gaap:NetAssetValuePerShare>
    <us-gaap:SharePrice
      contextRef="C_20230331"
      decimals="2"
      id="Fxbrl_20230531221149029"
      unitRef="USD_Per_Share">13.74</us-gaap:SharePrice>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20230331"
      decimals="-6"
      id="Fxbrl_20230531184656843"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20220930"
      decimals="-6"
      id="Fxbrl_20230531184949168"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20210930"
      decimals="-6"
      id="Fxbrl_20230531184951894"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20200930"
      decimals="-6"
      id="Fxbrl_20230531184706797"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20190930"
      decimals="-6"
      id="Fxbrl_20230531184708901"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20180930"
      decimals="-6"
      id="Fxbrl_20230531184711640"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20230331"
      decimals="0"
      id="Fxbrl_20230531184727098"
      unitRef="USD_Per_Share">4997</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20220930"
      decimals="0"
      id="Fxbrl_20230531184957071"
      unitRef="USD_Per_Share">4786</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20230531184750037"
      unitRef="USD_Per_Share">5714</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20230531184752956"
      unitRef="USD_Per_Share">4554</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20190930"
      decimals="0"
      id="Fxbrl_20230531184755513"
      unitRef="USD_Per_Share">4396</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20180930"
      decimals="0"
      id="Fxbrl_20230531184758054"
      unitRef="USD_Per_Share">4861</cef:SeniorSecuritiesCvgPerUnit>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20230531184037380"
          xlink:label="Fxbrl_20230531184037380"
          xlink:type="locator"/>
        <link:footnote id="FN20230531185159692" xlink:label="FN20230531185159692" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The closing price at which the Fund's shares were traded on the exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230531184037380"
          xlink:to="FN20230531185159692"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230531184049150"
          xlink:label="Fxbrl_20230531184049150"
          xlink:type="locator"/>
        <link:footnote id="FN20230531185215394" xlink:label="FN20230531185215394" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230531184049150"
          xlink:to="FN20230531185215394"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $A[QE8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !(>\96:R1EANX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+;
M2L0P$(9?17+?3@]8,'1[L^*5@N""XEU(9G>#S8%DI-VW-XV[740?0,A-9OY\
M\PVDEYY+%_ Y.(^!-,:;V8PV<NDW[$CD.4"41S0BEBEA4W/O@A&4KN$ 7L@/
M<4!HJJH#@R24( $+L/ KD0V]DEP&%.3"&:_DBO>?8<PP)0%'-&@I0EW6P(9E
MHC_-8P]7P (C#"9^%U"MQ%S]$YL[P,[).>HU-4U3.;4YEW:HX>WI\26O6V@;
M25B)Z574G$X>-^PR^;7=WN\>V-!435M473J[^HXW':]NWQ?7'WY78>.4WNM_
M;'P1''KX]2^&+U!+ P04    " !(>\96F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $A[QE9U_:!<,P8  .PE   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MK9I=3^,X%(;_BM4=[<Y(A2;]+@N5F-(DHQT81)F9"[07;N*V%DZ<C9V6_ONU
MW39MB@E%.DA FOA]G,0OQ\<'7ZYX]BP6A$CT$K-$7-464J87C88(%R3&XIRG
M)%%79CR+L50?LWE#I!G!D1'%K-%TG&XCQC2I#2_-N?ML>,ESR6A"[C,D\CC&
MV?HK87QU57-KNQ,/=+Z0^D1C>)GB.9D0^3.]S]2G1D&):$P207F",C*[JEV[
M%X$[T +3XA<E*W%PC/2C3#E_UA^^15<U1]\18224&H'5KR49$<8T2=W'?UMH
MK>A3"P^/=W3//+QZF"D69,39;QK)Q56M7T,1F>&<R0>^"LCV@3J:%W(FS$^T
MVK9U:BC,A>3Q5JSN(*;)YC=^V;Z( X';>D/0W J:1X)F_PU!:RMH'??0?D/0
MW@K:IPHZ6T'G5$%W*^B>*NAM!;U3!?VMH&]&=S,<9BQOL,3#RXRO4*9;*YH^
M,(8P:C6$--'>G<A,7:5*)X=W9TUTAGY.;M#G3U_0)]1 8H$S(A!-T,^$2E%7
M)]7Q+65,>4U<-J3J56L;X;:'T::'YAL]=-$M3^1"H'$2D:BL;ZB[+6ZYN;OE
M4;,2>(NS<]1RZZCI-%N6^[FIED](JN2.D3<M\O'I<M<B]TZ7.Q:Y?[+<'5CD
MP>GR?L50M KWM RO]09OQ)<D0T_74R$S%87^M;EC0VC;"3HT7X@4A^2JIF*O
M(-F2U(9__N%VG;]M0PL)&T/"/$B8#PD+@& E@[0+@[2KZ,-Q(JE<HQ%)E$$8
M^J9"P OZAZQM1JDF.8[C=EN=0:]G\T6E]J.^@(1YD# ?$A8 P4J^Z!2^Z%2.
MYK5*?R+U+9''\-SFAFK]##-!;$:HE'W4") P#Q+F0\("(%C)"-W""-W*@;SA
M86Y\\+A.;0,ZJI;?G8TF#Q.;$2IU'S4"),R#A/F0L  (5C)"KS!"[Y29XH',
MJ4XFE"/N<&QU1#7GD3PSC'[SC$4H()C)1:CR6>3E262S227LHS:!A'F0,!\2
M%@#!2C;I%S;I5V:<'DUP$E*52P1J5<KTRE2\DX#V(1-02-@8$N9!PGQ(6  $
M*_EE4/AE4!D.)B2A/$,3$N89E50M;*]CGB?29I0-J6-(NN:S'+IZC;8\'/\3
MVHQ/:..=T,8_H4U0W:;TREQG7Q-P/OC2S$(/SPE*U7I/UP6L=0#GU<VT!X/>
MT1NTM>KUNT?OT-*JTW/;1V_1QNITCEKYME:MP5&/@:U5O^N^\2X/ZBMN9<#R
M24+TTN>&B#"CJ2G8\=GA/%<=O;9XH/ %2AN#TCQ0F@]*"Z!H91,U]R9J5B^7
MDB37'J)+&JF%$[K':YTT6_VR(74/;.R<O_H;K.SNPS: I'F@-!^4%D#1RC;8
M5]O<REK-<*)+L^@^HZ$M,?[ZCOK)M0>8C:IW.(6TSGOM8\N EMY :1XHS0>E
M!5"TLF7V]3>WNFQV=_T+W:LYVUC':IIJ_5/3;IJ-JE_*.\Z[KTP#6I<#I7F@
M-!^4%D#1RJ;9%^?<ZNK:=RR)D"K0D)CF,?I\0T6HD^8O2'*D'?6D+!6J"<CN
MC0U\4)J!G'YW4/HZ=@IHX0Z4YH'2?%!: $4K.V5?O7.[U?\ PBF5*C.92!X^
MU]%WGLS/'DD6JW1W*NL(JUSEAUR0TEKBG7P7LJ)U TH;@](\4)H/2@N@:&5;
M[6N!;G41[T<NA53FH<E\YYQU'06$1>C)S&3"[IT-5:_DBM#3Z@W::N78.HXW
MH(4_4)H'2O-!:0$4K6P,7?TKG]G7=]SJ H_*:A\7!(6,"^V65"?'"$NT6M!P
M@53L,:7?O\1N7\.*J!1:A9^(1$@MQ74#\A(N<#(GYRK941/;F6F)(LX8SM 2
MLYSH%?L.54<A9F'.U!P9H>D:17I1IKO6#237T;#08,;,:;&/?C1!5 J4\DS.
M.*.\CE*6"Q4IUXB;2(F%(%*8T,F($(A1/*7,B.NZ/\U+\GBJFJH>]!WM'HWO
M_VK.;6^[<;!-)";9W&P9$LA,[9O_^1=GBVU)7\UFG%?G^Q>^V[=>&:@K9B=3
M8]_%9A_4+<[F-%$/1&:J.[4H55-7MME:M/D@>6HVJDRYE#PVAPNB!BK3#=3U
M&>=R]T%W4&SP&OX/4$L#!!0    ( $A[QE8OW*[0(P,  .X1   -    >&PO
M<W1Y;&5S+GAM;-U8;4_;,!#^*Y$9$T@3:1L(S6@K;960)FT3$GS8-^0V3FO)
ML3/'92V_'I^=IB_X$./#UBU5B7V/[[G'=Q<<=5";E6"W<\9,M"R%K(=D;DSU
M,8[KZ9R5M#Y3%9,6*90NJ;%3/8OK2C.:U^!4BKC7Z:1Q2;DDHX%<E->EJ:.I
M6D@S).>M*?*W+_F0=--S$GFZL<K9D-R?O/^Y4.;J7>3O1Q^.CCKWIU?[]A,'
MG)(X2'JQ2^K6G@'-23/$'--7J#GKX((LAE%?!C5UCK=4=8Z=<]QD;C0HE-PD
M,"'>8-EIR:('*H9D3 6?: Y>!2VY6'ES#PQ3)92.C*V<#=<%2_WHX:Z?05$;
MGI)+I5UL'\'_G33+]X#U# 1R(5J!/>(-HT%%C6%:7MN)6^R,SZ"H&=^M*JMP
MINFJV[L@&P=WLT$F2N=,MV&Z9&T:#00K0([FLSG<C:IB (U1I1WDG,Z4I$[#
MVJ,96-HI$^(6.OY'L<.]++;JUH&JR79H!35#3^,GP+_-YKFW:=_&&U7\09G/
M"[L=Z>;0:>Q&LX(OW7Q9M (P]B[.3JM*K#X)/I,E\YM_=<#1@*[]HKG2_-%&
M@U:96@/3)'I@VO#IMN67IM4=6YIU.RT+7'/O']3\9_,\8Y)I*K9%V]X_Y"R_
M67%S1/P-S>[?RKYB1.3%X8M,LL/7V!S!AR[R\O!%)H>I,6Z.QJWS=^?T;:T1
MO.4,R7=X9Q*;H-%DP87ALIG->9XS^>P0MO2&3NS+[ Z_79^S@BZ$N6O!(=F,
MO[&<+\JL774#B6A6;<9?87O=M'W%LK&XS-F2Y>-FJF<3-XSLP$9M+G#81Z[=
M%48P'X^%$<"P.)@"S,=[87'^I_WTT?UX#-/6#R)]U*>/^GBO$#)V'RQ.V">S
M5WBG698D:8IE=#P.*AAC>4M3^(;9,&W@@<6!2+^7:[S:>(>\W =835_J$&RG
M>"=B.\5S#4@X;^"19>%J8W'  ZL"UCL0/QP'>BKLDR1054P;]@3C2)9A"/1B
MN$?3%,E."I]P?;"G)$FR+(P %E:0)!@"3R..8 I  X8DB3L']\ZC>'U.Q9M?
M>$9/4$L#!!0    ( $A[QE:7BKL<P    !,"   +    7W)E;',O+G)E;'.=
MDKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<
M'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X9
M9K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.5
M6QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,
M<6*T_C6"R0_L?@!02P,$%     @ 2'O&5K9"5R8R 0  ( (   \   !X;"]W
M;W)K8F]O:RYX;6R-4=%*PT 0_)5P[YI:M&!I^F)1"U*+E;Y?DDVS].XV[&U:
M[=>[20@6?/%I;V>6869N<28^YD3'Y,N[$#-3BS3S-(U%#=[&6VH@*%,1>RNZ
M\B&-#8,M8PT@WJ73R626>HO!+!>CUI;3ZX4$"D$*"G; 'N$<?_EN34X8,4>'
M\IV9_NW )!X#>KQ F9F)26)-YU=BO% 0ZW8%DW.9N1N(/;!@\0?>=28_;1Y[
M1&S^8=5(9F83%:R0H_07O;Y5CR?0XV%KA9[1"?#*"KPPM0V&0R>C*=*K&'T/
MXQQ*G/-_:J2JP@)65+0>@@P],KC.8(@U-M$DP7K(S.9FVJ51^74Y)!.U=-43
MSU$)7I>#N=%1"14&*#<J$A77=HHM)]WH=:;W#W>/VD+KW)-B[^&-;#D&'#]G
M^0-02P,$%     @ 2'O&5B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW
M+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB
M688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:
MY$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?
M#'!X=/X!4$L#!!0    ( $A[QE9ED'F2&0$  ,\#   3    6T-O;G1E;G1?
M5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS
M3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV
M(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U
M2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z
M6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1
M.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_
M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 2'O&5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !(>\96:R1EANX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !(>\96F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $A[
MQE9U_:!<,P8  .PE   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !(>\96+]RNT",#  #N$0  #0
M        @ %V#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $A[QE:7BKL<
MP    !,"   +              "  <01  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( $A[QE:V0E<F,@$  " "   /              "  :T2  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !(>\96)!Z;HJT   #X 0  &@
M    @ $,%   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !(>\9699!YDAD!  #/ P  $P              @ 'Q%   6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   [%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>7</ContextCount>
  <ElementCount>11</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="tm2312569d1_ncsrs.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="N-CSRS" original="tm2312569d1_ncsrs.htm">tm2312569d1_ncsrs.htm</File>
    <File>ck0001635977-20230331.xsd</File>
    <File>ck0001635977-20230331_lab.xml</File>
    <File>ck0001635977-20230331_pre.xml</File>
    <File>tm2312569d1_ex99-906cert.htm</File>
    <File>tm2312569d1_ex99-cert.htm</File>
    <File>tm2312569d1_ex99-section19a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>j23125692_ab001.jpg</File>
    <File>j23125692_ac002.jpg</File>
    <File>j23125692_ba003.jpg</File>
    <File>j23125692_ba004.jpg</File>
    <File>j23125692_ba005.jpg</File>
    <File>j23125692_ba006.jpg</File>
    <File>j23125692_ba007.jpg</File>
    <File>j23125692_ba008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cef/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2312569d1_ncsrs.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/cef/2023": 15,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 7,
   "dts": {
    "inline": {
     "local": [
      "tm2312569d1_ncsrs.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001635977-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001635977-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001635977-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd"
     ]
    }
   },
   "elementCount": 197,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 11,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ck0001635977",
   "nsuri": "http://www.teklacap.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm2312569d1_ncsrs.htm",
      "contextRef": "C_20221001to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "true",
     "longName": "995470 - Disclosure - N-2",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "shortName": "N-2",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm2312569d1_ncsrs.htm",
      "contextRef": "C_20221001to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AllRisksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "localname": "AllRisksMember",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "localname": "AnnualCoverageReturnRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualDividendPayment": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "localname": "AnnualDividendPayment",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentCurrent": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "localname": "AnnualDividendPaymentCurrent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentInitial": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "localname": "AnnualDividendPaymentInitial",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualExpensesTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "localname": "AnnualExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateCurrentPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRateInitialPercent": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateInitialPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRatePercent": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_BdcFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "localname": "BdcFileNumber",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "localname": "BusinessDevelopmentCompanyFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_CapitalStockTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "localname": "CapitalStockTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DistributionServicingFeesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "localname": "DistributionServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "localname": "ExpenseExampleTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleYear01": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "localname": "ExpenseExampleYear01",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to10": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "localname": "ExpenseExampleYears1to10",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to3": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "localname": "ExpenseExampleYears1to3",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to5": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "localname": "ExpenseExampleYears1to5",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_FeeTableAbstract": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "localname": "FeeTableAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_FinancialHighlightsAbstract": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "localname": "FinancialHighlightsAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_HighestPriceOrBid": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "localname": "HighestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidNav": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "localname": "HighestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMinimumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationPercent": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveFeesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "localname": "IncentiveFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "localname": "InterestExpensesOnBorrowingsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IntervalFundFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "localname": "IntervalFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LatestNav": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV (Deprecated 2023-01-31)"
       }
      }
     },
     "localname": "LatestNav",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LatestPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LatestSharePrice": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price (Deprecated 2023-01-31)"
       }
      }
     },
     "localname": "LatestSharePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LoanServicingFeesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "localname": "LoanServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtPrincipal": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "localname": "LongTermDebtPrincipal",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtStructuringTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTitleTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LowestPriceOrBid": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "localname": "LowestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidNav": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "localname": "LowestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ManagementFeesPercent": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "localname": "ManagementFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NetExpenseOverAssetsPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "localname": "NetExpenseOverAssetsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "localname": "NewCefOrBdcRegistrantFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_NoPublicTradingTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "localname": "NoPublicTradingTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_NoTradingHistoryTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "localname": "NoTradingHistoryTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherAnnualExpense1Percent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 1.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense2Percent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 2.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense3Percent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 3.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpensesAbstract": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAnnualExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherAnnualExpensesPercent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherExpensesNoteTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "OtherExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherFeederFundExpensesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherFeederFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherMasterFundExpensesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherMasterFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "localname": "OtherSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityTitleTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionExpense1Percent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 1.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense2Percent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 2.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense3Percent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 3.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpensesAbstract": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherTransactionExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherTransactionExpensesPercent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximum",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "localname": "OutstandingSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityAuthorizedShares",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityHeldShares": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityNotHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "localname": "OutstandingSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PrimaryShelfFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfQualifiedFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ProspectusLineItems": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "localname": "ProspectusLineItems",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "xbrltype": "stringItemType"
    },
    "cef_ProspectusTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "localname": "ProspectusTable",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RegisteredClosedEndFundFlag": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "localname": "RegisteredClosedEndFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ReturnAtMinusFivePercent": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtMinusTenPercent": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusFivePercent": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusTenPercent": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtZeroPercent": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "localname": "ReturnAtZeroPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "localname": "RiskAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_RiskFactorsTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "localname": "RiskFactorsTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "localname": "RiskTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SalesLoadPercent": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "localname": "SalesLoadPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_SecurityDividendsTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "localname": "SecurityDividendsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "localname": "SecurityLiabilitiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityLiquidationRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityTitleTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "localname": "SecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityVotingRightsTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityVotingRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount (Deprecated 2023-01-31)"
       }
      }
     },
     "localname": "SeniorSecuritiesAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_SeniorSecuritiesAmt": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "localname": "SeniorSecuritiesAmt",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesCvgPerUnit": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesCvgPerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "auth_ref": [
      "r133",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "auth_ref": [
      "r134",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "auth_ref": [
      "r132",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePriceTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "localname": "SharePriceTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_TotalAnnualExpensesPercent": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "localname": "TotalAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_UnderwritersCompensationPercent": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "localname": "UnderwritersCompensationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "localname": "WarrantsOrRightsExercisePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r90",
      "r91",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r90",
      "r91",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r91",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r91",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r174",
      "r175",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r7",
      "r8",
      "r10",
      "r11",
      "r17",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r53",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r4",
      "r17",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r53",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk associated with changes in interest rates that effect the value of an interest-bearing asset or liability, and a servicing asset or liability.",
        "label": "Interest Rate Risk [Member]"
       }
      }
     },
     "localname": "InterestRateRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetAssetValuePerShare": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r61",
      "r68",
      "r69",
      "r71",
      "r72",
      "r75",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.",
        "label": "NAV Per Share"
       }
      }
     },
     "localname": "NetAssetValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r5",
      "r6",
      "r9",
      "r175",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock Liquidating Preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r174",
      "r175",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "59",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "Instruction 2",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r101": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "1",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r102": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "2",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r103": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r104": {
   "Name": "Form N-2",
   "Paragraph": "d",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r105": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r106": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r107": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r108": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r109": {
   "Name": "Form N-2",
   "Paragraph": "e",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r111": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r112": {
   "Name": "Form N-2",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r113": {
   "Name": "Form N-2",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r114": {
   "Name": "Form N-2",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r115": {
   "Name": "Form N-2",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r116": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 1",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r118": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r119": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a, g, h",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "f",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r121": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "g",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r122": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "i",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r123": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 11",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r124": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 4",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r125": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 5",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r126": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 6",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r127": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 7",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r128": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 7",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "b",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r129": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 8",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 9",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r131": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r132": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r133": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 3",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r134": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 8",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r135": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r136": {
   "Name": "Form N-2",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r137": {
   "Name": "Form N-2",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subparagraph": "Instruction 2",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r138": {
   "Name": "Form N-2",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subparagraph": "Instruction 3",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r139": {
   "Name": "Form N-2",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 1",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r141": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 4",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r142": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 5",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r143": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 8",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r144": {
   "Name": "Form N-2",
   "Paragraph": "b, d",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r145": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r146": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r147": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "1",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r148": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "2",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r149": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "3",
   "Subsection": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r151": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "4",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r152": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 2",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r153": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 3",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r154": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 4",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r155": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instructions 4, 5",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r156": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r157": {
   "Name": "Form N-2",
   "Paragraph": "e",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r158": {
   "Name": "Form N-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r159": {
   "Name": "Form N-4",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "Name": "Form N-6",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r161": {
   "Name": "Form S-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r162": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r163": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r164": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r165": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r166": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r167": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r168": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r169": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r171": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r172": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r173": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r87": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r89": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Form F-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r91": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r92": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r93": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r94": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "1",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r95": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "2",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r96": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "3",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r97": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "4",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r98": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "5",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r99": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "6",
   "Subsection": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001104659-23-068500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-068500-xbrl.zip
M4$L#!!0    ( $A[QE;"V)C38P8  %PR   9    8VLP,# Q-C,U.3<W+3(P
M,C,P,S,Q+GAS9-U:45/;.!!^[Z_PY=TXP+0]&*!#0^!R!R$#.8ZWCF)O$@V*
MY$IR(/WUMY+M)-!8MGN].<T]Q;:^;U>?M-*N[)Q\>EFP8 E24<%/._M[W4X
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MY2"TMN#; #"(:Q?Y3I1G0E+ ,&2C3*9"P7F,J5_9_W9AFDP)=U<0;<A^R7[
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ML]N=&:8M#W&IT17JM\IK(.9EDZR;^2I:(A;#C<NU24,LSFJ]]L@ 1;)HR%'
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MUPSK\SOV'_;OO9O0S_\#4$L#!!0    ( $A[QE9(6;NSG0$  (T$   =
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MG.5+[!_?$;=9W$HY%;C!1ZAR,"?XWHM:HCX[>;?<J\*.GI7A/U!+ P04
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M[2;9O+FN^WZ>'_YZ^_2<^4Q7==54];>JN\_,>5]^WP909"2D)0 P$ "8?GR
M]W, 5<S5Q,83  ,@ .#?IDN 2MCTJ[$98-K[T0(&#F!"@$/!(0( DA@ 4!P
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M7'Z.ZC.))L[DGZJ+7^*H2[)T:9V3I6]SAZ6;TVU<;%G>48YS;KV]]& >:N^
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MP:U@QW-R#/O>J0!CZ3CO%&\'NV<#YF^*?UUSHLZ_K(ZWQ[-_BW\@T1Z_^=[
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M_*TP7OOD_FEIH0=YB;CKH<?^A^S3CQ^G?DC?_C\OX*, 0.SP@Q  0  P@"$
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MG"$VM.2KI'8[LF:E.:@2_087%2J:JJ8VUG*($D23J  [/,.!Y1O&AQ]\4,\
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M@Y9?X;"@'3R.<PG=@6#[Y^]Q .S$ 5-$$A4J'NKZ-KA'.;S+F#/_,T9E?F-
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M=V@=7$ZC3]E$-OY65'>)^1]02P,$%     @ 2'O&5FQ<#MF2*P  2BP  !,
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M&U\S7D.8C%'LC,N"+D0?;1+F[D DN'C.""F4WF-FC!![=H_YB/3*8:,VYG&
M5,K![4[W!%4T[BC@;#\W0X@N@N1L?[)6/QEET!"6;'_](9-!GX:2LOV7_:=J
M"_G!\(R-UL@MY.Y)M.#6HYIA:R,',Y74K3W]KW9)MV4;3+^:',J" D/P&B\N
MJF[P&DXZW>.\$>UHR[1/[2+V)CJO:T\]$U)O-9\T#V\3FIM9?APN0)E8Q]G7
M\5EBZQ_P/A.DZ K6M/0HBD3_AQ\M2@WPE,"+R[T>#;<8^#T3E(^M]+WMO(-P
MMYMQG(-7S7>DLIT5A3/2)X0)VWV6D!]>D4V@%89NZZH'VVP5B''.[_ELV-F0
MCO =7$$'Z[G99R]8*O.O:&\,OCF.*4,);IY23[Z4&2[PUOZ"\;O;/DX@!X[#
MQ1\T(%%MILI:N'+PF>3,D%9\M#]1;)WX8Q:/F72<> LZ$+SP&#RX%QB#<E[?
M^YU(BM)*/':&Q/C3  "Y/8URJ%1^')?!KFLZF!W$@":O;JBNP8U1$X'-GH+<
M0B3F#"D6,KVPX:1.IZB:)ZZ#S$U/H&-22M1NAR-B)#(RLJK8DLC,LUH0?'@\
M:]/Y>&FR,9SXKFI/>G[W81C^P:+0Z_S4O.7^^^;]_5]"HA[EV6M:6Y\U%ZE)
M8Z0P]>_O'UF!/K(;T3&='&9B)6?+JIPDREQNO,NY9%Q R(#_?O+W^,D6Q:+L
M5L*(N7NRE#RN/R=K_4I2M2WLXX;D, UPP;^'=+W:WVC23B"4<WB./RB>RGY(
M!6_J8(K0Z06WI_W83@HKZ"C!2DV701AD'$=UZ[-4D9R;_HX.!&@QJ4LUBI]'
M[5MMFH1!F63Y1I>XL,2GG2&^_I _'[K['&!1&YWLT,]H_HM,W>0/.R>2M\_E
MSEKRZI;N(#22*S[IV1EB!]B0'#;^^K=JK *P-61.5;38!VS20*?+BI9PB;]C
MC0KG:=!/-]\8U7IVXWVL_*5'N-;W@.T.]3VSPUHTN= KO4G#\,YDT"EJ'OJH
MASYC?BC''-G2@'@OG/^QC@O.A<IDC__=1H>A(S&@R*WR!\,#L- D>)(JME S
M+F%B\;-LG%(D+>WG#_VS!(_I(800UR=815NFV.Z 7 X.2!O$@"JIZV#0CDDD
M8=['^WA<86ME9GY[^N9G434#?K-7/0$^UG$U_?[RU[;SFF[ \BKSM!R2[;ZJ
M/_>64I'[U)M=856"8'OS4'LM?KB=='&F]V=^:[RX2^([CMMN?S)$WOBE9ND+
M)F0QF7X?T^((KEG)S.-B7$%5S>^->[$;WM6(#-W:1\TIS>>B%:E#?9N;S7>#
M##T??'>=,<Q!GM.R6 W]Y<!AHF61,S#6<?J$9MEGQH@RY2G&[P35@/A:SNG+
MJ_(=& BA^.U8P)4$T5+[*F_];QZ%]OPR/P*O<UBF-+A8=9LHD+IJ>_FM#Z(>
M';_]>"!][6KRJYB?),9ECT^KM6%7<)<VN?:)?U15E$Y!QCT8\O*N>?E<-_Q@
MER?+]RI;*]CQ\<:X?<B3M9WVKK( C;PYG)5M#9"NTV\URATV8RB^;'G>!AN^
MF/_Z9OVU.\N=[TI7YS%5UMG'2/(@R&6Z\\74^,F2BNEH2$,H=:+41'C)NV13
M*=@N=20L,\G.=SIT^9[7CVC<9'=Q0H4<$++I5HO.S^"F*'3C% 7WJ(.SEU2=
M<X;64Y=R;@G6$QWCI$]U;IXB1Q%-'%".>;%<E-,GC^6WP!/U/.A.2R(B_6W7
M-#AQ#3NXX$,.AIY#;<]'OD?IW_$">(*@$W29ID@NH#?BO#@V;B 98(K==@I\
M%T.9Q)#H<J_%C!KT+8"_?<^"2578BK^F0YG=S[/I9FD35L&3I;,IG,_.!5OA
M$7]9?\9H4QY.M)80.HST/MQWP*"O-H=IGXR__+:LXXM07G[X5(NC\U4O(*SI
MN24?M=Q'024JJG)4X(4J11I'2.\8=E]%E<<]+;WB+,"*8EUNC& =?W).7N3V
M^[2S9G';LEDO8U]/T75@;SE(RR,0-TX\:?MJ$R&Q*R-6I%B6)E0K+VO1:5]O
M[A85AS?[@.YFZPC?]U,^"OJ-7$TH+)8\Z9SD7' U'6%[PM*BF-EN$;1R_DN6
M9!U<S^WQC]Q5>OMOQ74M?VJ1GD56Q<G%%J<'$6IQ?8P<7<4O1.+ND*$N@XGV
M&S@:D"/-(\]N%2K]\Y,F02OOBU^=L;+YF++NH2J2E'M-R=U3YNAR7&&A5IX2
M?P9#U4S$^UCL][]%R"Y;)O;B>C*T@=HUO?XU?[G,(^#$X(_8*"B*HKK5Z1-?
MYV]L38Y=RH!6@;ZE4*/)G9&%84N!K2TT8.4:G9P&810"OF&B9BQQ 8-VIJO!
MR<XC%&2;+HG-)_=RUY#379A>[]"OHQ\G/!8)/DXC1EU+_;W,N7)'CY"WIAUC
M?GR25+8TB9\A7OHT*I/F<?-*; ZB[QHD\EK%_;V-5!7R)%/9'N][Q,[(^3P/
M!+>9=H5]_PZUYL>$'H_[O1G_()G?.UBC;X6SEY=0BL8Z_).45WF#IK^N%?N5
M83TV!*L0@TN/<JL7B]*55G023CNYFUTW%WD0$ [X86,)'SMTU*M,]B<'TUXU
M^\S?588)M]Z^TQ:SY&\=X*@29<X'G\V<<?2Q%A5!JL:MO;%?SH*V1#.8-*&>
M+ U6D:/Q+<%MB$\!\-'?B)'^E@<5Y8BJ6<A[<O*U@>><O?'#6FG5WW6OON@U
MY\04+S,L9<;BIR<PQC@%XN^%#S-.+K$IG]^C#Y8__HX\]:;*)USB-N0S+#*_
MB=-P74]GV5OL\>7!LWZK+TB+7I(3.$LBFGV0"A_8US';[&H8M!1]VA[%S?KH
M]C!'XN'72 CGRJZZHHQ(R)Y55LY.DZR&?N9@T/DH[9&:6NP/4XN2[/E(O),W
M"+L'I5?$S2L6-'E\#G84N+X]'U4'#I!;1_,1'6#O"J)CBNC]](J^BXHB.1,6
M_J>Y%JB1X)'NNAA!HO72X?=FB1I%D_#0KSQ'2,SZTA^KG\KXAP&8T/*OTLN9
MHK+GL)A6HF;S/I>9>'Y^4>UVA5=/A7Y!];%.HKU:H:FBY;9N0PX-\!E0^.QO
M1+CLSI=G61U7=ME2XE;3N/G0\^C^RYWJNHWB38(L&28M@OO#_+QJ@S,.-JU-
ME^:Z+ )^2 ;?89WV]M[8:&C.O<!ZI\ ^W,>>IRC_H__5S,3)XQM;?4SC]X5+
MH/Y$ZP\POL/J P5E99N!&S=?2#:&O%]B1HR<]POQN.Z1K"3/<#933KWO1 -I
M@ZW38JPKY3(Z<IMU=W'GSH:>UR]D=9Z]CVY-;KI=ZGAJ/I>DD84%9T?J0M4#
M]@UT)_$=K&JW<(T;?YD$WDU\K Y+G-IU/_!TP7Y*'#;K:&P65_@U.KUD</_Y
M[)N*TMA7]GKR3X]KL4%](VG"569/R5,\,S&%_TUMY__.M>^(Y\T"7QZ'MW,1
MJ<Y,I]->((*44B?4L[E3BJM<QE4#U#%>XN(/'7:_;I21Z=9M T4UI %*)G$T
MX,I-)=;7[3;<<P6M)W*O*WB:3I@'9%N8OR0;:X1^D"'=Y5#/JN9LMS8PY5JX
M(RJ(:G\NELYBC[)'/:7;X1<BQW5;9W,#/JVOSD8S-09S[Q]6KTQ+VF5O6F@Y
M.)P]QVWR<!EYD/OPTGI-[_=%#V<__,0'2\@FL1;]B3J\4+ 7\BCLY.*HS2_?
MVB!N.^6-XS1_;9VKF>]J"Q$2MR-89]HV)! $B4K1?)N@%5202;?B+J&W5OS0
M:%<MFC@>;C1BGK&,!CE^-X4$>BQ)G6V[T7U?XYSTM[DB[G"\E?%,14*>WION
MT-8$3Y6FS! _B+KL>"(Q<.@+1"%8-.VKS>$:7ESN-68F3W?&T$,/IJYWE97Y
MF]?R&6?2XN!L+*;$GM)I5S2VA7S#QK%1&R3'X%'&J26$T]PXKUZ1)'E=L.KP
M#[O"\1':JF0-?M ]I$\9S(#[;"+T;M^:^")8]UE(3_2*W)=2&5:#TRW^FJ\:
M$;*W!,_9M/&)#4$>J(QJ1RV"C\592JEBW]QC1(Z3#BEM?Y[L6Y,7YCW!KB$M
MQK)* C&&%PF?O@]CT&R?YB,<;SA&I&Y^(D[S)1M6J!N9R16QZF9:"[[IM\W?
MW_C#[\QB1P-4\2MZ,V:N V(K$U]GN?_*QUO+-(1N_27\O=7TU3*ZU>1&V\$
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M@\SJ_'VCI63VCZ/J"4YW11"8]?R?)<JNC<7C)L(73IOZ30+>U X7BC]QJ]&
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M6#7#-Q_C0"(/:Q!^(8<#+Z=J7!#SVK7__JM3C%MPO"O5CM$0*?31RY),LY=
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M)M'H-=AMWX:FH""TZ?\#4$L#!!0    ( $A[QE9 N^;]G5L  '1@   3
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M.4%YL15@-/)U+^'7X==QZG5&$XJ)I?P$*]LW1+W:0%KTCUHRPGT:9*15[<;
M=N]YPXNR63RWK8/M;CDG?=!<-<)C*!H/<Q1A$W?,S4M)XNCY^4+YJUKN#</?
M4C6_(IFAW,[HAMD;$G?6K3G,>7$8J F#!*W2U!45G%Z6K:7?E^CJ_KJR0W*#
M@L]QO$/;6?M?;A8P?&*7 ?5IP8^GK45P-FOHTWS+A>+N;WW=U1\0/=G4W$'=
MJ3%[3[TQX*"J%$A_@+N*ZC:_7,][A7<@3(:/Y=;6H'D6]1#*@([\>5;Q' 3'
M^F6NWMH#$2&!YP.NUC97_RKJ!/JK2L7J5L?26UIFI-2%)&2ME87KW U7N%^
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M"AL9-CU\'\B2,5A8J_BQ7M"&N;R4I6Y;]L_1;D'V:""FQ2?'#>WW+A-H!MR
MEQ6$/'[H5U5MEQSR@I50[1[\A[[2P:-"0Z<,4#"#3]U+K,AB25]O?+MFGFZ!
MH&GYO<EI 61WS7D,#UM^_(,[GYR=[-H?N"&ZX<-'FMW1(!;%]NA=+<.58'N
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M7565FA:^FFT5&KM+'W;LDS?PCF$V=FH_/F]QJ*9!I[#P!HN#K@$1-?D=S=<
M05G!RWEQT(;5C"&7A\W)(?6,0.6S@+"6SP'-#Q@8GWYWE6B<5ATDY6Q2^%.C
MIW8;4^8Y;U 4,U@U($+_#BG(T-/-K"X@P7%L)?O3?["L<@]C+-VMT_]3F]K
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M>MDU98/]YVQZ@:CH)EB'A\WY-<!+YF(!#JM@BNE;+8G>KWND'Y@EQ3\Y]<9
M"],V3MR$MX:+K/,I[U4UU3OEU$.(73=Q2A_($C_]VH<%ULK7O8(X22]'S_.T
M^FR:+-&QX)O\_UR&V:F6&Q?UZ4QQCHV:\ @%W20VH6C.T(,9A-E5BMC,8[T)
MAH*8V:DLA5DA23[6Y/YIEXL%OH+R7<AC0BATP0CL=CF7,FR#FU[_-6YU@WB,
M$L!1MM'<=#F[KU,RNRCCZ@F4&,/1#;ICYZ<6>T1Z_R).@1-- L'.)@H72H3-
M_)-S+@H^<S:.VP*4.3YQ%;%:E <*0OX-,"X"8AA.]9]6$L>"(T^HZC4@Y1KP
MG#V>XJG,*#+I-5L5FQ30Z._6]QV6W01.[>'328U*Z9.^N69#<F<12EUE21>>
M'",+>RQU[AGH2!)7!(-TM&J)#2X1B.XF]16Z+8=BOWW,21?:JH(DG'\\_P?)
MH/17JF+*N;L+QT@K&I,Z^*CC,DOI<RG/GJ:_Z9RG>;J4RI9$R.IA,)?CG8\2
M-9_>!4CV!N)M$0-/7]1GOY;J3'FK&RBX]%&FZQTOG.MR!FXJ/] ZTW;GA5G,
MR#C!;![U7Y5G.E%3&D./]3277PN:->$B&$#L_T\H_:^AP0?SW9;W<3/>GNQU
MT4L/AO3V@R0';X*D!KH2+C7-0L7X/E#X,VG.@G. &&ZN6KLEY2@)"F\9MDMU
MA8*O >I_"AB%I;1JWG'=2&8$.FC=Z\&< X>S6_N[[M GRI@BA2< =\*/A'\>
MA&I9\7[\]Q^%F5@PV_EV^16W:[F?W.T>''@WKWBB1B=<(W,F743 "7SG:I69
M?9M4"!&-S/8,1.<IM_UN!%67B3@\N<Q?V>8_>[9J/C/$X*.';\"L-V/ON8>K
M.H1FN*Z:&BV+0+Q;RL2GF-USB_A-$YV2_=1!A)6@QH;).HG=MQGZ,>F\1MKW
M%7HZ&0]2N)PC>TMUTM\<4NWF"EJ:(GZ8K+VUXI)[W:?#5O;3OK1.;'NCS^;@
M1$A8Z$S5A)%CNZAO\M=? P7#KZI/'7/!1F3;G!J7YV;.7P""S"]E\K-<Z>!F
M"88D%/VK<N2O'PSFK,;9 ;^?HR^3F7#,M!%#^C8"D/HR'^BO.9/ IHY7H&87
MC):K*QF^ ;J 7,AT<T=_E6>UL&/+A\4<#-].4'Y66N)GO*VD1GI5L>4?4"E,
M!5>J.6C)8.PHF_,0Z/S:;:1WTLO^6"<RD3P_6U7%R U]P1;D[VL<\V3'Y?/
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M'.]TH/OG3R<##ZN0?[1H+*EOLL* "./IJH>',*H[U8C;<L7(WD[*)"VA^V*
MY>2$V=K6&3HGWV2<&]6[P!(K1$]!(9<?M1&5>^N0@5KF_(PX?8>A+^*7-1@K
MR$^M=5>@3LO"P.!VO+)S^;:4\@^"(J$)0J_AT1:Z!+]'$QG0,S=>]@2V6"#@
MI>[=\2KSR[:W,NOX@N!^>%7[HJ/S_6WACB]J]1S$9CQWI.#.$S3F 7F#&"2?
MG7T=0M"<P:_V$#[L8?9AQY.V<O]OABJLK]O:L5R5I85TLO!@HJBWQ4)I$Q%P
MT(]M+7.^T]-ZJ#K>KQ\.T UII-Q>=&D;;M^$[U:HP8VKIA=8W772([GG'4#>
MN:G!8"/SDYAW5OL6J]-M)9DH?;BE170CV$Y2O%$DR]*,G0H8< I,SNQZ@Y \
M^I$W\'Z./8]2S/0B&:*C(B042:44'BNZ8[TENQ6<*([900^:JMZ=CZYJTAQ
MPO==K Z;OSB("C_@U<PY99K-M$H5.AB5C695T3EDEVKT"/]0MJ+Q]G4AOL8[
M2BLIJZK6?[4$/A3 .[%G4;O0!L;/,$Q9!#?USBU(\G;PU!_ KP'.73$HNM1
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M5D 7)/5NAM,#40ZP- :"K=R^?]?]0C_%N[*ZH2O=_H<J!.XAZ2K3WU#@<JK
MZOE@SNR'1;3F\N2.!WF>,F[]66)AI?69]*H@;$;6_[*41%KKCY4^>57==4YT
M1\AIQ]RNH>'['<S!%7E61IUF;VD\AW*=FV?_C/59QQ?6I[SO;KV,TFF,JIQY
MX WU8+#QA1IL?O[&]3/_P5Y\Y@-U->HP^,4PL)4L)"TN!V7Q]CCQ*:RW8(_[
MIRE^ 2?V^3<L(=G-S?Y11?C&205R8[;</KQBH'^YO*(<J5F^DE?D'N:>,2*8
ME6K<JBQ<%"<??]7BE=:E,BHJU=@[EY>4^S9S<A+[YS9(.H@-;?'A+9ML.,.W
M[E3C;(&TR1AP<-]_E+C[==R--"',BZD8P?TTF-U5:IM_?6I5[R,&"&7M6;OP
MW]F38\26L!*4CMX6?H0-FT:F-63]B DP1G>L@>:F]P?G6W45-F/[O?[ZN6\N
M^=GC2T+A^Y^8LNL>G*XQQ$P2N>-L(>Q$ BF(X#)J=,L,1%^*$_9Y\\'E14#
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M*B#GCOF#R1'AD2,AP2 !.6+!WMD*:89FS-P$>OE1K"ZBVU \Q7P1]?K5-01
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MB)=H!SQ7YD Y(#!FB3Y_D#ED%K%V"6@S#DE8J#DW:'0/\H5Z)CG4M[Z4HNP
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M*4Q'1NB^H#B'\>IH/927K/J^K< #,/C83<IT3^GF2QDYH)>'@WLF.$7:2$?
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M#E:HG4(Q,R*-">L[-05S4G=8VQI19LR&><!F 6/O,3OA%@%MH(V9>I.'1T=
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M>CHZN#_M51J:M0/Q.MI##P14R.;O$/4<7/&9.HM/KA6[MTB3:7 '*T03*%-
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MFJCQ.2ZD&'?0<'ST;+@NH\X?7 6,Q5RX+/!^H 4'#K=U/[K^@<.HJ>_+[1Q
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MOVUAI%(OL)7A ?.^;$]F]JU,5Y 4QXV%\$S[=S84O+4%-\XQ67 +A0WT>5S
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MV])K:C'JQ4,;'^WN0)*8_[DR"[5;#\'M:.1>71*ZL2:C""RZ;:MY]]D\5"N
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MD[U^4!$6&LR,$ 1XOS9J.@F4LRPHW\)$J02T&8B]O5E;:V#81O& U!%2?^*
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M>G=(!&D,ZB#$RH7(;K1VA$[:^.V>59U$?=AL?3@%%*C%F"P8VK@7N9ZHNV&
MZKU*=TI:M@M+,U0F_^R3+EQD*6ZI=B.8QFR$HOS='B*=/S@A6!=0N "OC)FN
MREL<U-,U=N\GS-38E$3<ULHV,SE4MB+HWR5*\_&]C".58&AP24N],X@7C,<
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MUF..4HPK*HA0Z7@,,E2(QVXW]5,126%%$(<+^UZ-.2+1W0A2K88/^KQ'%W2
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M@XB%"7/W[5W5$)^Y,#E+N2]R#IM*^ZAD62,H;C1DP$8P>T6\/Z+*>O>2(/W
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MW#AK9NZ],^O.S+WKN_]\+VMEK9R7G#SG//O9>S_G#76*.@^XJJ:LJ@PX<Q8
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MCIS44OG<I>?"0!@O9ADC^VF@-U0=9U\Y+=[<(K1,\AZEQ95/F:;4N@<8U&=
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M-$ 5LNHT3MB*-8^I\315!,_[M3]JJI5[Q&GA7.)4YBR;XK-)*(GPLQ=C05-
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MK.65D9_2$O@0#5U2T=%J12T@_?R-?\Z7U8Y)GNI.-#2[&H,82#8'7 ,X_('
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M#NYQB;KYO'9_S-UVM2!2IU=V-'"0ELUTW/&58O&G3B(,:!YN#<4(-/F&BY5
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MPDE'D-]^ULO8_A-AP,M3304H[?+"VF1NRN!0<%DJH *:_N7Q4\:<"\.XON5
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M2S+)H$=;2&X;I#3I<D&655-N:-STU(-;GP!&"6KQCC_SL^7#+S::%@N4R<W
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M+?(2(J7^'DVPYPFW?XGHTOU:]&DK='QJ=23X'&!K0M&D.^;SHN>  ZDCZG,
MM@UW?1PY%F"P8@$SL'(J6"1;<(@R&J<Z_(C(F9N_U/X^YV56O47:8.L+^6GZ
M;9*1/O7GE*U<0WK-9QM2*\)N#EPW_\%_OO6W>W]Y6(<<W_PB< [@5W0.&-Y9
M"#D'P#(K0#LDT&(20?3LVK#,25E=("NHIN4/;3W$?.SX6LITW+:OQ0<.@>6R
M.-%KO@- TM&C:LL'U9LZ7(&2JVF]GG_E812N[HLF;LEI;'CQ,RH"OI8 S/1
M3W[I[&_!\X4LYMVWP'?EGZP,LN?4IM[R^<S3LAT(_ A"'2M02AG#G@&%-#"U
M#I%Q%A1%L$48(I,H3^^C=3(S3'WF1*34N,-,$B;SL"C??*;_-'D>SEM:.\>Y
MH-R#<-S.2E'J48O%<02]&=5TT@]7(HB_/>TN3GV3EU[CPQDZQ=BR"!+<[QRK
M=&$B?1GWHJ$9T;C$0$TC6U3 ?)_VV0\%N2'@S YFH(^D/_%>ZJ>IX3=Y1<[7
M][>H-:Y9N@?0&W\Y/1&=QW D61 _M3P"'5B?4B $CR3(G@/,R,;G #^+P$8E
M"J@TA 4N^*V#CE4I''J=ZQQ &!A&SQT&\J) '@L2AG0?+;@+-MQ,Y!B0",Y^
M"B7K]0TI^=%M*[":>/_G<5AT1*&Q_*=KME#WUM(LP&NYV'J2W6I3 USN3ZFY
M$63NC94NIYJ0XZ6))ZD3&O8W%C-R0.[^%$KF-B?L15/IQ+<8_/O9 ]6](B;E
MA&^7'KOE1?*I4-7\ZE LB4$"#<$E&]5>;%ZM'#'W1M[) *](&3'P6IURQB*,
M3?7U8QM^REJGK:[<:5)LNW2#;43M+NQ*IAUIJ,&OI0[,I'^GS9LG8]9PO/+5
M?8EL/JYO*KF:]C?S ;ZW]G8JOJ.K/:Y%;GFX(:6:2E;$ZXQXA/2?,TSS26]2
MW\G[$"W8'JD )$Q<[XTXGDY+@RT!K_M%YG6N(0KM<H.XIUMN/"Z->-2E/5)7
M$)FT=LWZ5J<QC%,]4C+F>.'):J![K7#<^]I9_$^4TU?=3]I6 HZX:1X]>;ID
MYC]]Z6<I:Y$V:T4#>YWPJ]5U4 $NGZ /=W4WJ:_P]6;<=AO+5Q'M!=;BU#6W
M!_UN'W,;1&3E]K9*/LAH.U)0\%" R>9%<K)",Y\6O!.H[*<V_^?EW)0\7&,0
MN.3\O:V\KV9&R1-)V_T"&B[J%"PE*,A^Y<'RZ#SD[,>:^=NU IF!7CA3=037
MU7_WDHJR^;+LM;V_$V_['K#:$NGVS8H&;#8K0.Q U9$EA'O*K7 ;KO2JOX5<
MN5T#!D+QNH,QIQDI=Q?R;-Y>J;OJJC4U'3R4[A\=.LA76BN87V\X+G?CQ^-D
MOMN.D(\]A0O UN'K'H2V'0W@JIM"B+1AE^5^]\B/NKIK5D*J_)=_?="SY[OY
M8,G[@ <:O$]^-_Z ?>*W%U-[5!QJCF:^7)SDXMBF-=-R0_!=Q[JX+K0Z$V[N
M2#9:8L^(SGT9XOUYSX&JV[O.*^4Y$NVS4]LWJ(,6$9H;/7F>Q_-LO-&^=]9
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M-3='$\HR;WL^FSL'3/$2P\X!!B W\L;/C9-,Q&[1BR*#+S,:>F-: @8*RNA
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M9ASROW"^\;%9X9Z!]WORFU/7S49SZJI:_5^],$9<)\%\L=>S<Z<''-D:G(V
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M,I%1*F<')NBR8VWIJ!,#"F%@97,+F@L\@<M3%(8://.D#OL@<Y7ROLUUDW/
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M$3,WC6^=U_61U:S&#4R%DB)_]UO]_#&ONZ.M+HW5BBWBM%#$-TVDXFF*:F7
M"C3LF^ADM@&5\#ZK_:-9L]:0KC6'W6/,O_-NH0-O6F/R"T/CA,,SI[1T'AC]
M"-#^>+&34&,72FX+<=?9X8-ICH1YC2K&Y>=@M<&-DO#8U$R9MX<IR?S[8?^*
M1[<E%<?D(O3BA?\--VH3:Z'$H:;[6.PB(3$M1S$RRN1M7N*("X22C[.@#0NZ
M4U=H)YW/.6 #M\]T)HP/W%SVM Q,HCN+9W,A<S;U4!)> X6[1/QT#DBX"]IX
MSW3J;IX[5+]SII "VM!VHXA'X9.F(6_MJ3<G_X6N$O]3%]#_Y\OD9)4%#PB7
M=;'IXA[/'THQSR&?"&]/G1:D*9\)4NA])&U=ZP[H3"'#\AR0VS1T9@H)U]I;
MO. +)>> =J]Z$-$!Z?\!^-=B[R?OF= 3RA?4QNN)"N> _"K>,P$1T.9JBT']
MSBW938[_0M.*D7^.*#T2M_(]!RS-GP.>9I+IRF(O!D&&_+]MO">=5KK.XCG<
M*5WX%\M!JLZ<5VJB4-T$>GM*8/U NZU3#Q36+\+6;W& K*?PIHB1;V13$.$-
MM.4HDLA+WI;>*;\^1TW6_9?R^<\6NSV^2<#UE@."->6E4M>9*7*3J+"H;*;X
M7^F4PL=QO65-W<7BE%)#UNC/ :V'>R:4(7A%J6#_NX9;]_'<.8"9A((2O5S6
M".1NOT1I,#IYZ'@)PZ+/&T236%R"Z%PI<G"4*)]8WG JW%CQGO5>'J^HX,A!
M2_L(8LB*L\?*8'09\<%R4_ @%Y2?7Z WZZXV,U7(<,R4R-D(@1>;3L28[?C,
MPASRT")(_I70%]QUM)$K18#18 ;F[NNKPU-_0[)1R@@23&%YFN4=N*0L:6;F
MMK2@E,%W=,)](Z$\2,MUX)/0CW_$#\$&TJI\;%G##UY?OXHQ9=L1!>Y%B>^%
M;J/9-DW-P[KG7QM=&BUZQ%,<^M309TI!A0,697_6L1+E9N&S5E)JHE"^7?6*
MR^Y+<*VW:@EG#/JQX=^\9X>N&;L6Q:?_/TX"Q>Z\EZ;^GMZIJ;)".?%0_HCB
M[N&!^*Y1:W8F8]E4'%A:^:YV3/:GK**^JU#/,O'+89+6(11ZBAAK/BFJA*MY
MP,*L3KH>!V%,3-B&GPD-G@-FTWUJQ,I//_Q6PK2PDNA6 M;;EF5X/&"61+J_
MY*JM9P3RR"^\0V44\;Z1@&JW^+.-0L8J+#R_9* :^"_$;'Z7TYVV&M&E-2[G
M!:KV$N'Q1TY 3?0U=NO=08PR[+/8>]IJ\?TCN+.T6@I5I&\2FS@61EUE#M=<
MR7)45Z]:7@N5'VH@ZL/_:WV0_F3YL9\#4L2: G==S@')6N> ZU,]%^>0_V_]
M2O/_TC?N#(6Q?:DZ&<NB#(O?*H5I3-_*3 WLOTXOO5"4U:N!_%NE>[I[K*C#
M -L:U![17:J%S-?0OYI1KQXW[-ZT#J;ZKJ%]U9TBL*"$N76T21>-4ATA<K$5
M7](4&SX0.01NK*'RH(G^*J8CS*C#K*VGJ/? AE,7\OO"4.4%^7AG,&Z+IB=R
M5B%A%D57)D-E=5VG;E<2ONZ^1(@W4E=@\WO6VU ,4P9I1W7J]ZB9:#]4N:TC
M^8?-*)J3"KB%%9'.V)ME(=[4J*\5V43#Q\"3*CHT[ NS/OVVR[_UU)3E1B<Z
M-!+;)O3?:'$+JVNPAE;>B^77K[AZX5[#A")M9<L2Q4D>@5X@'9Q_&X,\@_L[
MKT!+W%E-2F1BH=K;\691J>2?I:J^"6^MW%--:6]>'#^/^=9G6754;.MU+:YK
MK3REV)_1A":E?7+,VLW(6?]5JFQ_@!9S=':LH^JIOS]7CY#$OSNL%74VW*\O
MCK!<V[?@DNV[U!A8]_RA^;1<24M8D[0<V^Y.R_X;ZX*_#-/?;5U$O_0M^O8]
M_C((/M6#!00_WY.$T@__.U'NF'PS6YCR[U>UM6FXY0_UQ(4D#X;[M.7+?BO=
MYAM5XS1>5WT2&_CK_WBPZ_;0$C.1CM(<'%N<D?+L[;#)!%UX_G4#K6E;=>OZ
M&KF'CKX;5MBPTWL9JJ/V-/\8/YMS__?UH,)40T*+#'E@BZ9*KY%TQ769D#>>
MU0T^M55TM<EX[68XFSY4YV9B0,.C66+E73%][.&#L%\K^MZEILR2@N *O;$2
M0VE!"Y>QLP'I[1U_U[".;&@)7-L0VUM%E*-Y [<U)A+R.E[HJ"@#-;,Y/O49
M3+1%!9<VW\BP??&P1])1,_\-17W<J?21AS"QF27UK_"Y/?MN(W0X(Y2G69H1
MQ!;U,R\BM["XM 01*^"H:NP=7]7#*?#DD\J5BS0Z!Q@190R(4B(6O!,L0_33
M)H$TID>]$?/5Y"V)"J=*W4/HT6DD"++3*^LC#=LJ;5VI\!A=6>J8TE<)*XIJ
MU7\<_YF22S?_NUYA0V/.3,IE&*BFYE%HZHI*(\>'QC@IS?U$<!'2H\3 3"<J
MBN$C]OB/O72&EX>2MKJQGQ*W\XRJ/7>P@\/HPZ]<<5CX#S$V+J58:0-E/4_/
M=]U_?HE75L8R&[)\>G;A?O0/]6GI48^&45*G-8G"D/XR^U$M8. F,I^Q"E]J
M"!EPAHQ9'USD[.";J7=$$36&I#R2<[. 3:C^9T6]&RH+/@ZKH084"+L8ZS],
M'7[11SL9@]K@< Y_SV8[]Y7*NTMN:#C#K D'Y_>RWCX9=$?XS_:1==LR1+<:
MZ,?[2.F8S ^B71<7A837:J91A_:L.7%V:ZA\ZYI<V?S1ON1>?UI</7Y_5$^+
M7>+:IY_=:_M&UT.?/,[)SL] Y+WD#)6)2="B1!S8MH-OP*5WQ,VB]$6ZG0?O
M_?A3Y5!WHM90"Y2[&:/^2A185SSH 3\D8%N7/.@7]N/UHD?&=;OT%(1-Q;M8
MN+Y2VGBIOX25L[,?T;%&FB_\WBZ&VIK<_9C;O5[IZ1UZ<Q\>])B*\\K7R,IF
M1U^KV$&;S<6<[!"#6$2I_6*X9.P39 /1<,,K8+P4,P-.4JQWE4*U78KHM)5
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M5H_NTWXY(\1M WTX^8+M7^==IDG$YNM+7RA9KD10]H6> W3TM4=<K'$W@.>
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MM2H+YQP^.TK.0?L\Y(<=8/W5, ^>%SK\=>T@TLHP]O6N6/W,MZ'OR.-?I$S
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M1DEWO)-3F_5UI>,M "6Q7E3!&#NWOBN"R4TS<"W+=^:5SF&+TA!,V[:?XHK
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MU.)3FI/_HLR___T!AY/B/4PPZVCQ(G_[W.IQ[B#LQKS#ODY%!]K)^_U06+E
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MYKQ_.$DW%MMEVC_70&^Q_@U02P,$%     @ 2'O&5D-<)=.$AP  U)8  !,
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M$+BB6B1%>#,_M#84VKZ!OR2-&$O;HR*T0)+DIBV( $+T]S+22U%R%]-3DD3
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M!E-;5PSS<.Y"JT_3A9SK::@!1CS;9Q#N;+-@6N6\)FGP:16C7&O-*.75K]
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M:$C=4*,[4:Y*D\8;;[.5DR&47@HDSX75;)270%IJX?$(-.1']G_*;:]Q(D2
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M'3RLL<%:T?*LU"01F-_E8>ZV&[O_:S]]@(T5'^6Q>,P82J?S;+N@*&?('NL
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M.Q]=PY6=+?: P@A@P%I,7S6W"FF^$>>F"Y8BG)9WN]\J[-BELZ4621ECF;9
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M(3.0<%0<O5KFY"5UXSRMYHO_S@_+%\Q0E8(97M"'DTM=PZP$? Z3R))IXE&
M/@G J$AD1>+/#3NGZ'>ANF4)9QTUH+K]*DM8/O/5 /R,[]FX3[XQJGS_D5H3
MV./+O=P/<,XLX>'-)4)7R/),&B=P-)V#! !=F6XOGW>#-=_RI3Y_\QCXY[G,
M9ZWV1DO=<=:-3@ZK.;[2L0\G%G=D^*&+)Q8$01BXKP9#0]E0GP]3]H?UN(_7
M^#[N$,FU_$&=]T0)SYC)LU,K=3Y:&M\27Z%5[EKZ_1O3W$(G6GH"-(\73EIZ
MX_U4!IC&<<&1I^9940FJ3I(D 31^D !OL_+[:'U51K48->_'"3-_K%59.W_Z
MA*^#  .7/7WBP/E$BN.JWQY?RY?7E#3/J12!(F-2H^L232DA+AG<D4%3ZC7O
M*2J^Q]9[?XZ'Z62E4[ZFL?5IH;D;<=Q6I\C)% GN,\'(97TQQDDQWX$]) $\
MY,ZYGEB"52T_N0:0 %)E1CK?' Z (R"4CD;P[3A6#1IYVCTQA^NKN[LW'1G7
M;%AN.#BRO36<_#*;_%8XG0&\+O)2K!<TB4MX_B18K+$E[)!&'G&=S%LY-F^L
MWCBBD-<ZG=:0^0]N*/A_$F=KQ/[FE8/%-#F22N/8*9PH'Y:6R$11_I@_!P;<
M^'V+ATL5F&K@RF%$^?L**^!;=EUYV][D^;_;\T[9H]2"'C$:J:3<RE+5B/3H
M9".SYGRUEYTW&H0^_AAC5!EG#IY \&4J*B/+X72.WZ.@CZ4,@:)[V]?4#RGR
MC5/_FHY:5<B&\.26]ZS+RZM_9T4^U5_9.]SG@S^ROO_C^-!F-=#M\E_MU:SZ
M1)&)L8B@R]5MJ>^E[HU'"&>DH2)B&/>./JT0;9]Q\ASV> ^Y^!W'>7@*IVFU
MC'=<+[LAKDC\-HYLL[YQ2)$;=\B-RX )9T=]-K1O4PSYN6W5LN#GM?K9=L)K
M7^'/_@[GG;6[H_Y6HZF@F=F;+QN?U9\U/VRFO)Y[27'T!X#R]J51VQC<F%_;
M:I0/B];?/5P^-GZ^W!'<WGJ^A@L,^9@W"\F-#;/F>K] 2&T\Q]#6BQ1S-CA\
MB5U6-I*#8,UW&)IA&7,333'7+JI &2Q&=M+?#PVT#@:*3\6JQ9)I1P94]2#W
MU[,ZRK_RE^32I$<[E&H\+1&=S5'<7^H>]DO6Z/#B3$$_%<L$L5,!.'JGU]UN
M7I5O6=PO_:6.S@T[!7T(%ZHYY$_J#YF(O4@PNE5#5#R5V,O?ZR .]-C:@I (
M.^9&8SR^J05SL^FT39V6<Q[FNQ( A03;9GM7ZXME_^(_E$K[,F/D=NUR<U#H
M2%U]=<_EM^;Z!@6PFW\[#(C]YU2)YD=Z<FX1-PM:[)Z?N2H'0[D.-.Z"P JA
MSU'Q9[A'=9MNVHUGFO,LC4<O%(:%W^XGQ$DQT_H^M'KF4S:#/)B>3TKZTO;E
M\6W_E[W+Z-R;8]D[C5*^@K_'@6IKXV1D^I1PAM%4J/HJ)'(M_RZU:<$$;,F.
MC%C BYX7&NWKTT=9 ],&A1PX8X]O 7S7$Q^E^I( 3]"ILW0GQ7UK82ZNI]D:
M@<'E[T5<]32*KWI0Q&5'6#(M%C*;F[G;_BQ(S#@M=0'^/JF!>Z4"T98D0$11
M],][5?M!<BI$I:/=NTNP(9A,@CGWX?F9;1R=BE=#YZGD$1.*9=8Z-GE,RB[[
M24!19XL6,BF>.U;:S.!CO=6[@OI$S#*\C[CZT0;XMVE4!S]Y"];=LGSB#/XL
M60A)(8_0OP]:4KR)<RTJ,@E(/1S#W3_\'/HJP/E(';48F3Z;X<S%$M!Q!OR[
M]Z@MP+ASCJ]%]<,.EML?XS$$<C[=ZO-8./Q1&VOE)@"=SK7GU(POCE:Y1HN(
MNUB>UQ$-K>RYX,Z[$9!9.9>M [ZL/R9.<3J&M(P WHF<;RJ'WO):K6F2>_PX
MA9'9"DBMI!G;9>_B.J*JHYK0,ZI\C8M%@.9M";-+\7>32ZA'G.E9\L( GN\_
M6"X1F@\U;4XDM,-='M:98^OK$O/ 2T4SM)I92S@1^;'TEL8XKNA43QNS4/['
M2H\$Y05L=B>F.&8PR?*MRT&%BU@]V^J--UJ/VUN\*.= @GP]3WMUW+KN!@H8
MW/T^71RX (/@0/,#,\VO!8<.T'1CG]WK4*,$K8L9"G,59./(-0PD)B5:A!'!
MZ].B#NWS[W$-_))@?1CHK0_6BN=(>$3?/818^*S[9V<GZ6NI&WTKY&D<3QE6
M7%R0,U''4/G%1%KOE["EUP?N3'-'W/R'7F?PQFKQI<,;1HOHW.N6JG#M1:>Y
ME'L]?Y*T?#-?WGAV:9>S;1WH+3\%LL8,SH$72A7]-N):UBO:(XJ,H]H\/^JB
M?T6?I?Q](V'3'<OXW,*O<?8+3G[R689Y'J]+([VEG=LTC6&[RVN_-\%^'3QQ
MFS_\C2BZ)^J/XY@C2N4^?6!32;HQH;/F&IKDF=31^#O0RC^@;9.7R:3.]=:G
MB4[$^P:!88TG[UE>\I:I.;%0-T/GP$N#TH'S-W+G@H2NBC"=_:%1N7N_]$[N
M4G3IV\D[/R\9A.GKLQL,>61^:#C'WYN)JTG FQ25I",>F>L*)#=[M#TO.)EP
M$&702#IIEMG1>I=D[#0&> "@]CX]:O,T/YF>1.NYVXCEOJ7CT/W)H:BLS/HV
M9% [.$W:-_G4RJ#F_$ZZ(.5@J:J=E>FW@R13QG+T@OKCL/I7UV5,\#S;BO_V
M7L@'N='1-1J38WJ3O _X=75H=Y4_UMS+NV622.R93QP44ZF1Y<7= _T<?SK_
M4RI_.QZ4?XD$N+$CK5]]ZF@N.MCX>F5N+HN2Q]7BD\7NI$9UM8^#I%?)ZM8[
M^QM8Y)( U^\)7(TMGA'Y0&L 08M+&J,\?T\)<QLYH2:P_K&;O% ((;)57R%T
MH>4F92JB)$V6&DTB.;V+=/)-0CTQF+U-$L#GP4W8>!<#,5B1&"I",)W7)W2[
MIU%?" 49X^@Y</X8=+Q9%@G0@9W:?I]A8DP6;2!W-L8D=$E,375\=WW^"+.,
M!#N0NQ&H^$B,C&(@ 6*1H%0SP@#D 3B0J0LT_G<#>%"\=W'NIE6$V'Y*)^TF
M/YQ05EP<=?%WX /^:L57@X]F^7K3\J*:-%<T/XX<*EF([NKALR;EFQI2YEX\
M>_TB/?I\9Z+ARKHZ4(B%TS(# D=(5EMV'B8NW#:[<NX^<@S:"8O ':\UPJ^O
M]CJXU<R6OA04F(A_,:)O,-5ES1S,D@2K+XY6<XK0.S#-R_Q![>M>S(OEYW_(
MIKYO9JPBIZ;7*N5V/2<RCX\$$$H&RZ;L^ :<(I(4F7(_*PL /^:,_0C+-VZV
MK*6HI&_K"Z;Y#QQ/_+_5,"%3_N':C3OFYNIJU&P3$QT ]M.U_CUH*(+Y_N!'
MW86+=Z _.U&5X(HNY\2[,/6W),#-G3AX!$V,(&WR5U/:=VM=:WO\GNH-[VM^
M\1+;)TD A:FXTK].-HG"9;55AX_;!W*/D#,B[ NM0W)Y*K#-:Z!L*X9O&]K9
M-?/B(F5W7S:[S6G0&1[2_'[".)>I1>9M>F*?CSGVJO+K$O#NR9/;T<,70XD7
MY]AISWLD0--I//V4J@%1R1PFU((/73'T$M*DCC'B]\_-S6ISF:!X/#:E>5M@
M7^WZP2=!;QP%]/$D0VF/6-'Y2UIHUU42H+L%^P$Y>#!PE>/\A@5QF@W6';P-
M#L@@"DGOGWB/Y[-/$=ZSO6E]<59\+UO_KM; ?<@15!V+N1N6\O=95J1V(Z'2
M_((%@E7_+&E,_]3XXW0.S.X:"4!M&C$\_TCCFSQ'$C,#USTMZ:F66XQ1F5M"
M%*,QECILX<,MF>/> DS=WCIL+J E98H-[4H)RV)>ZTMW0@8U8<A[9NTRTX4X
MD:KHVS.A@Z>Z5>DJ.;^U'JA\>-G1*]8G5S.M'_YHLKA_+<G#TU\.?LM7T1=<
MG-WUD&=9]!EE#0G@IK"4U% V.S%KN:U[QO5H?+_DT02L$>3\RF&Y_@Q1&2 C
M7N^RIQ_9I^? N_%8DNO%/4T=DUC.V)+:EAS'B1]WNU9J^WS$3=^\)P%NY3TB
M 8+[[Q-G0C.?+'31Y=QJ?F,#[&&.WH4&NS%3GQ85M6,*QVEN9GO;/5)R#^WR
M$!OR8NP7ZWHUVK\4 ;]U7ME>3(/B1F>.M'V IU4?ZZFB  E;8T=M^[]$^"V?
M%8=:\)( 09R2A[O,F9&U[&P26YU)0:PRB3PD@)T=%3TA 9YJLV3^H;X]K>@L
MV+8Y.W5D9+$#)P[[:46>93XX'9PG-&XQJZP@*:QG?8"WH[QY^SL)8-B.@!EC
M85(EIRV4H0VV.L.E,+, CK]#Y@0!'W%H_Z.JC6G5ZD;\9=='P^LW'FF,HF+Q
M3YSXBHL&XS\H2;M?@NK@J:'D/*E]7HPFP2C]$9%"'G(^T-C(9OY5)]?\-^Q7
M>"D> ]MBN$! )3?IW4^K^JP0G1A7?GTFH)6MY -@2("Y Y<OLP%X2O8RPC]
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MR3G1AQ&C>*T3<W9;02Y8QJ#.>C&H8PR3N\DKRG4L<I&TU#ZX#OJS/1L22K0
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M>P+4&7,F>QO&#+\'RW\%6IL@,RD#T2.YINA;+NWCS:"#?A(@O%Q+OVEW&!/
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MP@=;F]QYL[%])K[TYQD)$%E+ O3XD;DT@GBM+NVSPN& X3W:*[KM_&G%ED:
M0A4%>><]B/52>ZA%0AB3(9XM@?B.3%V:79;G=(*)Z95</;,J+/Z$A;TINTF&
M9C["(V.T9+=N:X" 2<[+W^"])F0?:Z*[+PQ*6%#]^:<8IT1/  1C3YS=0'.A
M2MD[.@H@A_#*[MD]X;*)5R]AU_/\U_DT$K8C\D0?/8-)-)"E(N!)@(##1-59
M9ON+&S+8$VO[U5%1X(ZF*"Q"21M)F-[-&^B"%X)V2Y^NYKPE1H]/]_:#?IA
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M;!47_FU5M_][D%'MT*[EBFL =Q]EWV5#2C8;EILU",:;=DGY;VLI#FC9M:Q
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MO'4TQ.M>:WI;7E#+T2!Q/"0Q(I,U:%W@.7MQ.^"? I.W2(#_//N)KAH$QB"
MY2T4'(@ 8>>+KGE\M-#8V<;;!%Z=BQ_0@(G^M+BM0U#)J>=6KDD9465R_/T
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M?-2!971'LRZTRW@$.\=3B7ED[(=9@#F!P0(6Z@"PU.&,)4 0P5_&U0H/PP>
MY\@R2[+!H4#2S'7JD87H % K ,_*@T;^F,=WV 8(C$7*N#%BKJC/S9B-0C4U
M[(,</;DJ:*+)AG_+)*$8V,Y7 0(^(NS#?#MS:FEQ)TVJ>4R2\=()QG[4"P0Q
M\V6O[$O)D6WCR,<5CGB/COEG;;YEZM3D+,A#-+*0:C22>/Q@=MS>$Q"ZS$'+
M),"J'(:"H,$$4#4,I1G3,.H6P4V0JZ#G0!H_5";#.'(@6H4$4'1*M/)%@/=
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M,5>OT%7/P)J]%7]>DE7;M1HGXZN_=P=!C)?^'V_1<>5SV(=^"Z5_W]ZW-BQ
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MOQQ.%S7%V"_A[-Q.&C,W*N?+"42+[HL2.)Q FDYM.",;&0)I5 @5!Z!+=;)
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M,?+XD,>'/#YD\IQ:+L0_H:O%S=5X/N*$/#Z,$CZBA">5H:O%VM4X*XN1QX=
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MFCHM84KYP1-?O7 _?GG*/'_H>,L>NRF!9AYQ/#OZN9ESD.0*<W#@C$@_\(>
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M]\2:_X)AIW91+Z //"P5]A)8DJ$0DUU_O,F.Q,B".;DV2X,T_TX5!.[0Y%9
M$,.$?\3O,](6U5"7@:B" ="NZX0#$9"+E\<:(LT+@@%Z^ Y\- 9A)#<,N:#
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MF@ R(RZ0*X0#2 Y_B#D>[ '$")\##)#K1#$ W%&P@SCP%;O=DTP/VRD8CX0
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MC:PTO7]V"]^"[ M0E"!\QJ< _QS!I0&,ZDC*GO1N#K%I%'D+7(B;A87ON)R
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MK99^*HL;.FJS[Q)M'35X;!\^BK[8\&S?C?&(:(H]<U<":_@88]Z<7C!S\72
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M>#!BH4U@@_6=6^ZFXO[? M\0Q';AWUB1I=9&.IV%K<;= GA*P*5W@@L X_2
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MK75*_I>TFY?GC5;K&PS\IGE]=3-3#'H0Q,,9,-PKP%&/BZ2.V4K7WRPRP6U
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M6,J!J0SJ]X/^:HR@3U&)_!FX440]91@O:QB?.L,A>06,RE">AX/-6WP)N72
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M2EHE;@LL;J\#.G;</J%/8^J%=#:(O_JY*NDJN71M5#5;B=9MT+P4I.W?W=$
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M\J<-LUS?Z 0HF5.@%*Z^A*O2Y5$9U7)EHQ.19$Z 5KA:+%RME"U+\56%JT7
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M;S ):02,_A8E%6.=P22,F"X&X@N \MT)>@-B(R(8-@-10._=$.@%Q9O7!WF
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M9 R\W-6/EBP/",2>-_%KXA03^*[.X8TX;6@ULZI9U=HF(+AF74(*B+U5B&T
MM62"AX+!.Y4<!1L%&P6;%#;SDAHY=%[*;&07^#.!K!7UA'V%:>F#V="J-7O)
MA++#]0O$;9A.1?LECE?SW03*-:!< Q)!]<?\%/"$,\:MOGHYU(X9Y:% G7L(
M-N0G:)A:M;YB%G-Q0;DMU\ L!N^"'>\KU$L?;,W4#<VN6RNFFRM7@%+9E2M
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M=86@%WL11[%PC%-*XN$2+HXOQ9D&-,Q;>.+N:(8V\H^<A.+&>2Q@EG%D^_2
MY!\Z/3HML++30IA6HN% 'QQ/-W3"9.)MYLH90"2].W*L(TNY(1&3S!PO[W**
M!6YV;=+X9E;NBE%3SIFY9)FM)'^52NZ8&S)RP[ND3)[I47=(O[=8*HUC\)*B
MY"AG<:=7NKQR5 SNY:7C^98U";8RKB<I1VL.P2"*!ZG';6=8VZ-\RX>A@.0(
M/M['[)PS!CY7^U7M@L]KGSJ:F%MQTR7388A/2*%/V!:(-73"/CQ#-O.(64T/
MO.'(](S'F9N&G$T-6)NI,3<R!,,5G;<6,N3ISAW,2@7*!>P0%NH<50MD-/7"
MM#P_WN^45L> A[XT[MS*N&RX<<7-)D\H9:ES:(;UL5&9N9<B^.]PLA\JB#'3
M3C7'F9X1Y:Q*DBQWRD"<4OX\RMTP^!J^C_2:</9I[+#+!!-DIA_,5B<4FMB_
M#LH(W^N<1XG[G5G;N5AVX55FL@%#N3$.;WE%[49;&3C0HS=WS_.[-B.HKIUG
MUC6 ]<1(;?(L>+G,=>*7X"_IR^=(Y";#I&E[,E[HK"Z3]F_[4 %3T]8,HRYF
MS(N-XO>-NE:%YS!_P9OUP1V8G3<TT3B:8.OS20B26YX7'I_RQ]CH_)F?N78Z
MG*_C"#24C?C?3"@CY]QC+#H!B), A+>4FOM;ROESS4:P'4T(W!$MB3##(+/C
M85.:R0Y63J?F)6W2GK6Y'702:VU^6Y)D]D>VXR/S#3+O%W<C:BGG3O:6 0F+
M,&*[2M3[&!28;O$@"+=/[QPV4B< P>+]#";CJ/<<TUXZ1R=12C)0X]D#G/,#
M-7WT<6 HZQ>7G>220"C+3(3/CTE5VE\<I9J_I7@@+.@]O$.0EDP-SEB]/0!H
M$$L V)/8(<[GG<6!60\Q;[?%&G/P<2YQ$"6V%+ ]F&"B[FCL9X8#S0967#3$
M;G/VC]Q,Y2SNLX]G>8U329\E9RG7F:FJSC*>#OJ$L3GT*;!N%WGD'&$O*MX6
MTNVE4P>XR$2%/!Y_*7S+L1,"J9^/DD1_2$@,DQ->,J@0^R@Y3TPB/J.W@O$K
M[HT0KA.6A> EXWUC]UAB^KN8!(!8A2)-#$OMYY;(Q\@^\WGR_/".1>\M,;>:
M,,_L\'EJ9RP9@0UMQVR&Z5FSY(<7PRGVI_&'9U1G/M"3MX1$$+[V'MCS![UL
M&-4:0IMOFLVIQS\P%"K41JYP<6-<@"_6QC!"#:L= FIR*9++@V8#URD54[AX
M$&^J)URR-HS?)%N<V1IS0[&5CT!UQF:';(?YG7D4)T]A*T$V+Q..ZCEUOV7B
MJ D;8<$@]/'=($N>((;VA2.5KR =<PS,!#;NAH,YD[2=E*ER3(\O&;'78Z?"
M#$B%5Q=#(MWL4\0P>S:E[\&ECQE )'@H\%M\(XT_PZRKR9%KX:,Y1A+PP!&?
M1!Q[+(0DY(-P[^YH.JXK2S/I?*[9<9-YKL9$)=*R-LU-T;X4WZ1C;",VX2Y/
M=Y)+TPYC:QF]XSKP 5]&DHM4T!6YD84&EC;%<.*X$&=L'GUTAG,4T3'?*!/*
MP[@G,6.G>>UN,L8O#!ZQ02F8;60GALR[<>]KZF4'WSHH5$^8,!5]G(6Y_M<)
M,#*CPNS#2AE@GK1E95XYMF361#K9I+G")KFHVM!6E]Z7Q3GXPL6X83IC&^-V
M'@B''LW) C%4&F/!<;=G)@#ZDQX5D?M0M./,]##/->/,IS*)/4R1.,IHGB7)
M)T?+B?)G:8O7UP+8\?[8"?$K.G0<4=:*T=*U#$(Q+.B[?6949$U0T @%M&(?
MY7SZD9R_G=,^,_&ZF!\B.U.+^$S5!#&%LOP>?8T/2>_%XHFK45,9*LF0=XXX
M?D;M9%F449A7>A>&5N?HO_BUEZT S,E1#;W-+'C+DOHPF4?#M+[XU.(4%^P:
MQ)J@PANXN1"* 0BQPBPIT<[S!V8(#P>FPW:3%%*^/S]T,^8<G[0>S\R8,ULT
M'L,0]V)&ICADN8VY/NAW J;X"I$/RYV::4]G^N3$0^UC-7X&J3JBF2^7 YEQ
M((. <HXCN\J3=2#(SA*RH12P,D-&;5,V_[1).C]GKDPZF&0\9>UB0G_<19G-
M)P:-&DYVA(4'C-D("N1(PW@''_/"W8,CINWB1'3N6OS:;%XSI O32>D]&B8N
M"<PY]@-'U!H \H"=A!B<O98]2&1)P%X>V9 83"//^L&TO%<AH"=QBA[_=2;#
M+K]Q#?3T,$0'2YP_.)M0,O6^F1SA^ZD\3&T*MFP?R/:8=1SE E81JG%PA]@F
MW,CT,NZG"S'7IS^D_*4S&=7!SY/(/^%*CI9,*<BE7HH<39%YXOM\;C<<80KG
M.$([HL$]#=#SR/(.DI@CQXT1)I]F9GZC%SJV>GAOX# [FCS#]P5T$M/HCC.F
M],BX.V,^>DG*S+O,O32:B/GJ^>/&X1!<?[\#_@L 0E:()\5G*P2)9PI$9CJ^
MG;MY$K=\.H Z]$'/HN$G)CQS[EINCN9D:B9.,25>>2AIFA:2VJ#X"_XV+BZX
M)TIDH/!5B(S=*<;!$@+BK<3U&*B*L\3^N)\^2[)AQ\NBN9F<?_$Z/GE@P5NC
MS((6/XD[P/ITC,R.1?/F^[JE<0FMG.+24"ZAN22926K(C,  GNBXC+\(Q31#
MDEE_9$;UB>>4W#IQM.3M+&D7;IQLQ/L41>8Y,)(B:#<LHLW9%#(8EHG"O^,>
M<1[8=^<$]M-MQF:3N$5H&_WX+L$(ELH*8 M)4O47+@X09,"R J(IY5YR/&%!
MIK@ZQ..EM$ U?.Z.Y-B2QGCB.7O!/9BM7.=!#<_O\6D$&O==W8$N@PHQ[C/Q
MFPG*3_-!^TDA7VR##:?P 7F,QXH2 I<7X$T2MS)P'U27'2]Q-;F@YTSB%/5X
ML6723#+2A\]:C)@>WHIIY9,@9/??8I$.#<.,B<AX>2B&SR0Y V(VBK#%A+ -
MA,4X8CDS?&+)5"H99I=.0OK*A*PDU)3+4T JFW@_/:1'EN<+G[EQ&I<UBW)'
M>(<[RJSE5BB2,:!3[R->P;+D47%XQNRI'M.2 &#?0!U^P+AYPI%37I\%#\M>
MR\^F8WEZ7+,"2>!'*WGT=D"4ESZJ"SP927(:S&1#\)$XF)SVP3!M3==U_#]A
M,P%1UX13=*/48_6[X['#:?L/#NGT_,AU>!3X4MQPRFXX%I:E&!N)Y_Y7QYN@
MR6@F_O(EO"K]P $T[2.NPO+T9'F)JIU_;6S0/HH$]I@D>(*@(/K$%9Y1-;@#
M! OBN0/ZJA?YZ&7EJS(3YVFRB=K,<O&=.-WH/I,Y$T_TC"/1>KEF_T+&PPG"
MNW-U?@,,!0OOF#AC7W.]9T@?,-& 71%PJS]RN+*<K* ^LP)WF04TWKB ;N8M
MK!8X?A7O:L"E$>9,QIZ+/MB,S\!I>$6V,\PPUVGLFEFDH?]"2F.67.M-1L=E
M<BU$1OZXYV58<0L.4'\R!B2)EX0/Q4(:L396&C:]"K'&3(4+MX&$34[[LUA0
MSX9(^-N'6+ <,M$UO\3-F:E 2 H8\NL9BSTG R]SV5'\G8_,<L!3$.7$R<$'
MZ2S =(Q3%OLQBQ'CG(E=G](!)Z\9&O!GRHVQ@MLNFWJ]_HNHK$MI=*JRCD>1
M(H?K7D'P+$ [21-_I[$"8V-/PBQEZK_CQL$D+DT2&Y%9S@Q0Q'.8\/*SZ<^L
MVCVM LM *#[CJ>>)V!.#/%]YYD%I!L<TDV12]#:-9_.2STO61L",M87,+@8N
M' M ])F4.H"E;9!QQ#HNG#;*RZ !@SH3-@XW=B[+KHDF1#MP,HG>9V@C.&"6
M<)]*L__@AC[H9)>7IZ3$?SP6_1906Q-4CF478O="G0N%']:C/$LR$:$ $)\/
MUA99W-GH9I:5@!$?K\9A;$S,F0.>F/8+2-(Y!8.[RQ%\6IS+V?&\QA#?18*7
ML*7&F30W3B^+]I?R(FD\,I:^STDZ.Z#MDGG,>TKQ?S,=#P1A\!C %?-#-L%6
M&[J,Q9_38I$_.UFN.&&]$YFWT23YG6N\L]\?IT3.?D2/_/44.>6D^>PC<HK,
M<YA]%N8%BF1'9 99I8G54G*^P!05>+Q1!OR<9@?+,H'R-%.(9VK&JI.HOLT\
M W,6)[FP=]8 SY3U,\&9T3TDCA(LP(Y$OLU@Q-L18<[Y!]0=W:)+(8\%J*K%
M/HZ$%6=FN<[46P&<8W=9""IN'+5+PN_HL.#USN%4D.@4%)0[S&@>PUFB^G[%
MG3%ELGP6BR8<$&(5H9!;?*T?+%NSZGI2F3/M\KL2X8V(WB.5P$H3+\X\5V):
M%X5]H^XINUO$/\-)P+:0#LW-/(I[*W!%$\])F1CF*O&"H-;,M=-B,D6%S,S=
M^)R25S'C!$]0Q.43T@Y8DR,<&IA.Y!7YSLB.,&V ST:]<\(!"PYFDL>F<W4Q
M,!2[S;(D^CCPQ9O ?IN^(D94R<F1<<5<32! Z\+C42/>2DA (=:W?; *6.\R
MH>(%&FN;Y?49/MS%R<V99A/3C__=Q^@M=[2BJ0N/1_/7#0#?0HPJI$I;WQ=#
M5WG%6^8Y?3>@;* Z/'#K)[4+S<'*:0[G:/;\C4F>[]1!_V01RLB2<V6= QR>
M'G,"/"'(&&_,&'!]M.__S1,:03Q.1N,DB>&.QNP%JRN\\02=V\PO CB:#KR.
M:&_@N?^:<*?SB$,I8R]R-)N[!-90!Y^+;@MX-T",*0*"!GA6SVW@.WW>U0Y0
MEINE1LQS0S;P/.XIR<M)F.TNC&$Q!9VUG.HYPXQS(WF6F3Y+/"23E,+[5HD&
M)G!DS)?-.L*A$!/Y9FP'I;02+;\D5MLNYHAG7J]-F?1:;(^C(UDC-.J5CSGH
MW R;B*>:/\!G+%=QGA/7@O>3*2B<+4Q55;'Z#.#'_-20][IB?<B%*4A*GWDV
M>"LN, GN>:\*N&T2N:B=Q:'RV,>02T_AU68G:&H-,:B1( =/ OB8A/SSS^=9
M,QS%1%>PYZPC@^^,P0^SA\)\[=+,=T'.A;&$_R+& .MU#,B>_<1[\?2S,2(6
MK$B(BI>[\2?'5V;6E>^?=ARG,HDW^%GH/:<-#?'>J:K[N$PO+KI![9FUK>G'
M@9@X(1UC%K! O\<U!Z%TX!IX73=<A14-;RO/VVZSV[Q6ETD-GZ_;!93[ 3U1
M)WN'DBI.Y!;,1AK_P*H9&Y91)/_ E@5CFN;$FAMPL?.<>'/9T7/R<N;6T_N"
M7.=F^<Q%&JX"\^'AOQWI1Z!@#X>BKW?R&2[OQ9_94?QVA&=QM,R@B\I8] 8W
M!2C?/K0\TTJ\496BEWBLF<5)$Q'7QUY2P=[7:7V-T,R15J,F%3R%)E5 .!H2
MPM$L'AQK,N*C53PX2D;7771UO@>*<Z<K&8T9>)KCI2925.JFW-.J8L"UL<FM
M#Z(\B%A3,@QLOFCI;VN.U9* ED1>GS./Y3NIUU@)"*SCHX""::X.A5\?!VY$
M3U %H\ .'@-GO ' ?%@-A5;=N/T&-K2=C?_W?]5-PUQQFM["[0L[I3Z[V]>1
MB=];WPC>O6'RSG[@G27KQDW-MJJ:WJ@JS-M+S*LT9-WX)CB>=&BG!*UL&Y>>
MX:U;X97;L+C _ :OOPG+X4T'::YBB*V?8=BU-1Y7<?FX45_K*0@Z6_S,->#-
M*N.F-X W5N'PQM3T:D.S=5UASBXQI](H'.9L1',L'-HH0:48SEXZ1W]X+B9:
M_ $K[_NCS3M)%YMJFR ;6:ECOQR0B[T^F]"]9#W3BE;'X7BFM+:NQ*>J'&?;
M/-(#9[[2$^IA.:6$!L(J4$+EFBJLQJ]<4Q(X& KHFJJ9FMVP-2LSN%"ACO)-
M*=^4DE2*X[S/.?6N'$DIE,.T4U^:!GD=5P*NF@MYP$KV*CF02KN6D&<I[5H"
M%:F VK7"&PGPIH"JM:E5&C6M:E:4<JT$U>X11S[=NNB!WY5R 57004XY? BQ
M07DCONI,]R_>:VJ&CLW4+!7QW1_FNYE#51%?%?$]:%5?^18D\"THGY3"FP/Q
M25E:HV)I-;VA?%)*4.T><>3S2>U3O'<T\CU0$?W>3Q7F71I\S0F.N1BZCM*J
M"\NL:EJE:@"SVJ/*J2+J1TJO5GAS('JU2J-4@DH)JKV-])XZGM-?4B-4L89W
MQQIJ6MVP90TT2!P3E#?.:YB:;:P[5_P0CE3>,*\JZ]T[QEO1-<LR9:72P_)#
MG0Y<3_F@BJO:&YIN&IJA[U$29Q%]"<H'I?!&^:"4#TH)J@,25'OI@SJC'LY0
M5$ZH+9%%7=.MAF8IK\5>.:)4P8'R1"E/E.*^RANEFE\<DI9?U6I 4U9UC_KU
M%-&MH-Q1"F^4.TJYHY2@.B!!M9?NJ*\T&#G>LW)';8<L@"0:EF99*BU*>:/4
MF2IOE/)&*>9[J,XH-8.SZ$J^H36JMF;6]RCF7$2O@O)&*;Q1WBCEC5*"ZH $
MU5YZHR["P*%#Y8S:4MEJHZXUZM*&YB5V6RA7U/Z=J7)%*5>48KV'Z(CZJP._
M*3=48;7[NE8SJYJ]]EX#A;,+E1M* LFJ\$:YH90;2@FJPQ!4>^F&:M-H0 ,,
M3B[9E%\91._/%ZS6@#2L=7MH#\%SH;Q1^W>FRANEO%&*^1ZF/ZKSZ$;_YOJ'
M\DH55MG'+FRF#E2U1R40170O%- M96B->AWLQ'7W\%.8HQQ3RC&E9-6LK#(U
M2V]H>F7?YP(5W3,E!D;^ 2OO^R/EG-I2)W,0R$95J]7JLAI($GLRE'=J_\Y4
M>:>4=TIQWP-U3ZFAU?NA]%NUJF8U3*VR]FGPA3,8E8=* C&K\$;YIY1_2HFJ
M0Q%5>^F@BL=6=P9^$)U$-!B1"^^!AM&(>M&[YE<KV^DMCEVMT:AK57/=9',(
M3@YY'5<US;8,35_[O-%#.%7ENE*NJZT=*<[+-!LR\]_#<EW%VLEW=P@JB>]1
M4$Y 1X&_5]1,E$-+0FI33@D)G!+*F:7PYD"<6093PM>;,E,\M%%B2@*T48ZL
M3:F*73]RAEOT6]WZ09\&@'T>%7^?1/[X4^@/W3YY=+V^_XAP(T9R[0F'TJ>^
M/[D=TNPU9MFT%Y/./.-,#@J)8?_AC5JY!,"5UR:-@6OKEE:Q:YI5:Q0 S+MV
M46V1+.>XP>3"G"*3I;0^W1BX#4.K&C61[20[E!55RH,X!:9*>7WR,7#K6K4&
M1&G:!0#RCCW_2H'="YJ47X&M@@);LTVM7C<+ .;M1&Z,QEO-[DI]%4?.#@WR
M9AC2E3-)5HO7[*5#X]P/'IV@3TXG04"]WC,YA=\#IQ=MH<=1X1CXAS4QDL(Q
MU_VJB2J<,K]IO)/6_&V86K5N*+3;2[23U[[;JYPK)66+(F7EYG:':EE<NLZM
M.W0CERKSHE#FA4HVW3_5767ZXYF6L/"INJX.<O,9R+PSEF/WQZOMNVAHI]1B
M58J@.$EA.,EAE4I<C2/7]\)4C2-_!FX441D&)2TT= N7"UK:N E<.)!8-5W3
M*^MJ1;V(414.+&_C8)O)_%[HWRP<5#?N;R\<1 Z]&$;A]M+62^$@<N#=9Y3:
MI-0FI3:M46W:2T>^*GS:?6IC226.;A"Z*:LL$(@+X6:+(7S\1M@6+/]<VGR>
M?<@_ES8F%P/7J&J6400NLNM0KJ+(O:!(><.5,7!3^UYV$*L:+6F01NG:&]6U
M;4NK67JQ0'RXNC;S:'R,'  1_+?O/F0VFP%0CV+;O(7K,ZSQTZ_9/7;=$0U)
MFSZ2&W\$=UQW-#+UG?CBZ(MEDF[KC\LF^?/JYO*,?&LU+[O?3ILW+7+^HWU&
M_D,ZK>\7S7;[1_.2W+2NKVZZV0T/@G@Y XJ$ JCS].O,RN/#U?5?9ET]]X'S
M_.O8N:<GMP%U?IXX=W#')V?XZ#R'1^3CE\\ EBD$J(O#KR=>F44H4I_O EHO
M?AAL#=T!)7?^<.@#KM\3-R0."6C/]WKNT'4PN$_\.W))'^B06,1A577_O[UO
M_6H;21[]GG/R/_3-[MR%WY&-GQB2W3G' 9)XE@ 7DYG-IWMDNXVUD26/'A#F
MW#_^5E5W2RU9-K:QL0R:1P*VU(_J>E=U%3SO,<#>_HCYL#1K"!,Z 0L=MP<S
MWB%:,,N9A/#D/?<X"WT^8('+!APK/5L.3&A:'A),R,L9Z$B(Q01!_NL=*&M]
M;MN2R*/?D6[4[W1.@+5P4.\6<;4U%*.HS684DA%D\HIL)M#,8@)K/*^63L]:
MN6R ]11Q+S!"E_=#;WX:\Q*NNXT".4&.1\UG!/-'TS:=/@?$!S)8#<J3@(][
MW&/UBK'* +5*;?;%Y5P>T/%STL$%#X!?P6Q_\<$JX+TU+8?MV:[O[S/127OI
M(?HCT[GE*U)AZ#QE]>9D LQ:\.E5WM\;\'B V2I"+M&L]9QH=N+ZP8H<8!)Z
M@"%^!IM=Y(!71$D7Q(/G8VK>;AWJ<99K9E.'>N6Y?<X'*QW,T*/&JDN_YYLV
MZ+.O[5@/LYQ"&Q0)JP W\&">(8!WE9<M)W!78L!NB'QEFO4N\*Y4RG<+$UI9
MOH@-:V\K,5Y4^-@J;WXU@=^S>G55;6_E \W,,ZBU5DTT:!XW\YU['LMFY(J!
MA4;CE<>!A+T,;2J_5S,S[<8M7,WT)*TL *ZB[,%KN QT?%@Q6M7U-B4IRA[D
M)GLQMS[K5M5H'FTZ1S&OF]_";=:"(Z<H([<;KQJ'E2.C<=PL>'*!>,^Y\9=5
M-:)@>*F<G6I>-_ZB2@P4:+<KJ6(UD+$MX["V+B5TW8BW;@=$OAT]'8_;PF.^
M=D_.BG5?BF96R^JMQY6:<5A=;S&[';I4N<(=R@T@SNY=S*L!VK1:M37KG3N'
M-UMF.+MWJ_V5W^'.![LIT*9@-RM9HP7>["2[*5H#+VUF5BM-HWZTYA#;BVGR
MFI/(>/?>"O[BWN(VZ*Z4%LUOZ+EF5!HMH[ENRG@5Q45S&]K<J]</C>K:K+DB
MLILO9I);-_:+"B(\*RO)[9'N58U6M6HTUN91+)A)KIA)$9%\<>T3\AOMR_>1
MOJY8WS<'#GS NH$9\ 5[PA01OQS25-TX;M2-5N7XQ;@V=M(%OWL1O[WJT:8-
MQ)V#29ZJNN>#(>Y>:&E]:%VPPE>",D4T,@>LIHA&[BB[*:*1KUYE7_^-Z%S8
MR-%-<\OF?N ZG'7PACW\O.2MY\+/4/@9=MS/4*T?&<U:Y<6PK)U4K7?/HMYK
M&<V-QXYV#BJ%GZ$P&@N&6*!-X6LH? T%N]D=M-D]7T.U7C4J+]W3L.MYSZ^@
MQUMN$]Q>0">8_&:7*^ >&<?'=:-:/]P!(&\Y4ZSH!1.CS4[W@LEM1FM4 K5:
M,PY;K=T"\4[D#!=]%_-U#KO,1G(/7%$J;S<822';<X,V.RW;=X HXUL[.P3D
M0KKGXA@*Z?Y</5QS>_NJZ.&Z_1T5%+D%BLSMY;G8EP:ZMM&J-7< R,]R1:^6
MX?XO-]7NZO,# -6E(LCK/E-LJA=UM6-QBSJF]YMCR>9Q##MB,778/0];H,Z9
MPM+Z5_J!9=MLQ.V!Z+/(HA8Z#/OAL#0B;3@U;^XA)3G>SL7=5JWHNS!,=C$6
M6:L_H:3^-&1R$HU4_9G3,#Z4\-UNC^$_0],)K !XQQUG \OOVZX?>IR9/>R(
M]EA;8>HH#*PI@(%55^&H63%^&#<8GFY?O)66PX<*2VI)+%E*""W1OVUJOG7U
M;WO.3GZ?\!1_IU,T5^KIM[5>;%LZG,:V\P82 ,23$U1YP_LCQ_HSG&[%MV(6
MP?/!-+,CZ?9@^DWGAAWDAKL'TFHUR[^P*8A=HQZ["OWO_<%1L0%)T[[CGGG+
M5VZ0O-[LH*.<7ZW97E_&]:33+:36@PF:%_UUTTV)%DE*%>!8]\Z.C&;CT&A5
M#Q<V*Q4V+&HPKB&ED+:^R334E1E%J[%-)\(-]E,V^R3_)YX5MQ9=^R&^&I#N
MF?L+ _'*<WMFS[*MX %-(+" G&#JHF,N8+I<G^&U^[H.VEM&S'5K![E2 M9[
M1SG'Y>V:N8V9;237?B/QK">PY6?@%#I'-0?_#?V #Q9F'>2+6JL385'NFF6_
M;A(T4\+F4=C<6&/T"RXAI38AA)X!3/7C<J7R2^F8_F)[A\URM?[+XB*]6FY6
M2M4:_,GV&N5J=9\]<--;%ERKBIL5C,_'6<)&[+KGC'GO7+3C!03#%[)(\PGU
M'8R2Y^0RYC.9;-O3E"/CXGG\8T]0* IXKA.>U>HZV=EN W1NX+J18MP;#5RW
MI+^%W8S :L68M>,F@]:6,W2]L8AO!2Z;>.Z=->"8P1*,X/$Q#T;N )7:,3<I
MM T?QEDOS)_P/H:XLZ+1LT+VS[+S:B41!&GLBP,2?UYYUIT9<';BCN%EB_O,
M= ;L,@ @L6O8FF?UJ:P6[X>>%5A46FLFNLQ"Y6?.3/@$2,G&YH,\'<PKF,AM
M]A/;=&F;7KQ-/]HFLRCOP.?Z9_=N: ,QA)X'!VX_T&B>!<]40?MW/69S7Z8[
M.>8MAIE$>@*B7)R[,#6JAUE7/L;3!JSVBTIXP$W\PT\-Q<P@E4NU"+9MX1C:
MZ74:T:;8R$2&,AY;,EL,-OQW=&C4X?\CAJVA [0>@021[R(YFC;3T\LP3^3>
MG3[3+%@<#*P[#2)3$<S9^ZA/?G[080%&+1S6!;]GU^X8WKCJ&BSUF?P L/#L
MW^=M]L?E]?DI^W+6/K_Y<M*^/F.?OEV<LO_'NF=?.^V+BV_M<W9]=G5Y?</J
M=7W-(T\M9T0!2Q \/V?'7L'RG!8WMY[Y\&$"F%/J>=S\43*'\,9[T[XW'_QW
M:)4"6%)8<I3$DCF2:6N)1B*I9\ #T[)]0BBS_V=H^80D; #(8  V^ '\:7K>
M [XBR&X"9!XZ%GR!9*^3HJ*SY1G$-"FRB/G :BS$['M8E<M1U 2 ]B!C<$:R
M?!"]!WR,DP0C&,H/821M]!X\QV\M'UVL@ZTD.#76ERR@*T>-PVWK0(F< "G8
M'F*Q%OT=3G[]&WP<(A?95$;&&H&<X@I9M1HV!<1V3(6KY&6< N%M)B]K4^ ]
M6B$VL$'XG[CKB\)D [&2 47R1^B0),:6^ 0)/_&!-0:9]-X"5@P[3IT  )RE
M3R'C! 1T:7)<B_Q5CH%P?O1DYKS[V!FQ^)!8?$J/KVG.,2[T,AWMXKLX4>*/
M<BUGV'G/NB*0P$M8#B__A+!<\>Z)E9SQO=]E#"XG);)!M\FWXZ<]=NV'@%V-
M3&]LLFZ["W:]A]KF"3NY"\KL:KA@/^1M>-4JZZQEO0'@5JH'M>9!;<D&Q[G+
M@\Q7F&73J9#UG8.(*(-2/WPY+>;7<Y35W;NGMFGDWKUZY;5R_=4VU2J8]DMF
MVLWCAE&KKGHG-7_(O7;-.1<Z'+SG!]RD&*$YX2&\[!NLX_3+2E/^N*2FO!%%
M.!>PJK0.:O#?@CTW=B;KMYY?'G)8J1B52F,'\GX7[RB0<?MX$_UL\GJHS7)S
M74UK<G&>!9'FFTA?F</KDVUB)KH[1Z"WZX7OZ^FZ0 ,4@8-:Q6#5RD'MZ&#9
M_FTOMY7'#AHK=:/:J!FMUIIYV.Y8XBLXE(H>?( XA^77ZY4LF,UJ.'-<J1N-
MHF]0SOTB9\Z FW>NQSY:[I@/K+[E\,(Q,B<0"/\MZ,@N;*XG!PW WJH9C:,U
M1PX*Q\@V#[51;KVH\WSM1%HUCH^/\?^<'NIK<XR$/J;,BTR@/OE%3%M)]!-W
M/*9,WL(;LIH"<'Q0JRRL !0^D!RRJR7]5SDV2 K?Q_,XS<KUEV/$%DSFF>J4
M&\UJZ\5@S<MT?70NV3E=V/OBVKC^=/BH5O@]XB!0O4)!H$KSH(JI(?#3\4&U
M"3]A>Y]:8\&N\H6U]61I5&\9E74[XPN'R)85C*.7=)ZOGD0;=:-5.<SID;XR
M=\AE/[0M7XEXUOY<^$">J@S4#RJ'^;@-59@GJ\95FLTCHU%9<X+BKMFUA2]D
M^3R09I$'4C";9>-#1T=&L_IRKG^]3'?(E6=14223G0>#V M2.$$4'E<.\&),
MQ8 ?JL?%]9AGU%9JATVC>ORBC.37[O2H5LI'>;U*45#I2E1:K32->FX/]97Y
M/:Y-R[&XE[@>PS([O!1ND)5308X6U@(*-T@.65:U43>J+^CF?N$$><XF3>7*
M*T\E*AA.+MI[[: C9([C8_82GZ)CS/$DK#!AKCKL9-D=^<#VE]"^*+?FE@)N
MM6X<-EM&@X11WJ&\24-]\;9H&>WC"B90,(%=9@(5X[!U9+2:.]2K;+V.G?PT
M(M);\/Q-_Z7+.>OV1WP0VM2BHJ/U/<%F$7W7\[@_<1U*5!FZ;N"X ??A)X^-
M72_9Q0C^XV9_Q"S?#[FW2*N8VE8A(;-$]8^4"XIYO,^M.S[ ?DP3TPL0.":"
M8^)ZV+A#-B9'.)ALXO$[RPU]^P%[<,1].Q[RWIRIF6C.U Y*P8B7OIK>#QZP
MR^$0AG)NEZBCOM4.3",X*5-V,?$$0OH!'!5UR\*CLHCR@Q%U1>F>G1A,-@:
M8P,K@O>I+1<\>0IG/^YQCQU2IY6:P<PP&+F>]1=UA5$3!J[ =.:/3, 9^ )L
MD]L1T W+AB3;:]]\W<?.+/@+/&;>WL)Z$9VB'C'A!,?]>[6)99WH?]'GQ55C
M8,,9V*CONWW+Q!XQT99D:QF8(WX:%L;,R<1S?UI I!QV^O<:,.7FT2%.!O(
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M1&N#S(R=+,3TD#!)6=<:8PL[QPT%_3_ Q,SLJ5\1BD/7MER=.@5[TCMEHSN
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M<F&)MGE/?J,T+0NYC81.BU7)?Z1K"-:,FHRV!6,*%-'%)AG.HKUE^UU,31F
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M(J01BH((Q0^2Y3_)>'H093*5[2\UT@LJA8QU$:/8:S>*O5(ERND:R9B3@SA
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M,S,Q+GAS9%!+ 0(4 Q0    ( $A[QE: +WQ\?PX   [>   =
M  "  9H&  !C:S P,#$V,S4Y-S<M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( $A[QE9(6;NSG0$  (T$   =              "  505  !C:S P,#$V
M,S4Y-S<M,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( $A[QE9GF8YO50(
M 'X%   3              "  2P7  !J,C,Q,C4V.3)?86(P,#$N:G!G4$L!
M A0#%     @ 2'O&5C:%C\/(/P  ST   !,              ( !LAD  &HR
M,S$R-38Y,E]A8S P,BYJ<&=02P$"% ,4    " !(>\960\"9T,TK  "'+
M$P              @ &K60  :C(S,3(U-CDR7V)A,# S+FIP9U!+ 0(4 Q0
M   ( $A[QE9L7 [9DBL  $HL   3              "  :F%  !J,C,Q,C4V
M.3)?8F$P,#0N:G!G4$L! A0#%     @ 2'O&5D"[YOV=6P  =&   !,
M         ( !;+$  &HR,S$R-38Y,E]B83 P-2YJ<&=02P$"% ,4    " !(
M>\96GSUCYFQ_  ##AP  $P              @ $Z#0$ :C(S,3(U-CDR7V)A
M,# V+FIP9U!+ 0(4 Q0    ( $A[QE9UFWMD58X   N<   3
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M>#DY+6-E<G0N:'1M4$L! A0#%     @ 2'O&5F,+TJ8\%0  F>@! !\
M         ( !+K " '1M,C,Q,C4V.60Q7V5X.3DM<V5C=&EO;C$Y82YH=&U0
M2P$"% ,4    " !(>\96>T6APV8! 0 #=0X %0              @ &GQ0(
K=&TR,S$R-38Y9#%?;F-S<G,N:'1M4$L%!@     /  \ !@0  $#' P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
